0001193125-22-159696.txt : 20220525 0001193125-22-159696.hdr.sgml : 20220525 20220525160909 ACCESSION NUMBER: 0001193125-22-159696 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20220524 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220525 DATE AS OF CHANGE: 20220525 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CHINOOK THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001435049 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37345 FILM NUMBER: 22962961 BUSINESS ADDRESS: STREET 1: 400 FAIRVIEW AVENUE NORTH, SUITE 900 CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 206-485-7051 MAIL ADDRESS: STREET 1: 400 FAIRVIEW AVENUE NORTH, SUITE 900 CITY: SEATTLE STATE: WA ZIP: 98109 FORMER COMPANY: FORMER CONFORMED NAME: ADURO BIOTECH, INC. DATE OF NAME CHANGE: 20111107 FORMER COMPANY: FORMER CONFORMED NAME: ADURO BIOTECH DATE OF NAME CHANGE: 20080514 8-K 1 d535079d8k.htm 8-K 8-K
false 0001435049 0001435049 2022-05-24 2022-05-24

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 24, 2022

 

 

CHINOOK THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-37345   94-3348934

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

400 Fairview Avenue North, Suite 900

Seattle, WA

(Address of Principal Executive Offices)

98109

(Zip Code)

(206) 485-7241

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.0001 Par Value Per Share   KDNY  

The Nasdaq Stock Market LLC

(The Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 1.01. Entry into a Material Definitive Agreement.

On May 24, 2022, Chinook Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with SVB Securities LLC, Cantor Fitzgerald & Co., and William Blair & Company, L.L.C. as the representatives of the several underwriters named in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 6,428,572 shares of its common stock (the “Shares”), and (b) pre-funded warrants to purchase 1,071,428 shares of its common stock (the “Pre-Funded Warrants”) to the Underwriters (the “Offering”). The Shares will be sold at the public offering price of $14.00 per share. The Pre-Funded Warrants will be sold at a public offering price of $13.9999 per Pre-Funded Warrant, which represents the per share public offering price for the common stock less a $0.0001 per share exercise price for each such warrant. Pursuant to the Underwriting Agreement, the Company has granted the Underwriters a 30-day option to purchase up to an additional 1,125,000 shares of its common stock at the same price. The Company estimates that net proceeds from the Offering will be approximately $98.3 million, after deducting underwriting discounts and commissions and estimated Offering expenses, and assuming no exercise of the Underwriters’ option to purchase additional shares.

The Pre-Funded Warrants are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage, but not in excess of 19.99%, by providing at least 61 days’ prior notice to the Company.

The Company intends to use the net proceeds from the Offering to continue its phase 3 ALIGN and phase 2 AFFINITY trials of atrasentan, fund a phase 3 clinical trial of BION-1301, continue development of CHK-336, and prepare for the potential commercial launch of atrasentan. The remainder of the net proceeds, if any, will be used for general corporate purposes.

The Underwriting Agreement contains customary representations, warranties, and agreements by the Company, conditions to closing, termination provisions and indemnification obligations, including for liabilities under the Securities Act of 1933, as amended. The Offering is being made pursuant to the shelf registration statement on Form S-3ASR (File No. 333-265168) that was filed by the Company with the Securities and Exchange Commission (“SEC”) on May 24, 2022 and automatically declared effective upon filing, and a related prospectus supplement.

The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement. A copy of the Underwriting Agreement is filed with this Current Report on Form 8-K as Exhibit 1.1 and is incorporated herein by reference. The form of Pre-Funded Warrant is filed as Exhibit 4.1 to this report and the foregoing description of the terms of the Pre-Funded Warrants is qualified in its entirety by reference to such exhibit.

A copy of the opinion of Fenwick & West LLP, relating to the validity of the Shares in connection with the Offering, is filed with this Current Report on Form 8-K as Exhibit 5.1.

Item 8.01. Other Events.

On May 24, 2022, the Company issued a press release, announcing the pricing of the Offering. A copy of the press release is filed with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
Number
  

Description of Exhibit

1.1    Underwriting Agreement by and among Chinook Therapeutics, Inc. and SVB Securities LLC, Cantor Fitzgerald & Co., and William Blair & Company, L.L.C. as Representatives of the several underwriters, dated May 24, 2022
4.1    Form of Pre-Funded Warrant
5.1    Opinion of Fenwick & West LLP
23.1    Consent of Fenwick & West LLP (contained in Exhibit 5.1)
99.1    Press Release relating to the pricing of the Offering, dated May 24, 2022
104    Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document)

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements relating to the expected net proceeds of the Offering, the anticipated use of proceeds of the Offering, and the timing of the closing of the Offering, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the potential impact of the COVID-19 pandemic and the risks identified in the Company’s filings with the SEC, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, the prospectus supplements related to the Offering, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect the Company’s results of operations, which would, in turn, have a significant and adverse impact on the Company’s stock price. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

CHINOOK THERAPEUTICS, INC.
By:  

/s/ Eric H. Bjerkholt

  Eric H. Bjerkholt
  Chief Financial Officer

Date: May 25, 2022

EX-1.1 2 d535079dex11.htm EX-1.1 EX-1.1

Exhibit 1.1

CHINOOK THERAPEUTICS, INC.

(a Delaware corporation)

6,428,572 Shares of Common Stock

and

Pre-Funded Warrants to Purchase 1,071,428 Shares of Common Stock

UNDERWRITING AGREEMENT

May 24, 2022

SVB Securities LLC

Cantor Fitzgerald & Co.

William Blair & Company, L.L.C.

as Representatives of the several Underwriters

c/o SVB Securities LLC

255 California Street, 12th Floor

San Francisco, California 94111

c/o Cantor Fitzgerald & Co.

499 Park Avenue

New York, NY 10022

c/o William Blair & Company, L.L.C.

150 North Riverside Plaza

Chicago, IL 60606

Ladies and Gentlemen:

Chinook Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement with SVB Securities LLC (“SVB Securities”), Cantor Fitzgerald & Co. (“Cantor”), William Blair & Company, L.L.C. (“William Blair”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for which SVB Securities, Cantor and William Blair are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of common stock, par value $0.0001 per share, of the Company (“Common Stock”) and pre-funded warrants to purchase Common Stock, at an exercise price equal to $0.0001 per share (the “Pre-Funded Warrants”), set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 1,125,000 additional shares of Common Stock. The aforesaid 6,428,572 shares of Common Stock (the “Initial Securities”) and 1,071,428 Pre-Funded Warrants to be purchased by the Underwriters, and all or any part of the 1,125,000 shares of Common Stock subject to the option described in Section 2(b) hereof (the “Option Securities”) are herein called, collectively, the “Securities.” The shares of Common Stock issuable upon exercise of the Pre-Funded Warrants are hereinafter referred to as the “Warrant Shares.”


The Company understands that the Underwriters propose to make a public offering of the Securities as soon as the Representatives deem advisable after this Underwriting Agreement (this “Agreement”) has been executed and delivered.

The Company has filed with the Securities and Exchange Commission (the “Commission”) an automatic shelf registration statement on Form S-3 (No. 333-265168), covering the public offering and sale of certain securities, including the Securities and the Warrant Shares, under the Securities Act of 1933, as amended (the “1933 Act”) and the rules and regulations of the Commission promulgated thereunder (the “1933 Act Regulations”), which automatically became effective on May 24, 2022. Such registration statement, as of any time, means such registration statement as amended by any post-effective amendments thereto at such time, including the exhibits and any schedules thereto at such time, the documents incorporated or deemed to be incorporated by reference therein at such time pursuant to Item 12 of Form S-3 under the 1933 Act and the documents otherwise deemed to be a part thereof as of such time pursuant to Rule 430B under the 1933 Act Regulations (“Rule 430B”), is referred to herein as the “Registration Statement;” provided, however, that the “Registration Statement” without reference to a time means such registration statement as amended by any post-effective amendments thereto as of the time of the first contract of sale for the Securities, which time shall be considered the “new effective date” of such registration statement with respect to the Securities within the meaning of paragraph (f)(2) of Rule 430B, including the exhibits and schedules thereto as of such time, the documents incorporated or deemed incorporated by reference therein at such time pursuant to Item 12 of Form S-3 under the 1933 Act and the documents otherwise deemed to be a part thereof as of such time pursuant to the Rule 430B. Each preliminary prospectus used in connection with the offering of the Securities, including the documents incorporated or deemed to be incorporated by reference therein pursuant to Item 12 of Form S-3 under the 1933 Act, are collectively referred to herein as a “preliminary prospectus.” Promptly after execution and delivery of this Agreement, the Company will prepare and file a final prospectus relating to the Securities in accordance with the provisions of Rule 424(b) under the 1933 Act Regulations (“Rule 424(b)”). The final prospectus, in the form first furnished or made available to the Underwriters for use in connection with the offering of the Securities, including the documents incorporated or deemed to be incorporated by reference therein pursuant to Item 12 of Form S-3 under the 1933 Act, are collectively referred to herein as the “Prospectus.” For purposes of this Agreement, all references to the Registration Statement, any preliminary prospectus, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval system (or any successor system)(“EDGAR”).

As used in this Agreement:

“Applicable Time” means 6:45 P.M., New York City time, on May 24, 2022 or such other time as agreed by the Company and the Representatives.

“General Disclosure Package” means any Issuer General Use Free Writing Prospectuses issued at or prior to the Applicable Time, the most recent preliminary prospectus (including any documents incorporated therein by reference) that is distributed to investors prior to the Applicable Time and the information included on Schedule B-1 hereto, all considered together.

“Issuer Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433 of the 1933 Act Regulations (“Rule 433”), including without limitation any “free writing prospectus” (as defined in Rule 405 of the 1933 Act Regulations (“Rule 405”)) relating to the Securities that is (i) required to be filed with the Commission by the Company, (ii) a “road show for an offering that is a written communication” within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission, or (iii) exempt from filing with the Commission

 

2


pursuant to Rule 433(d)(5)(i) because it contains a description of the Securities or of the offering that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company’s records pursuant to Rule 433(g).

“Issuer General Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is intended for general distribution to prospective investors (other than a “bona fide electronic road show,” as defined in Rule 433 (a “Bona Fide Electronic Road Show”)), as evidenced by its being specified in Schedule B-2 hereto.

“Issuer Limited Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.

“Testing-the-Waters Communication” means any oral or written communication with potential investors undertaken in reliance on Rule 163B or Section 5(d) of the 1933 Act.

“Written Testing-the-Waters Communication” means any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the 1933 Act.

All references in this Agreement to financial statements and schedules and other information which is “contained,” “included” or “stated” (or other references of like import) in the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include all such financial statements and schedules and other information incorporated or deemed incorporated by reference in the Registration Statement, any preliminary prospectus or the Prospectus, as the case may be, prior to the execution and delivery of this Agreement; and all references in this Agreement to amendments or supplements to the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include the filing of any document under the Securities Exchange Act of 1934, as amended (the “1934 Act”), and the rules and regulations promulgated thereunder (the “1934 Act Regulations”), incorporated or deemed to be incorporated by reference in the Registration Statement, such preliminary prospectus or the Prospectus, as the case may be, at or after the execution and delivery of this Agreement.

SECTION 1.    Representations and Warranties.

(a)    Representations and Warranties by the Company. The Company represents and warrants to each Underwriter as of the date hereof, the Applicable Time, the Closing Time (as defined below) and any Date of Delivery (as defined below), and agrees with each Underwriter, as follows:

(i)    Registration Statement and Prospectuses. The Company meets the requirements for use of Form S-3 under the 1933 Act. The Registration Statement is an “automatic shelf registration statement” (as defined in Rule 405) and the Securities have been and remain eligible for registration by the Company on such automatic shelf registration statement. Each of the Registration Statement and any amendment thereto has become effective under the 1933 Act. No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued by the Commission under the 1933 Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued by the Commission and no proceedings for any of those purposes have been instituted by the Commission or are pending or, to the Company’s knowledge, contemplated by the Commission. The Company has complied with each request (if any) from the Commission for additional information.

 

3


Each of the Registration Statement and any post-effective amendment thereto, at the time of its effectiveness and at each deemed effective date with respect to the Underwriters pursuant to Rule 430B(f)(2) under the 1933 Act Regulations, complied in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus, the Prospectus and any amendment or supplement thereto, at the time each was filed with the Commission, complied in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus delivered to the Underwriters for use in connection with the offering and the Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.

The documents incorporated or deemed to be incorporated by reference in the Registration Statement, any preliminary prospectus and the Prospectus, when they became effective or at the time they were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements of the 1934 Act and the 1934 Act Regulations.

The Registration Statement, any preliminary prospectus and the Prospectus, and the filing of the Registration Statement, any preliminary prospectus and the Prospectus with the Commission have been duly authorized by and on behalf of the Company, and the Registration Statement has been duly executed pursuant to such authorization.

(ii)    Accurate Disclosure. Neither the Registration Statement nor any amendment thereto, at its effective time, at the Closing Time or at any Date of Delivery, contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. As of the Applicable Time, none of (A) the General Disclosure Package, (B) any individual Issuer Limited Use Free Writing Prospectus, when considered together with the General Disclosure Package, nor (C) any individual Written Testing-the-Waters Communication, when considered together with the General Disclosure Package, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. Neither the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of any filing with the Commission pursuant to Rule 424(b), at the Closing Time or at any Date of Delivery, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The documents incorporated or deemed to be incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus, at the time the Registration Statement became effective or when such documents incorporated by reference were filed with the Commission, as the case may be, when read together with the other information in the Registration Statement, the General Disclosure Package or the Prospectus, as the case may be, did not and will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.

The representations and warranties in this subsection shall not apply to statements in or omissions from the Registration Statement (or any amendment thereto), the General Disclosure Package or the Prospectus (or any amendment or supplement thereto, including any prospectus wrapper) made in reliance upon and in conformity with written information furnished to the Company by any Underwriter through the Representatives expressly for use therein. For purposes of this Agreement, the only information so furnished shall be the information in the first sentence of the fifth paragraph under the caption “Underwriting” in the Prospectus concerning the terms of

 

4


the offering by the Underwriters, and the second sentence of the twelfth paragraph under the caption “Underwriting” in the Prospectus concerning stabilization by the Underwriters (collectively, the “Underwriter Information”).

(iii)    Issuer Free Writing Prospectuses. No Issuer Free Writing Prospectus conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including any document incorporated by reference therein, and any preliminary or other prospectus deemed to be a part thereof that has not been superseded or modified. No filing of any “road show” (as defined in Rule 433(h)) is required in connection with the offering of the Securities. Any Issuer Free Writing Prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the 1933 Act and the 1933 Act Regulations. Each Issuer Free Writing Prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the 1933 Act or that was prepared by or behalf of or used or referred to by the Company complies or will comply in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Except for the Issuer Free Writing Prospectuses, if any, identified in Schedule B-2 hereto, and electronic road shows, if any, each furnished to the Representatives before first use, the Company has not prepared, used or referred to, and will not, without the prior consent of the Representatives, prepare, use or refer to, any issuer free writing prospectus. Any offer that is a written communication relating to the Securities made prior to the initial filing of the Registration Statement by the Company or any person acting on its behalf (within the meaning, for this paragraph only, of Rule 163(c) of the 1933 Act Regulations) has been filed with the Commission in accordance with the exemption provided by Rule 163 under the 1933 Act Regulations (“Rule 163”) and otherwise complied with the requirements of Rule 163, including without limitation the legending requirement, to qualify such offer for the exemption from Section 5(c) of the 1933 Act provided by Rule 163.

(iv)    Well-Known Seasoned Issuer. (A) At the original effectiveness of the Registration Statement, (B) at the time of the most recent amendment thereto for the purposes of complying with Section 10(a)(3) of the 1933 Act (whether such amendment was by post-effective amendment, incorporated report filed pursuant to Section 13 or 15(d) of the 1934 Act or form of prospectus), (C) at the time the Company or any person acting on its behalf (within the meaning, for this clause only, of Rule 163(c) under the 1933 Act) made any offer relating to the Securities in reliance on the exemption of Rule 163 under the 1933 Act, and (D) as of the Applicable Time, the Company was and is a “well-known seasoned issuer” (as defined in Rule 405).

(v)     Testing-the-Waters Materials. The Company (A) has not engaged in any Testing-the-Waters Communication other than Testing-the-Waters Communications with the consent of the Representatives with entities that are qualified institutional buyers within the meaning of Rule 144A under the 1933 Act or institutions that are accredited investors within the meaning of Rule 501 under the 1933 Act and (B) has not authorized anyone other than the Representatives to engage in Testing-the-Waters Communications. The Company reconfirms that the Representatives have been authorized to act on its behalf in undertaking Testing-the-Waters Communications. The Company has not distributed any Written Testing-the-Waters Communications other than those listed on Schedule B-3 hereto.

(vi)    Company Not Ineligible Issuer. At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or another offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) of the 1933 Act Regulations) of the Securities and at the date hereof, the Company was not and is not an “ineligible issuer,” as defined in Rule 405, without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an ineligible issuer.

 

5


(vii)    [Reserved.]

(viii)    Independent Accountants. The accountants who certified the financial statements and supporting schedules included in the Registration Statement, the General Disclosure Package and the Prospectus are independent public accountants as required by the 1933 Act, the 1933 Act Regulations, the 1934 Act, the 1934 Act Regulations and the Public Company Accounting Oversight Board (United States).

(ix)    Financial Statements; Non-GAAP Financial Measures. The financial statements included or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus, together with the related schedules and notes, comply as to form in all material respects with Regulation S-X under the 1933 Act and present fairly, in all material respects, the financial position of the Company and its consolidated Subsidiaries (as defined below) at the dates indicated and the statement of operations, stockholders’ equity and cash flows of the Company and its consolidated Subsidiaries for the periods specified; said financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) applied on a consistent basis throughout the periods involved. The supporting schedules, if any, present fairly, in all material respects, in accordance with GAAP the information required to be stated therein. The summary financial information included in the Registration Statement, the General Disclosure Package and the Prospectus present fairly, in all material respects, the information shown therein and have been compiled on a basis consistent with that of the audited financial statements included therein. Except as included therein, no historical or pro forma financial statements or supporting schedules are required to be included or incorporated by reference in the Registration Statement, the General Disclosure Package or the Prospectus under the 1933 Act or the 1933 Act Regulations. All disclosures contained in the Registration Statement, the General Disclosure Package or the Prospectus, or incorporated by reference therein, regarding “non-GAAP financial measures” (as such term is defined by the rules and regulations of the Commission) comply with Regulation G of the 1934 Act, and Item 10 of Regulation S-K, to the extent applicable. The interactive data in eXtensible Business Reporting Language incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and guidelines applicable thereto.

(x)    Compliance with the Sarbanes-Oxley Act of 2002. There is and has been no failure on the part of the Company or any of the Company’s directors or officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith, including Section 402 related to loans and Sections 302 and 906 related to certifications.

(xi)    No Material Adverse Change in Business. Except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, since the date of the latest audited financial statements included or incorporated by reference in the General Disclosure Package, (A) there has been no material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its Subsidiaries (as defined below) considered as one enterprise, whether or not arising in the ordinary course of business (a “Material Adverse Effect”), (B) there have been no transactions entered into by the Company or any of its Subsidiaries, other than those in the ordinary course of business, which are material with respect to the Company and its Subsidiaries considered as one enterprise, (C) there

 

6


have been no material liabilities or obligations, direct or contingent, entered into by the Company or any of its Subsidiaries and (D) there has been no dividend or distribution of any kind declared, paid or made by the Company on any class of its capital stock.

(xii)    Good Standing of the Company. The Company has been duly organized and is validly existing as a corporation in good standing under the laws of the State of Delaware and has corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and to enter into and perform its obligations under this Agreement; and the Company is duly qualified as a foreign corporation to transact business and is in good standing in each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified or to be in good standing would not result in a Material Adverse Effect.

(xiii)    Good Standing of the Company’s Subsidiaries. Each subsidiary of the Company, as defined in Rule 405 under the Securities Act (each, a “Subsidiary” and, collectively, the “Subsidiaries”) has been duly organized and is validly existing in good standing under the laws of the jurisdiction of its incorporation or organization, has corporate or similar power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and is duly qualified to transact business and is in good standing (where such concept exists) in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified or to be in good standing would not result in a Material Adverse Effect. Except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, all of the issued and outstanding capital stock of each Subsidiary has been duly authorized and validly issued, is fully paid and non-assessable and is owned by the Company, directly or through Subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance, claim or equity. None of the outstanding shares of capital stock of any Subsidiary was issued in violation of the preemptive or similar rights of any securityholder of such Subsidiary. The only significant Subsidiaries of the Company are the entities listed on Exhibit 21 to the Company’s annual report on Form 10-K for the year ended December 31, 2020.

(xiv)    Authorization of Agreement. This Agreement has been duly authorized, executed and delivered by the Company.

(xv)    Authorization and Description of Securities. The Securities to be purchased by the Underwriters from the Company have been duly authorized for issuance and sale to the Underwriters pursuant to this Agreement and, when issued and delivered by the Company pursuant to this Agreement against payment of the consideration set forth herein, will be validly issued and fully paid and non-assessable; and the issuance of the Securities is not subject to the preemptive or other similar rights of any securityholder of the Company. The Pre-Funded Warrants have been duly authorized by the Company and, when executed and delivered by the Company in accordance with this Agreement, will constitute valid and legally binding agreements of the Company enforceable against the Company in accordance with their terms, except as enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting creditors’ rights generally or by equitable principles relating to enforceability. The Warrant Shares have been duly authorized and validly reserved for issuance upon exercise of the Pre-Funded Warrants in a number sufficient to meet the current exercise requirements. The Warrant Shares, when issued and delivered upon exercise of the Pre-Funded Warrants in accordance therewith, will be validly issued, fully paid and non-assessable, and the issuance of the Warrant Shares is not subject to any preemptive or other

 

7


similar rights to subscribe for or purchase the Warrant Shares. The Common Stock and Pre-Funded Warrants conform to all statements relating thereto contained in the Registration Statement, the General Disclosure Package and the Prospectus and such description conforms to the rights set forth in the instruments defining the same.

(xvi)    Registration Rights. There are no persons with registration rights or other similar rights to have any securities registered for sale pursuant to the Registration Statement or otherwise registered for sale or sold by the Company under the 1933 Act pursuant to this Agreement, other than those rights that have been disclosed in the Registration Statement, the General Disclosure Package and the Prospectus and have been waived.

(xvii)    Absence of Violations, Defaults and Conflicts. Neither the Company nor any Subsidiary is (A) in violation of its charter, by-laws or similar organizational document, (B) in default in the performance or observance of any obligation, agreement, covenant or condition contained in any contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement or instrument to which the Company or any Subsidiary is a party or by which either of them may be bound or to which any of the properties or assets of the Company or any Subsidiary is subject (collectively, “Agreements and Instruments”), except for such defaults that would not, singly or in the aggregate, result in a Material Adverse Effect, or (C) in violation of any law, statute, rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental body, regulatory body, administrative agency or other authority, body or agency having jurisdiction over the Company or its Subsidiaries or any of their respective properties, assets or operations (each, a “Governmental Entity”), except for such violations that would not, singly or in the aggregate, result in a Material Adverse Effect. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated herein and in the Registration Statement, the General Disclosure Package and the Prospectus (including the issuance and sale of the Securities and the Warrant Shares and the use of the proceeds from the sale of the Securities as described therein under the caption “Use of Proceeds”) and compliance by the Company with its obligations hereunder have been duly authorized by all necessary corporate action and do not and will not, whether with or without the giving of notice or passage of time or both, conflict with or constitute a breach of, or default or Repayment Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any properties or assets of the Company or its Subsidiaries pursuant to, the Agreements and Instruments (except for such conflicts, breaches, defaults or Repayment Events or liens, charges or encumbrances that would not, singly or in the aggregate, result in a Material Adverse Effect), nor will such action result in any violation of the provisions of the charter, by-laws or similar organizational document of the Company or its Subsidiaries or any law, statute, rule, regulation, judgment, order, writ or decree of any Governmental Entity. As used herein, a “Repayment Event” means any event or condition which gives the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or its Subsidiaries.

(xviii)    Listing. The Securities have been approved for listing on the Nasdaq Global Select Market, subject to notice of issuance.

(xix)    Absence of Labor Dispute. No labor dispute with the employees of the Company or its Subsidiaries exists or, to the knowledge of the Company, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or its Subsidiaries’ principal suppliers, manufacturers, customers or contractors, which, in either case, would result in a Material Adverse Effect.

 

8


(xx)    Absence of Proceedings. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, there is no action, suit, proceeding, inquiry or investigation before or brought by any Governmental Entity (including, without limitation, any action, suit proceeding, inquiry or investigation before or brought by the U.S. Food and Drug Administration (the “FDA”) or the European Medicines Agency (the “EMA”)) now pending or, to the knowledge of the Company, threatened, against or affecting the Company or its Subsidiaries, which would reasonably be expected to result in a Material Adverse Effect, or which would reasonably be expected to materially and adversely affect their respective properties or assets or the consummation of the transactions contemplated in this Agreement or the performance by the Company of its obligations hereunder; and the aggregate of all pending legal or governmental proceedings to which the Company or any such Subsidiary is a party or of which any of their respective properties or assets is the subject which are not described in the Registration Statement, the General Disclosure Package and the Prospectus, including ordinary routine litigation incidental to the business, would not reasonably be expected to result in a Material Adverse Effect.

(xxi)    Accuracy of Exhibits. There are no contracts or documents which are required to be described in the Registration Statement, the General Disclosure Package or the Prospectus or to be filed as exhibits to the Registration Statement which have not been so described and filed as required.

(xxii)    Absence of Further Requirements. No filing with, or authorization, approval, consent, license, order, registration, qualification or decree of, any Governmental Entity is necessary or required for the performance by the Company of its obligations hereunder, in connection with the offering, issuance or sale of the Securities hereunder or the consummation of the transactions contemplated by this Agreement, except such as have been already obtained or as may be required under the 1933 Act, the 1933 Act Regulations, the rules of the Nasdaq Stock Market LLC, state securities laws or the rules of the Financial Industry Regulatory Authority, Inc. (“FINRA”).

(xxiii)    Possession of Licenses and Permits. The Company and its Subsidiaries possess such permits, licenses, approvals, consents and other authorizations (collectively, “Governmental Licenses”) issued by the appropriate Governmental Entities necessary to conduct the business now operated by them (including, without limitation, all such permits, licenses, approvals, consents and other authorizations required by the FDA, the EMA, or any other federal, state, local or foreign agencies or bodies engaged in the regulation of clinical or preclinical studies, pharmaceuticals, biologics, biohazardous substances or activities related to the business now operated by the Company and its Subsidiaries), except where the failure so to possess would not, singly or in the aggregate, result in a Material Adverse Effect. The Company and its Subsidiaries are in compliance with the terms and conditions of all Governmental Licenses, except where the failure so to comply would not, singly or in the aggregate, result in a Material Adverse Effect. The Company has fulfilled and performed all of its material obligations with respect to the Governmental Licenses and, to the knowledge of the Company, no event has occurred which allows, or after notice or lapse of time would allow, revocation or termination thereof or results in any other material impairment of the rights of the Company as a holder of any permit, except where the failure to so fulfill or perform, or the occurrence of such event, would not, singly or in the aggregate, result in a Material Adverse Effect. All of the Governmental Licenses are valid and in full force and effect, except where the invalidity of such Governmental Licenses or the failure of such Governmental Licenses to be in full force and effect would not, singly or in the aggregate, result in a Material Adverse Effect. Neither the Company nor its Subsidiaries has received any notice of proceedings relating to the revocation or modification of any Governmental Licenses which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Effect.

 

9


(xxiv)    Title to Property. The Company and its Subsidiaries have good and marketable title to all real property owned by them and good title to all other properties owned by them, in each case, free and clear of all mortgages, pledges, liens, security interests, claims, restrictions or encumbrances of any kind except such as (A) are described in the Registration Statement, the General Disclosure Package and the Prospectus or (B) do not, singly or in the aggregate, materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company or its Subsidiaries; and all of the leases and subleases material to the business of the Company and its Subsidiaries, considered as one enterprise, and under which the Company or its Subsidiaries holds properties described in the Registration Statement, the General Disclosure Package or the Prospectus, are in full force and effect, and neither the Company nor any such Subsidiary has any notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company or any Subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company or such Subsidiary to the continued possession of the leased or subleased premises under any such lease or sublease.

(xxv)    Title to Intellectual Property. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, and as would not, individually or in the aggregate, result in a Material Adverse Effect, the Company and its Subsidiaries own or possess adequate rights or can acquire on reasonable terms sufficient licensed rights to use all inventions, patent applications, patents, trademarks, trade names, service names, domain names, copyrights, trade secrets, know-how and other intellectual property (collectively, “Intellectual Property”) as are (i) necessary or material for the conduct of their respective businesses as currently conducted or as currently proposed to be conducted and as described in the Registration Statement, the General Disclosure Package and the Prospectus and (ii) necessary or material for the commercialization of the products described in the Registration Statement, the General Disclosure Package and the Prospectus as being under development. There is no pending or, to the Company’s knowledge, threatened (i) action, suit, proceeding, or claim by others challenging the rights of the Company or any of its Subsidiaries in or to any such Intellectual Property that, if decided adversely to the Company or such Subsidiary would, individually or in the aggregate, have a Material Adverse Effect, and the Company is unaware of any facts which would form a reasonable basis for any such claim; (ii) action, suit, proceeding, or claim by others that the Company or any of its Subsidiaries infringes, misappropriates, or otherwise violates any Intellectual Property of others that, if decided adversely to the Company or such Subsidiary would, individually or in the aggregate, have a Material Adverse Effect, and the Company is unaware of any facts which would form a reasonable basis for any such claim; or (iii) action, suit, proceeding, or claim by others challenging the validity, scope, or enforceability of any such Intellectual Property owned or licensed by the Company or its Subsidiaries and the Company is unaware of any facts which would form a reasonable basis for any such claim. To the Company’s knowledge, the operation of the business of the Company and its Subsidiaries as now conducted, and as described in the Registration Statement, the General Disclosure Package and the Prospectus, and in connection with the development and commercialization of the products described in the Registration Statement, the General Disclosure Package and the Prospectus does not infringe, misappropriate, conflict with or otherwise violate any claim of any patent or published patent application of any other person or entity. There is no prior art of which the Company or any of its Subsidiaries is aware that may render any patent owned or licensed by the Company or its Subsidiaries, and material to the Company or its Subsidiaries operations, invalid or any patent application owned or licensed by the Company or its Subsidiaries unpatentable which has not been disclosed to the applicable government patent office. The

 

10


Company’s granted or issued patents, registered trademarks and registered copyrights have been duly maintained and are in full force and effect, and none of the patents, trademarks and copyrights have been adjudged invalid or unenforceable in whole or in part. The Company knows of no infringement, misappropriation or violation by others of any Intellectual Property owned or licensed by the Company or its Subsidiaries which would reasonably be expected to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries is a party to or bound by any options, licenses or agreements with respect to the Intellectual Property of any other person or entity that are required to be set forth in the Registration Statement, the General Disclosure Package and the Prospectus and that are not described therein in all material respects. The Company and its Subsidiaries have taken all reasonable steps necessary to secure their interests in the Intellectual Property of the Company and its Subsidiaries from their employees and contractors and to protect the confidentiality of all of their confidential information and trade secrets. None of the technology or intellectual property used by the Company and its Subsidiaries in its business has been obtained or is being used by the Company or its Subsidiaries in violation of any contractual obligation binding on the Company or its Subsidiaries, or, to the Company’s knowledge, any of its officers, directors or employees or otherwise in violation of the rights of any persons. No third party has been granted by the Company or its Subsidiaries rights to the Intellectual Property of the Company or its Subsidiaries, including any rights that, if exercised, could enable such party to develop products competitive to those of the Company as described in the Registration Statement, the General Disclosure Package and the Prospectus. All Intellectual Property owned or exclusively licensed by the Company or its Subsidiaries are free and clear of all liens, encumbrances, defects or other restrictions (other than non-exclusive licenses granted in the ordinary course of business), except those that could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. The Company and its Subsidiaries are not subject to any judgment, order, writ, injunction or decree of any court or any federal, state, local, foreign or other governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, or any arbitrator, nor has it entered into or is it a party to any agreement made in settlement of any pending or threatened litigation, which materially restricts or impairs their use of any Intellectual Property.

(xxvi)    Patents and Patent Applications. The Company has duly and properly filed or caused to be filed with the U.S. Patent and Trademark Office (the “USPTO”) and applicable foreign and international patent and trademark authorities all patents, trademarks, copyrights and applications relating to the same owned by the Company and its Subsidiaries (the “Company Patent and Trademark Applications”). To the knowledge of the Company, the Company has complied with the USPTO’s duty of candor and disclosure for the Company Patent and Trademark Applications and has made no material misrepresentation in the Company Patent and Trademark Applications. To the Company’s knowledge, the Company Patent and Trademark Applications disclose patentable subject matter. The Company has not been notified of any inventorship challenges nor has any interference been declared or provoked nor is any material fact known by the Company that would preclude the issuance of patents with respect to the Company Patent and Trademark Applications or would render such patents, if issued, invalid or unenforceable. Except as would not have a Material Adverse Effect, neither the Company nor any of its Subsidiaries has breached and is currently in breach of any provision of any license, contract or other agreement governing the use by the Company or its Subsidiaries of Intellectual Property owned by third parties (collectively, the “Licenses”) and no third party has alleged any such breach and the Company is unaware of any facts that would form a reasonable basis for such a claim. To the Company’s knowledge, no other party to the Licenses has breached or is currently in breach of any provision of the Licenses. Each of the Licenses is in full force and effect and constitutes a valid and binding agreement between the parties thereto, enforceable in accordance with its terms, and there has not occurred any breach or default under any such Licenses or any event that, with the giving of notice or lapse of time, would constitute a breach or default thereunder. Except as would not have a

 

11


Material Adverse Effect, neither the Company nor any of its Subsidiaries has been and is currently involved in any disputes regarding the Licenses. To the Company’s knowledge, all patents licensed to the Company pursuant to the Licenses are valid, enforceable and being duly maintained. To the Company’s knowledge, all patent applications licensed to the Company pursuant to the Licenses are being duly prosecuted.

(xxvii)    FDA Compliance. The Company and each of its Subsidiaries (i) are and have at all times been in material compliance with all applicable laws, statutes, rules, regulations or guidance applicable to the Company and its Subsidiaries and the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, advertising, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any pharmaceuticals or biohazardous substances, materials or any other products developed, manufactured or distributed by the Company (including, without limitation, from the United States Food and Drug Administration (“FDA”), European Medicines Agency (“EMA”) and any local or other Governmental Entities performing functions similar to those performed by the FDA or EMA) (collectively, “Applicable Laws”), except as could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect, (ii) have not received any notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the FDA or any other federal, state or foreign governmental authority having authority over the Company, any of its Subsidiaries or their activities alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (collectively, the “Authorizations”), (iii) have made all filings with, the appropriate local, or other governmental or regulatory agencies or bodies that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as described in the Registration Statement and the Prospectus, except where any failures to possess or make the same would not, singularly or in the aggregate, have a Material Adverse Effect, (iv) possess all material Authorizations necessary to conduct their respective businesses as described in the Registration Statement and the Prospectus, and such Authorizations are valid and in full force and effect and are not in violation of any material term of any such Authorizations, (v) have filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct in all material respects on the date filed (or were corrected or supplemented by a subsequent submission), and (vi) are not a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders or similar agreements with or imposed by any governmental authority. All Authorizations are valid and in full force and effect, except where the validity or failure to be in full force and effect would not, singularly or in the aggregate, have a Material Adverse Effect. Neither the Company nor any Subsidiary has received notification of any revocation, modification, suspension, termination or invalidation (or proceedings related thereto) of any such Authorization and the Company has no reason to believe that any such Authorization will not be renewed. Neither the Company, any of its Subsidiaries nor, to the Company’s knowledge, any of their respective directors, officers, employees or agents has been convicted of any crime under any Applicable Laws or has been the subject of an FDA debarment proceeding. Neither the Company nor any of its Subsidiaries has been nor is now subject to the FDA’s Application Integrity Policy. To the Company’s knowledge, neither the Company, any of its Subsidiaries nor any of its directors, officers, employees or agents has made, or caused the making of, any false statements on, or material omissions from, any other records or documentation prepared or maintained to comply with the requirements of the FDA or any other governmental authority.

 

12


(xxviii)    Compliance with Health Care Laws. The Company has operated and currently is in compliance with all applicable health care laws, rules and regulations (except where such failure to operate or non-compliance would not, singly or in the aggregate, result in a Material Adverse Effect), including, without limitation, (i) the Federal, Food, Drug and Cosmetic Act (21 U.S.C. §§ 301 et seq.); (ii) all applicable federal, state, local and all applicable foreign healthcare related fraud and abuse laws, including, without limitation, the federal Anti-kickback Statute (42 U.S.C. § 1320a-7b(b)), the U.S. Physician Payments Sunshine Act (42 U.S.C. § 1320a-7h), the civil False Claims Act (31 U.S.C. §§ 3729 et seq.), the criminal False Claims Law (42 U.S.C. § 1320a-7b(a)), all criminal laws relating to healthcare fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287, the healthcare fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) (42 U.S.C. Section 1320d et seq.), the exclusion laws (42 U.S.C. § 1320a-7), and the civil monetary penalties law (42 U.S.C. § 1320a-7a); (iii) HIPAA, as amended by the Health Information Technology for Economic Clinical Health Act (42 U.S.C. Section 17921 et seq.); (iv) the regulations promulgated pursuant to such laws; and (v) any other similar local, state, federal, or foreign laws (collectively, the “Health Care Laws”). Neither the Company, nor to the Company’s knowledge, any of its officers, directors, employees or agents have engaged in activities which are, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or any other state or federal healthcare program. The Company has not received written notice or other correspondence of any claim, action, suit, audit, survey, proceeding, hearing, enforcement, investigation, arbitration or other action (“Action”) from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of any Health Care Laws, and, to the Company’s knowledge, no such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action is threatened. The Company is not a party to and does not have any ongoing reporting obligations pursuant to any corporate integrity agreement, deferred prosecution agreement, monitoring agreement, consent decree, settlement order, plan of correction or similar agreement imposed by any governmental or regulatory authority. Additionally, neither the Company, nor to the Company’s knowledge, any of its employees, officers or directors, has been excluded, suspended or debarred from participation in any U.S. state or federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.

(xxix)    Environmental Laws. Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect: (i) neither the Company nor any of its Subsidiaries is in violation of any United States federal, state or local, or any foreign, statute, law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the emissions, discharges, release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products (collectively, “Hazardous Materials”) or otherwise related to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, “Environmental Laws”), which violation includes, but is not limited to, noncompliance with any permits or other governmental authorizations required for the operation of the business of the Company or any of its Subsidiaries under applicable Environmental Laws, or noncompliance with the terms and conditions thereof, nor has the Company or any of its Subsidiaries received any written communication, whether from a governmental authority, citizens group, employee or otherwise, that alleges that the Company or any of its Subsidiaries is in violation of any Environmental Law; (ii) the Company and its Subsidiaries have all material permits,

 

13


authorizations and approvals required under any applicable Environmental Laws and are in compliance with their requirements; (iii) there are no pending or, to the Company’s knowledge, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any of its Subsidiaries, or any investigation with respect to which the Company or any of its Subsidiaries has received written notice or any written notice by any person or entity alleging potential liability for investigatory costs, cleanup costs, governmental responses costs, natural resources damages, property damages, personal injuries, attorneys’ fees or penalties arising out of, based on or resulting from the presence, or release into the environment, of any Hazardous Materials at any location owned, leased or operated by the Company or any of its Subsidiaries, now or in the past; and (iv) to the Company’s knowledge, there are no past or present actions, activities, events, conditions, incidents or circumstances that might reasonably be expected to result in a violation of any Environmental Law or form the basis of an order for clean-up or remediation, or an action, suit, investigation or proceeding by any private party or governmental body or agency, against or affecting the Company or any of its Subsidiaries relating to Hazardous Materials or any Environmental Laws.

(xxx)    Accounting Controls and Disclosure Controls. The Company and each of its Subsidiaries maintain effective internal control over financial reporting (as defined under Rule 13-a15 and 15d-15 under the rules and regulations of the Commission under the 1934 Act Regulations) and a system of internal accounting controls sufficient to provide reasonable assurances that (A) transactions are executed in accordance with management’s general or specific authorization; (B) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (C) access to assets is permitted only in accordance with management’s general or specific authorization; (D) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (E) the interactive data in eXtensible Business Reporting Language incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the Commission’s rules and guidelines applicable thereto. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, since the end of the Company’s most recent audited fiscal year, there has been (1) no material weakness in the Company’s internal control over financial reporting (whether or not remediated) and (2) no change in the Company’s internal control over financial reporting that has materially adversely affected, or is reasonably likely to materially adversely affect, the Company’s internal control over financial reporting. The Company and each of its Subsidiaries maintain an effective system of disclosure controls and procedures (as defined in Rule 13a-15 and Rule 15d-15 under the 1934 Act Regulations) that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and is accumulated and communicated to the Company’s management, including its principal executive officer or officers and principal financial officer or officers, as appropriate, to allow timely decisions regarding disclosure.

(xxxi)    Tests and Preclinical and Clinical Trials. The research, non-clinical and pre-clinical studies and clinical trials and tests conducted or being conducted by or on behalf of the Company or any of its Subsidiaries or in which any of their respective product candidates have participated and, to the Company’s knowledge, the preclinical studies and clinical trials directed or sponsored by the Company’s collaborators (collectively, the “Studies”) that are described in, or the results of which are referred to in, the Registration Statement, General Disclosure Package and the Prospectus were and, if still pending, are being conducted with reasonable care and in all material

 

14


respects in accordance with the protocols, procedures and controls pursuant to all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder, and with standard medical and scientific research procedures; each description of the results of such Studies is accurate and complete in all material respects and fairly presents the data derived from such Studies, and the Company and its Subsidiaries have no knowledge of any other research, non-clinical studies or tests the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, General Disclosure Package and the Prospectus; the Company and its Subsidiaries have made all such filings and obtained all such approvals as may be required by the EMA, the FDA or any committee thereof or from any other United States or foreign government agency with jurisdiction over the types of products being developed by the Company; neither the Company nor any of its Subsidiaries has received any notice of, or correspondence from, any governmental authority requiring the termination, suspension or material modification of any Study; and the Company and its Subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of all governmental authorities. There have been no material serious adverse events resulting from any Study. To the Company’s knowledge, the manufacturing facilities and operations of its suppliers are operated in compliance in all material respects with all Authorizations and Applicable Laws.

(xxxii)    Payment of Taxes. All United States federal income tax returns of the Company and its Subsidiaries required by law to be filed have been filed and all taxes shown by such returns or otherwise assessed, which are due and payable, have been paid, except assessments against which appeals have been or will be promptly taken and as to which adequate reserves have been provided in conformity with GAAP. The United States federal income tax returns of the Company have been settled and no assessment in connection therewith has been made against the Company, except assessments that are being contested in good faith and as to which adequate reserves have been established by the Company. The Company and its Subsidiaries have filed all other tax returns that are required to have been filed by them pursuant to applicable foreign, state, local or other law except insofar as the failure to file such returns would not result in a Material Adverse Effect, and have paid all taxes due pursuant to such returns or pursuant to any assessment received by the Company and its Subsidiaries, except for such taxes, if any, as are being contested in good faith and as to which adequate reserves have been established by the Company. The charges, accruals and reserves on the books of the Company in respect of any income and corporation tax liability for any years not finally determined are, in conformity with GAAP, adequate to meet any assessments or re-assessments for additional income tax for any years not finally determined, except to the extent of any inadequacy that would not result in a Material Adverse Effect.

(xxxiii)    Insurance. The Company and its Subsidiaries carry or are entitled to the benefits of insurance, with financially sound and reputable insurers, in such amounts and covering such risks as is generally maintained by companies of established repute and comparable size engaged in the same or similar business, and all such insurance is in full force and effect. The Company has no reason to believe that it or its Subsidiaries will not be able (A) to renew its existing insurance coverage as and when such policies expire or (B) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result in a Material Adverse Effect. Neither of the Company nor its Subsidiaries has been denied any insurance coverage which it has sought or for which it has applied.

(xxxiv)    Investment Company Act. The Company is not required, and upon the issuance and sale of the Securities as herein contemplated and the application of the net proceeds therefrom as described in the Registration Statement, the General Disclosure Package and the Prospectus will not be required, to register as an “investment company” under the Investment Company Act of 1940, as amended (the “1940 Act”).

 

15


(xxxv)    Absence of Manipulation. Neither the Company, not any of its Subsidiaries, nor, to the knowledge of the Company, any affiliate of the Company has taken, nor will the Company or any affiliate take, directly or indirectly, any action which is designed, or would reasonably be expected, to cause or result in, or which constitutes, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities or to result in a violation of Regulation M under the 1934 Act.

(xxxvi)    Foreign Corrupt Practices Act. None of the Company, its Subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee, affiliate or other person acting on behalf of the Company or its Subsidiaries is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the “FCPA”), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA and the Company has and, to the knowledge of the Company, its affiliates have conducted their businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.

(xxxvii)     Money Laundering Laws. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the “Money Laundering Laws”); and no action, suit or proceeding by or before any Governmental Entity involving the Company or its Subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

(xxxviii)     OFAC. None of the Company, its Subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee, affiliate or representative of the Company or its Subsidiaries is an individual or entity (“Person”) currently the subject or target of any sanctions administered or enforced by the United States Government, including, without limitation, the U.S. Department of the Treasury’s Office of Foreign Assets Control, the United Nations Security Council, the European Union, Her Majesty’s Treasury, or other relevant sanctions authority (collectively, “Sanctions”), nor is the Company located, organized or resident in a country or territory that is the subject of Sanctions; and the Company will not directly or indirectly use the proceeds of the sale of the Securities, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture partners or other Person, to fund any activities of or business with any Person, or in any country or territory, that, at the time of such funding, is the subject of Sanctions or in any other manner that will result in a violation by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions.

 

16


(xxxix)    Lending Relationship. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company (i) does not have any material lending or other relationship with any banking or lending affiliate of any Underwriter and (ii) does not intend to use any of the proceeds from the sale of the Securities to repay any outstanding debt owed to any affiliate of any Underwriter.

(xl)     Statistical and Market-Related Data. Any statistical and market-related data included in the Registration Statement, the General Disclosure Package or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate and, to the extent required, the Company has obtained the written consent to the use of such data from such sources.

(xli)    [Reserved.]

(xlii)    Privacy and Data Protection. The Company and its Subsidiaries have taken reasonable steps to maintain the confidentiality of its personally identifiable information, protected health information, consumer information and other confidential information of the Company, its Subsidiaries and any third parties in its possession (“Sensitive Company Data”). The tangible or digital information technology systems (including computers, screens, servers, workstations, routers, hubs, switches, networks, data communications lines, technical data and hardware), software and telecommunications systems used or held for use by the Company and its Subsidiaries (the “Company IT Assets”) are adequate and operational for, in accordance with their documentation and functional specifications, the business of the Company and its Subsidiaries as now operated and as currently proposed to be conducted as described in the Registration Statement, General Disclosure Package and the Prospectus. The Company and its Subsidiaries have used reasonable efforts to establish, and have established, commercially reasonable disaster recovery and security plans, procedures and facilities for the business consistent with industry standards and practices in all material respects, including, without limitation, for the Company IT Assets and data held or used by or for the Company and its Subsidiaries, and the Company and its Subsidiaries have been and are in compliance with internal policies and procedures reasonably designed to ensure compliance with the Health Care Laws that govern privacy and data security and take, and have taken, reasonably appropriate steps designed to assure compliance with such policies and procedures. The Company and its Subsidiaries have not suffered or incurred any security breaches, compromises or incidents with respect to any Company IT Asset or Sensitive Company Data; and there has been no unauthorized or illegal use of or access to any Company IT Asset or Sensitive Company Data by any unauthorized third party; in each case, except where such breaches, compromises, incidents, use or access, would not, individually or in the aggregate, be material to the Company or any of its Subsidiaries. The Company and its Subsidiaries have not been required to notify any individual of any information security breach, compromise or incident involving Sensitive Company Data. The Company is presently in material compliance with all applicable laws and contractual obligations relating to the privacy and security of the Company IT Assets and Sensitive Company Data.

(xliii)    No Broker Fees. Except as disclosed in the General Disclosure Package, there are no contracts, agreements or understandings between the Company and any person that would give rise to a valid claim against the Company or any Underwriter for a brokerage commission, finder’s fee or other like payment in connection with the offering of the Securities contemplated hereby.

(xliii) Maintenance of Registration. The Company shall, at all times while the Company is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act and any Pre-Funded Warrants are outstanding, use its best efforts to maintain a registration statement covering the issuance and sale of the Warrant Shares.

 

17


(xliv) Warrant Shares Reserved. The Company shall, at all times while any Pre-Funded Warrants are outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved shares of Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of such Pre-Funded Warrants, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of the then-outstanding Pre-Funded Warrants.

(b)    Officer’s Certificates. Any certificate signed by any officer of the Company or any of its Subsidiaries delivered to the Representatives or to counsel for the Underwriters in connection with the offering, or the purchase and sale, of the Securities, shall be deemed a representation and warranty by the Company to each Underwriter as to the matters covered thereby.

SECTION 2.    Sale and Delivery to Underwriters; Closing.

(a)    Initial Securities and the Pre-Funded Warrants. On the basis of the representations and warranties herein contained and subject to the terms and conditions herein set forth, the Company agrees to sell to each Underwriter, severally and not jointly, and each Underwriter, severally and not jointly, agrees to purchase from the Company, at the price per share set forth in Schedule A, that number of Initial Securities and Pre-Funded Warrants set forth in Schedule A opposite the name of such Underwriter, plus any additional number of Initial Securities and Pre-Funded Warrants which such Underwriter may become obligated to purchase pursuant to the provisions of Section 10 hereof, subject, in each case, to such adjustments among the Underwriters as the Representatives in their sole discretion shall make to eliminate any sales or purchases of fractional shares.

(b)    Option Securities. In addition, on the basis of the representations and warranties herein contained and subject to the terms and conditions herein set forth, the Company hereby grants an option to the Underwriters, severally and not jointly, to purchase up to an additional 1,125,000 shares of Common Stock, at the price per share set forth in Schedule A, less an amount per share equal to any dividends or distributions declared by the Company and payable on the Initial Securities but not payable on the Option Securities. The option hereby granted may be exercised for 30 days after the date hereof and may be exercised in whole or in part at any time and from time to time upon notice by the Representatives to the Company setting forth the number of Option Securities as to which the several Underwriters are then exercising the option and the time and date of payment and delivery for such Option Securities. Any such time and date of delivery (a “Date of Delivery”) shall be determined by the Representatives, but any Date of Delivery after the Closing Time shall not be later than seven full business days nor earlier than two full business days after the exercise of said option, nor in any event prior to the Closing Time. If the option is exercised as to all or any portion of the Option Securities, each of the Underwriters, acting severally and not jointly, will purchase that proportion of the total number of Option Securities then being purchased which the number of Initial Securities set forth in Schedule A opposite the name of such Underwriter bears to the total number of Initial Securities, subject, in each case, to such adjustments as the Representatives in their sole discretion shall make to eliminate any sales or purchases of fractional shares.

(c)    Payment. Payment of the purchase price for, and delivery of certificates or security entitlements for, the Initial Securities and Pre-Funded Warrants, shall be made at the offices of Latham & Watkins LLP, or at such other place as shall be agreed upon by the Representatives and the Company, at 10:00 A.M. (New York City time) on the second (third, if the pricing occurs after 4:30 P.M. (New York City time) on any given day) business day after the date hereof (unless postponed in accordance with the provisions of Section 10), or such other time not later than ten business days after such date as shall be agreed upon by the Representatives and the Company (such time and date of payment and delivery being

 

18


herein called “Closing Time”). Delivery of the Initial Securities at the Closing Time shall be made through the facilities of The Depository Trust Company unless the Representatives shall otherwise instruct. The Pre-Funded Warrants shall be delivered to the Representatives in definitive form, registered in such names and in such denominations as the Representatives shall request in writing not later than the Closing Date. The Pre-Funded Warrants will be made available for inspection by the Representatives on the business day prior to the Closing Time.

In addition, in the event that any or all of the Option Securities are purchased by the Underwriters, payment of the purchase price for, and delivery of certificates or security entitlements for, such Option Securities shall be made at the above-mentioned offices, or at such other place as shall be agreed upon by the Representatives and the Company, on each Date of Delivery as specified in the notice from the Representatives to the Company. Delivery of the Option Securities on each such Date of Delivery shall be made through the facilities of The Depository Trust Company unless the Representatives shall otherwise instruct.

Payment shall be made to the Company by wire transfer of immediately available funds to a bank account designated by the Company, against delivery to the Representatives for the respective accounts of the Underwriters of certificates or security entitlements for the Securities to be purchased by them, which delivery shall be made through the facilities of The Depository Trust Company unless the Representatives shall otherwise instruct. It is understood that each Underwriter has authorized the Representatives, for their accounts, to accept delivery of, receipt for, and make payment of the purchase price for, the Initial Securities, Pre-Funded Warrants and the Option Securities, if any, which it has agreed to purchase. Each of SVB Securities, Cantor and William Blair, individually and not as Representatives of the Underwriters, may (but shall not be obligated to) make payment of the purchase price for the Initial Securities and the Pre-Funded Warrants, or the Option Securities, if any, to be purchased by any Underwriter whose funds have not been received by the Closing Time or the relevant Date of Delivery, as the case may be, but such payment shall not relieve such Underwriter from its obligations hereunder.

SECTION 3.    Covenants of the Company. The Company covenants with each Underwriter as follows:

(a)    Compliance with Securities Regulations and Commission Requests. The Company, subject to Section 3(b), will comply with the requirements of Rule 430B, and will notify the Representatives as soon as practicable, and confirm the notice in writing, (i) when any post-effective amendment to the Registration Statement shall become effective or any amendment or supplement to the Prospectus shall have been filed, (ii) of the receipt of any comments from the Commission, (iii) of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus (including any document incorporated by reference therein) or for additional information, (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment or of any order preventing or suspending the use of any preliminary prospectus or the Prospectus, or of the suspension of the qualification of the Securities for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any of such purposes or of any examination pursuant to Section 8(d) or 8(e) of the 1933 Act concerning the Registration Statement and (v) if the Company becomes the subject of a proceeding under Section 8A of the 1933 Act in connection with the offering of the Securities. The Company will effect all filings required under Rule 424(b), in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and will take such steps as it deems necessary to ascertain promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company will make every reasonable effort to prevent the issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest possible moment. The Company shall pay the required Commission filing

 

19


fees relating to the Securities within the time required by Rule 456(b)(1)(i) under the 1933 Act Regulations without regard to the proviso therein and otherwise in accordance with Rules 456(b) and 457(r) under the 1933 Act Regulations (including, if applicable, by updating the “Calculation of Registration Fee” table in accordance with Rule 456(b)(1)(ii) either in a post-effective amendment to the Registration Statement or in the fee table exhibit of a prospectus filed pursuant to Rule 424(b)).

(b)    Continued Compliance with Securities Laws. The Company will comply with the 1933 Act, the 1933 Act Regulations, the 1934 Act and the 1934 Act Regulations so as to permit the completion of the distribution of the Securities as contemplated in this Agreement and in the Registration Statement, the General Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172 of the 1933 Act Regulations (“Rule 172”), would be) required by the 1933 Act to be delivered in connection with sales of the Securities, any event shall occur or condition shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i) amend the Registration Statement in order that the Registration Statement will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii) amend or supplement the General Disclosure Package or the Prospectus in order that the General Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading in the light of the circumstances existing at the time it is delivered to a purchaser or (iii) amend the Registration Statement or amend or supplement the General Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements of the 1933 Act or the 1933 Act Regulations, the Company will promptly (A) give the Representatives notice of such event, (B) prepare any amendment or supplement as may be necessary to correct such statement or omission or to make the Registration Statement, the General Disclosure Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representatives with copies of any such amendment or supplement and (C) file with the Commission any such amendment or supplement; provided that the Company shall not file or use any such amendment or supplement to which the Representatives or counsel for the Underwriters shall object. The Company will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters may reasonably request. The Company has given the Representatives notice of any filings made pursuant to the 1934 Act or the 1934 Act Regulations within 48 hours prior to the Applicable Time; the Company will give the Representatives notice of its intention to make any such filing from the Applicable Time to the Closing Time and will furnish the Representatives with copies of any such documents a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or use any such document to which the Representatives or counsel for the Underwriters shall reasonably object.

(c)    Delivery of Registration Statement. The Company has furnished or will deliver to the Representatives and counsel for the Underwriters, upon request and without charge, signed copies of the Registration Statement as originally filed and each amendment thereto (including exhibits filed therewith or incorporated by reference therein and documents incorporated or deemed incorporated by reference therein) and signed copies of all consents and certificates of experts, and will also deliver to the Representatives, without charge, a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) for each of the Underwriters. The copies of the Registration Statement and each amendment thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.

(d)    Delivery of Prospectuses. The Company has delivered to each Underwriter, without charge, as many copies of each preliminary prospectus as such Underwriter reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted by the 1933 Act. The Company

 

20


will furnish to each Underwriter, without charge, during the period when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, such number of copies of the Prospectus (as amended or supplemented) as such Underwriter may reasonably request. The Prospectus and any amendments or supplements thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.

(e)    Blue Sky Qualifications. The Company will use its reasonable best efforts, in cooperation with the Underwriters, to qualify the Securities for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Representatives may reasonably designate and to maintain such qualifications in effect so long as required to complete the distribution of the Securities; provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.

(f)    Rule 158. The Company will timely file such reports pursuant to the 1934 Act as are necessary in order to make generally available to its securityholders as soon as practicable an earning statement for the purposes of, and to provide to the Underwriters the benefits contemplated by, the last paragraph of Section 11(a) of the 1933 Act.

(g)    Use of Proceeds. The Company will use the net proceeds received by it from the sale of the Securities in all material respects in the manner specified in the Registration Statement, the General Disclosure Package and the Prospectus under the heading “Use of Proceeds.”

(h)    Listing. The Company will use its best efforts to effect and maintain the listing of the Common Stock (including the Securities) on the Nasdaq Global Select Market.

(i)    Restriction on Sale of Securities. During a period of 90 days from the date of the Prospectus, the Company will not, without the prior written consent of SVB Securities and Cantor, (i) directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or file or confidentially submit any registration statement under the 1933 Act with respect to any of the foregoing, (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Common Stock, whether any such swap or transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise or (iii) publicly announce an intention to effect any such swap, agreement or other transaction described in clauses (i) and (ii). The foregoing sentence shall not apply to (A) the Securities to be sold hereunder; (B) any shares of Common Stock issued by the Company upon the exercise of an option or warrant or the conversion of a convertible security outstanding on the date hereof and referred to in the Registration Statement, the General Disclosure Package and the Prospectus; (C) any shares of Common Stock issued or options to purchase Common Stock granted pursuant to existing employee benefit plans of the Company referred to in the Registration Statement, the General Disclosure Package and the Prospectus; (D) any shares of Common Stock issued pursuant to any existing non-employee director stock plan or dividend reinvestment plan referred to in the Registration Statement, the General Disclosure Package and the Prospectus; (E) the filing by the Company of any registration statement on Form S-8 or a successor form thereto; (F) issuances of Common Stock or securities exercisable for, convertible into or exchangeable for Common Stock in connection with any acquisition, collaboration, merger, licensing or other joint venture or strategic transaction involving the Company; provided that in the case of clause (F), that such issuances shall not be greater than 5% of the total

 

21


outstanding shares of the Company immediately following the initial closing hereunder and the recipients of such shares of Common Stock agree to be bound by a lockup letter in the form executed by directors, officers and certain stockholders pursuant to Section 5(i) hereof; or (G) the issuance of options, restricted stock units or other awards to newly hired employees, including granting inducement grant awards, as permitted by Nasdaq Stock Market Rule 5635.

(j)    Reporting Requirements. The Company, during the period when a Prospectus relating to the Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, will file all documents required to be filed with the Commission pursuant to the 1934 Act within the time periods required by the 1934 Act and 1934 Act Regulations. Additionally, the Company shall report the use of proceeds from the issuance of the Securities as may be required under Rule 463 under the 1933 Act.

(k)    Issuer Free Writing Prospectuses. The Company agrees that, unless it obtains the prior written consent of the Representatives, it will not make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a “free writing prospectus,” or a portion thereof, required to be filed by the Company with the Commission or retained by the Company under Rule 433; provided that the Representatives will be deemed to have consented to the Issuer Free Writing Prospectuses listed on Schedule B-2 hereto and any “road show that is a written communication” within the meaning of Rule 433(d)(8)(i) that has been reviewed by the Representatives. The Company represents that it has treated or agrees that it will treat each such free writing prospectus consented to, or deemed consented to, by the Representatives as an “issuer free writing prospectus,” as defined in Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433 with respect thereto, including timely filing with the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement, any preliminary prospectus or the Prospectus or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.

(l)    Testing-the-Waters Materials. If at any time following the distribution of any Written Testing-the-Waters Communication there occurred or occurs an event or development as a result of which such Written Testing-the-Waters Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such untrue statement or omission.

SECTION 4.    Payment of Expenses.

(a)    Expenses. The Company will pay or cause to be paid all expenses incident to the performance of its obligations under this Agreement, including (i) the preparation, printing and filing of the Registration Statement (including financial statements and exhibits) as originally filed and each amendment thereto, (ii) the preparation, printing and delivery to the Underwriters of copies of each preliminary prospectus, each Issuer Free Writing Prospectus and the Prospectus and any amendments or supplements thereto and any costs associated with electronic delivery of any of the foregoing by the Underwriters to investors, (iii) the preparation, issuance and delivery of the certificates or security entitlements for the Securities to the Underwriters, including any stock or other transfer taxes and any stamp or other duties

 

22


payable upon the sale, issuance or delivery of the Securities to the Underwriters, (iv) the fees and disbursements of the Company’s counsel, accountants and other advisors, (v) the qualification of the Securities under securities laws in accordance with the provisions of Section 3(e) hereof, including filing fees and the reasonable fees and disbursements of counsel for the Underwriters in connection therewith and in connection with the preparation of a “Blue Sky Survey” and any supplement thereto, (vi) the fees and expenses of any transfer agent or registrar for the Securities, (vii) the costs and expenses of the Company relating to investor presentations on any “road show” undertaken in connection with the marketing of the Securities, including without limitation, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations, travel and lodging expenses of the representatives and officers of the Company and any such consultants, and the cost of aircraft and other transportation chartered in connection with the road show, (viii) the filing fees incident to, and the reasonable fees and disbursements of counsel to the Underwriters in connection with, the review by FINRA of the terms of the sale of the Securities, (ix) the fees and expenses incurred in connection with the listing of the Securities on the Nasdaq Global Select Market, and (x) the costs and expenses (including, without limitation, any damages or other amounts payable in connection with legal or contractual liability) associated with the reforming of any contracts for sale of the Securities made by the Underwriters caused by a breach of the representation contained in the third sentence of Section 1(a)(ii); provided, however, that the fees and disbursements of counsel for the Underwriters contemplated by clauses (v) and (viii) above shall not exceed $25,000, in the aggregate. Except as provided in this Section 4, Section 6 or Section 7, the Underwriters shall pay their own expenses, including the fees and disbursements of their counsel.

(b)    Termination of Agreement. If this Agreement is terminated by the Representatives in accordance with the provisions of Section 5, Section 9(a)(i), Section 9(a)(iii) or Section 10 hereof, the Company shall reimburse the Underwriters for all of their reasonably documented out-of-pocket expenses, including the reasonable fees and disbursements of counsel for the Underwriters.

SECTION 5.    Conditions of Underwriters’ Obligations. The obligations of the several Underwriters hereunder are subject to the accuracy of the representations and warranties of the Company contained herein or in certificates of any officer of the Company or any of its Subsidiaries delivered pursuant to the provisions hereof, to the performance by the Company of its covenants and other obligations hereunder, and to the following further conditions:

(a)    Effectiveness of Registration Statement. The Registration Statement has become effective and, at the Closing Time, no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued under the 1933 Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company’s knowledge, contemplated; and the Company has complied with each request (if any) from the Commission for additional information to the reasonable satisfaction of counsel to the Underwriters. The Company shall have paid the required Commission filing fees relating to the Securities within the time period required by Rule 456(b)(1)(i) under the 1933 Act Regulations without regard to the proviso therein and otherwise in accordance with Rules 456(b) and 457(r) under the 1933 Act Regulations and, if applicable, shall have updated the “Calculation of Registration Fee” table in accordance with Rule 456(b)(1)(ii) either in a post-effective amendment to the Registration Statement or in the fee table exhibit of a prospectus filed pursuant to Rule 424(b).

(b)    Opinion of Counsel for Company. At the Closing Time, the Representatives shall have received the opinion and the negative assurance letter, each dated the Closing Time, of Fenwick & West LLP, counsel for the Company, together with the opinion of Fish & Richardson P.C., special counsel for the Company with respect to intellectual property matters, each in form and substance reasonably satisfactory to counsel for the Underwriters, together with signed or reproduced copies of each such letter for each of the other Underwriters.

 

23


(c)    Opinion of Counsel for Underwriters. At the Closing Time, the Representatives shall have received the opinion, and negative assurance letter, each dated the Closing Time, of Latham & Watkins LLP, counsel for the Underwriters, together with signed or reproduced copies of such letters for each of the other Underwriters in form and substance satisfactory to the Representatives. In giving such opinion such counsel may rely, as to all matters governed by the laws of jurisdictions other than the law of the State of New York, the General Corporation Law of the State of Delaware and the federal securities laws of the United States, upon the opinions of counsel satisfactory to the Representatives. Such counsel may also state that, insofar as such opinion involves factual matters, they have relied, to the extent they deem proper, upon certificates of officers and other representatives of the Company and its Subsidiaries and certificates of public officials.

(d)    Officers’ Certificate. At the Closing Time, there shall not have been, since the date hereof or since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its Subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business, and the Representatives shall have received a certificate of the principal executive officer of the Company and of the principal financial officer of the Company, dated the Closing Time, to the effect that (i) there has been no such material adverse change, (ii) the representations and warranties of the Company in this Agreement are true and correct with the same force and effect as though expressly made at and as of the Closing Time, (iii) the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied at or prior to the Closing Time, and (iv) no stop order suspending the effectiveness of the Registration Statement under the 1933 Act has been issued, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to their knowledge, contemplated.

(e)    Accountant’s Comfort Letter. At the time of the execution of this Agreement, the Representatives shall have received from PricewaterhouseCoopers LLP a letter, dated such date, in form and substance satisfactory to the Representatives, together with signed or reproduced copies of such letter for each of the other Underwriters containing statements and information of the type ordinarily included in accountants’ “comfort letters” to underwriters with respect to the financial statements and certain financial information contained in the Registration Statement, the General Disclosure Package and the Prospectus.

(f)    Bring-down Comfort Letter. At the Closing Time, the Representatives shall have received from PricewaterhouseCoopers LLP a letter, dated as of the Closing Time, to the effect that they reaffirm the statements made in the letter furnished pursuant to subsection (e) of this Section, except that the specified date referred to shall be a date not more than three business days prior to the Closing Time.

(g)    Approval of Listing. At the Closing Time, the Securities shall have been approved for listing on the Nasdaq Global Select Market, subject only to official notice of issuance.

(h)    [Reserved.]

(i)    Lock-up Agreements. At the date of this Agreement, the Representatives shall have received an agreement substantially in the form of Exhibit B hereto signed by all of the Company’s directors, officers and certain securityholders, as the case may be.

(j)    [Reserved.]

 

24


(k)    Maintenance of Rating. Neither the Company nor its subsidiaries have any debt securities or preferred stock that are rated by any “nationally recognized statistical rating agency” (as defined in Section 3(a)(62) of the 1934 Act).

(l)    Conditions to Purchase of Option Securities. In the event that the Underwriters exercise their option provided in Section 2(b) hereof to purchase all or any portion of the Option Securities, the representations and warranties of the Company contained herein and the statements in any certificates furnished by the Company and any of its Subsidiaries hereunder shall be true and correct as of each Date of Delivery and, at the relevant Date of Delivery, the Representatives shall have received:

(i)    Officers’ Certificate. A certificate, dated such Date of Delivery, of the principal executive officer of the Company and of the principal financial officer of the Company confirming that the certificate delivered at the Closing Time pursuant to Section 5(d) hereof remains true and correct as of such Date of Delivery.

(ii)    Opinion of Counsel for Company. If requested by the Representatives, the opinion, and negative assurance letter, of Fenwick & West LLP, counsel for the Company, together with the opinion of Fish & Richardson P.C., special counsel for the Company with respect to intellectual property matters, each in form and substance satisfactory to counsel for the Underwriters, dated such Date of Delivery, relating to the Option Securities to be purchased on such Date of Delivery and otherwise to the same effect as the opinions and negative assurance letter required by Section 5(b) hereof.

(iii)    Opinion of Counsel for Underwriters. If requested by the Representatives, the opinion, and negative assurance letter, of Latham & Watkins LLP counsel for the Underwriters, dated such Date of Delivery, relating to the Option Securities to be purchased on such Date of Delivery and otherwise to the same effect as the opinion and negative assurance letter required by Section 5(c) hereof.

(iv)    Bring-down Comfort Letter. If requested by the Representatives, a letter from PricewaterhouseCoopers LLP, in form and substance satisfactory to the Representatives and dated such Date of Delivery, substantially in the same form and substance as the letter furnished to the Representatives pursuant to subsection (f) of this Section, except that the “specified date” in the letter furnished pursuant to this paragraph shall be a date not more than three business days prior to such Date of Delivery.

(v)    [Reserved.]

(m)    Additional Documents. At the Closing Time and at each Date of Delivery (if any), counsel for the Underwriters shall have been furnished with such other documents and opinions as they may reasonably require for the purpose of enabling them to pass upon the issuance and sale of the Securities as herein contemplated, or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Securities as herein contemplated shall be reasonably satisfactory in form and substance to the Representatives and counsel for the Underwriters.

(n)    Termination of Agreement. If any condition specified in this Section shall not have been fulfilled when and as required to be fulfilled, this Agreement, or, in the case of any condition to the purchase of Option Securities on a Date of Delivery which is after the Closing Time, the obligations of the several Underwriters to purchase the relevant Option Securities, may be terminated by the Representatives by notice to the Company at any time at or prior to Closing Time or such Date of Delivery, as the case may

 

25


be, and such termination shall be without liability of any party to any other party except as provided in Section 4 and except that Sections 1, 4, 6, 7, 8, 14, 15 and 16 shall survive any such termination and remain in full force and effect.

SECTION 6.    Indemnification.

(a)    Indemnification of Underwriters. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates (as such term is defined in Rule 501(b) under the 1933 Act (each, an “Affiliate”)), its selling agents and each person, if any, who controls any Underwriter within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act as follows:

(i)    against any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant to Rule 430B, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading or arising out of any untrue statement or alleged untrue statement of a material fact included (A) in any preliminary prospectus, any Issuer Free Writing Prospectus, any Written Testing-the-Waters Communication, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto), or (B) in any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Securities (“Marketing Materials”), including any roadshow or investor presentations made to investors by the Company (whether in person or electronically), or the omission or alleged omission in any preliminary prospectus, any Issuer Free Writing Prospectus, any Written Testing-the-Waters Communication, the General Disclosure Package, the Prospectus (or any amendment or supplement thereto) or in any Marketing Materials of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;

(ii)    against any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the extent of the aggregate amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; provided that (subject to Section 6(d) below) any such settlement is effected with the written consent of the Company;

(iii)    against any and all expense whatsoever, as incurred (including the fees and disbursements of counsel chosen by the Representatives), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission, to the extent that any such expense is not paid under (i) or (ii) above;

provided, however, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue statement or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the Underwriter Information.

(b)    Indemnification of Company, Directors and Officers. Each Underwriter severally agrees to indemnify and hold harmless the Company, its directors, each of its officers who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section 15 of the

 

26


1933 Act or Section 20 of the 1934 Act, against any and all loss, liability, claim, damage and expense described in the indemnity contained in subsection (a) of this Section, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the Underwriter Information.

(c)    Actions against Parties; Notification. Each indemnified party shall give notice as promptly as reasonably practicable to each indemnifying party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying party shall not relieve such indemnifying party from any liability hereunder to the extent it is not materially prejudiced as a result thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity agreement. In the case of parties indemnified pursuant to Section 6(a) above, counsel to the indemnified parties shall be selected by the Representatives, and, in the case of parties indemnified pursuant to Section 6(b) above, counsel to the indemnified parties shall be selected by the Company. An indemnifying party may participate at its own expense in the defense of any such action; provided, however, that counsel to the indemnifying party shall not (except with the consent of the indemnified party) also be counsel to the indemnified party. In no event shall the indemnifying parties be liable for the reasonable fees and expenses of more than one counsel (in addition to any local counsel) separate from their own counsel for all indemnified parties in connection with any one action or separate but similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances. No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect to any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever in respect of which indemnification or contribution could be sought under this Section 6 or Section 7 hereof (whether or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent (i) includes an unconditional release of each indemnified party from all liability arising out of such litigation, investigation, proceeding or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.

(d)    Settlement without Consent if Failure to Reimburse. If at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by Section 6(a)(ii) effected without its written consent if (i) such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request, (ii) such indemnifying party shall have received notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (iii) such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.

SECTION 7.    Contribution. If the indemnification provided for in Section 6 hereof is for any reason unavailable to or insufficient to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and expenses incurred by such indemnified party, as incurred, (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Securities pursuant to this Agreement or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company, on the one hand, and of the Underwriters, on the other hand, in connection with the statements or omissions which resulted in such losses, liabilities, claims, damages or expenses, as well as any other relevant equitable considerations.

 

27


The relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Securities pursuant to this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering of the Securities pursuant to this Agreement (before deducting expenses) received by the Company, on the one hand, and the total underwriting discount received by the Underwriters, on the other hand, in each case as set forth on the cover of the Prospectus, bear to the aggregate initial public offering price of the Securities as set forth on the cover of the Prospectus.

The relative fault of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.

The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section 7 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to above in this Section 7. The aggregate amount of losses, liabilities, claims, damages and expenses incurred by an indemnified party and referred to above in this Section 7 shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement or omission or alleged omission.

Notwithstanding the provisions of this Section 7, no Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions received by such Underwriter in connection with the Securities underwritten by it and distributed to the public.

No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.

For purposes of this Section 7, each person, if any, who controls an Underwriter within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act and each Underwriter’s Affiliates and selling agents shall have the same rights to contribution as such Underwriter, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act shall have the same rights to contribution as the Company. The Underwriters’ respective obligations to contribute pursuant to this Section 7 are several in proportion to the number of Initial Securities and Pre-Funded Warrants set forth opposite their respective names in Schedule A hereto and not joint.

SECTION 8.    Representations, Warranties and Agreements to Survive. All representations, warranties and agreements contained in this Agreement or in certificates of officers of the Company or any of its Subsidiaries submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i) any investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter, its officers or directors or any person controlling the Company and (ii) delivery of and payment for the Securities.

 

28


SECTION 9.    Termination of Agreement.

(a)    Termination. The Representatives may terminate this Agreement, by notice to the Company, at any time at or prior to the Closing Time (i) if there has been, in the judgment of the Representatives, since the time of execution of this Agreement or since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its Subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business, or (ii) if there has occurred any material adverse change in the financial markets in the United States or the international financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change or development involving a prospective change in U.S. or international political, financial or economic conditions, in each case the effect of which is such as to make it, in the judgment of the Representatives, impracticable or inadvisable to proceed with the completion of the offering or to enforce contracts for the sale of the Securities, or (iii) if trading in any securities of the Company has been suspended or materially limited by the Commission or the Nasdaq Global Select Market, or (iv) if trading generally on the NYSE MKT or the New York Stock Exchange or in the Nasdaq Global Market has been suspended or materially limited, or minimum or maximum prices for trading have been fixed, or maximum ranges for prices have been required, by any of said exchanges or by order of the Commission, FINRA or any other governmental authority, or (v) a material disruption has occurred in commercial banking or securities settlement or clearance services in the United States or with respect to Clearstream or Euroclear systems in Europe, or (vi) if a banking moratorium has been declared by either Federal or New York authorities.

(b)    Liabilities. If this Agreement is terminated pursuant to this Section, such termination shall be without liability of any party to any other party except as provided in Section 4 hereof, and provided further that Sections 1, 4, 6, 7, 8, 15, 16 and 17 shall survive such termination and remain in full force and effect.

SECTION 10.    Default by One or More of the Underwriters. If one or more of the Underwriters shall fail at the Closing Time or a Date of Delivery to purchase the Securities which it or they are obligated to purchase under this Agreement (the “Defaulted Securities”), the Representatives shall have the right, within 24 hours thereafter, to make arrangements for one or more of the non-defaulting Underwriters, or any other underwriters, to purchase all, but not less than all, of the Defaulted Securities in such amounts as may be agreed upon and upon the terms herein set forth; if, however, the Representatives shall not have completed such arrangements within such 24-hour period, then:

(i)    if the number of Defaulted Securities does not exceed 10% of the number of Securities to be purchased on such date, each of the non-defaulting Underwriters shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions that their respective underwriting obligations hereunder bear to the underwriting obligations of all non-defaulting Underwriters, or

(ii)    if the number of Defaulted Securities exceeds 10% of the number of Securities to be purchased on such date, this Agreement or, with respect to any Date of Delivery which occurs after the Closing Time, the obligation of the Underwriters to purchase, and the Company to sell, the Option Securities to be purchased and sold on such Date of Delivery shall terminate without liability on the part of any non-defaulting Underwriter.

No action taken pursuant to this Section shall relieve any defaulting Underwriter from liability in respect of its default.

 

29


In the event of any such default which does not result in a termination of this Agreement or, in the case of a Date of Delivery which is after the Closing Time, which does not result in a termination of the obligation of the Underwriters to purchase and the Company to sell the relevant Option Securities, as the case may be, either the (i) Representatives or (ii) the Company shall have the right to postpone Closing Time or the relevant Date of Delivery, as the case may be, for a period not exceeding seven days in order to effect any required changes in the Registration Statement, the General Disclosure Package or the Prospectus or in any other documents or arrangements. As used herein, the term “Underwriter” includes any person substituted for an Underwriter under this Section 10.

SECTION 11.    Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted by any standard form of telecommunication. Notices to the Underwriters shall be directed to SVB Securities at 1301 Avenue of the Americas, 12th Floor, New York, New York, 10019, attention of Stuart R. Nayman, to Cantor at Attn: General Counsel, 499 Park Avenue, New York, New York, 10022 and to William Blair at 150 North Riverside Plaza, Chicago, IL 60606.

SECTION 12.    No Advisory or Fiduciary Relationship. The Company acknowledges and agrees that (a) the purchase and sale of the Securities pursuant to this Agreement, including the determination of the public offering price of the Securities and any related discounts and commissions, is an arm’s-length commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b) in connection with the offering of the Securities and the process leading thereto, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company, any of its Subsidiaries or their respective stockholders, creditors, employees or any other party, (c) no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering of the Securities or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company or any of its Subsidiaries on other matters) and no Underwriter has any obligation to the Company with respect to the offering of the Securities except the obligations expressly set forth in this Agreement, (d) the Underwriters and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company and (e) the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering of the Securities and the Company has consulted its own respective legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.

SECTION 13.    Recognition of the U.S. Special Resolution Regimes. In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.

In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.

For purposes of this Agreement, (A) “BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k); (B) “Covered Entity” means any of the following: (i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b); (ii) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (iii) a “covered FSI” as that term is defined in, and interpreted in accordance with,

 

30


12 C.F.R. § 382.2(b); (C) “Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable; and (D) “U.S. Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.

SECTION 14.    Parties. This Agreement shall each inure to the benefit of and be binding upon the Underwriters and the Company and their respective successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or corporation, other than the Underwriters and the Company and their respective successors and the controlling persons and officers and directors referred to in Sections 6 and 7 and their heirs and legal representatives, any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision herein contained. This Agreement and all conditions and provisions hereof are intended to be for the sole and exclusive benefit of the Underwriters and the Company and their respective successors, and said controlling persons and officers and directors and their heirs and legal representatives, and for the benefit of no other person, firm or corporation. No purchaser of Securities from any Underwriter shall be deemed to be a successor by reason merely of such purchase.

SECTION 15.    Waiver of Trial by Jury. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates) and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.

SECTION 16.    GOVERNING LAW. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS.

SECTION 17.    Consent to Jurisdiction; Waiver of Immunity. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby shall be instituted in (i) the federal courts of the United States of America located in the City and County of New York, Borough of Manhattan or (ii) the courts of the State of New York located in the City and County of New York, Borough of Manhattan (collectively, the “Specified Courts”), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court, as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party’s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.

SECTION 18.    TIME. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME.

SECTION 19.    Partial Unenforceability. The invalidity or unenforceability of any Section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other Section, paragraph or provision hereof. If any Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.

 

31


SECTION 20.    Counterparts. This Agreement may be executed in any number of counterparts (which may include counterparts delivered by any standard form of telecommunication), each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same agreement. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

SECTION 21.    Effect of Headings. The Section headings herein are for convenience only and shall not affect the construction hereof.

SECTION 22.    Entire Agreement. This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company and the Underwriters, or any of them, with respect to the subject matter hereof.

[SIGNATURE PAGES FOLLOW]

 

32


If the foregoing is in accordance with your understanding of our agreement, please sign and return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts, will become a binding agreement among the Underwriters and the Company in accordance with its terms.

 

Very truly yours,
CHINOOK THERAPEUTICS, INC.
By:  

/s/ Eric Dobmeier

  Name: Eric Dobmeier
  Title: President and Chief Executive Officer

 

CONFIRMED AND ACCEPTED
  As of the date first above written:
SVB SECURITIES LLC
By:  

/s/ Murphy Gallagher

  Name: Murphy Gallagher
  Title: Senior Managing Director

 

CANTOR FITZGERALD & CO.
By:  

/s/ Sage Kelly

  Name: Sage Kelly
  Title: Global Head of Investment Banking

 

WILLIAM BLAIR & COMPANY, L.L.C.
By:  

/s/ Steve Maletzky

  Name: Steve Maletzky
  Title: Managing Director

For themselves and as Representatives of the other Underwriters named in Schedule A hereto.

[SIGNATURE PAGE TO UNDERWRITING AGREEMENT]


SCHEDULE A

The public offering price per share for the Securities shall be: (i) $14.00 in respect of the shares of Common Stock and (ii) $13.9999 in respect of the Pre-Funded Warrants.

The purchase price per share for the Securities to be paid by the several Underwriters shall be: (i) 13.16 in respect of the shares of Common Stock, being an amount equal to the public offering price set forth above less $0.84 per share and (ii) $13.1599 in respect of the Pre-Funded Warrants, being an amount equal to the public offering price set forth above less $0.84 per share underlying the Pre-Funded Warrant, in each case, subject to adjustment in accordance with Section 2(b) for dividends or distributions declared by the Company and payable on the Initial Securities and Pre-Funded Warrants but not payable on the Option Securities.

 

Name of Underwriter    Number of
Initial Securities
     Number of
Pre-Funded Warrants
 

SVB Securities LLC

     2,892,857        482,143  

Cantor Fitzgerald & Co.

     1,767,857        294,643  

William Blair & Company, L.L.C.

     1,285,715        214,285  

Wedbush Securities Inc.

     482,143        80,357  
  

 

 

    

 

 

 

Total

     6,428,572        1,071,428  
  

 

 

    

 

 

 


SCHEDULE B-1

Pricing Terms

1.    The Company is selling 6,428,572 shares of Common Stock.

2.    The Company is selling 1,071,428 Pre-Funded Warrants.

3.    The Company has granted an option to the Underwriters, severally and not jointly, to purchase up to an additional 1,125,000 shares of Common Stock.

3.    The public offering price per share for the Securities shall be: (i) $14.00 in respect of the shares of Common Stock and (ii) $13.9999 in respect of the Pre-Funded Warrants.


SCHEDULE B-2

Free Writing Prospectuses

None


SCHEDULE B-3

List of Written Testing-the-Waters Communications

None

EX-4.1 3 d535079dex41.htm EX-4.1 EX-4.1

Exhibit 4.1

CHINOOK THERAPEUTICS, INC.

FORM OF WARRANT TO PURCHASE COMMON STOCK

Number of Shares: [    ]

(subject to adjustment)

 

Warrant No. [    ]

   Original Issue Date: [    ], 2022

Chinook Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [    ] or its registered assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company up to a total of [    ] shares of common stock, $0.0001 par value per share (the “Common Stock”), of the Company (each such share, a “Warrant Share” and all such shares, the “Warrant Shares”) at an exercise price per share equal to $0.0001 per share (as adjusted from time to time as provided in Section 9 herein, the “Exercise Price”) upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”) at any time and from time to time on or after the date hereof (the “Original Issue Date”), subject to the following terms and conditions:

1. Definitions. For purposes of this Warrant, the following terms shall have the following meanings:

(a) “Affiliate” means any Person directly or indirectly controlled by, controlling or under common control with, a Holder, as such terms are used in and construed under Rule 405 under the Securities Act, but only for so long as such control shall continue.

(b) “Commission” means the United States Securities and Exchange Commission.

(c) “Closing Sale Price” means, for any security as of any date, the last trade price for such security on the Principal Trading Market for such security, as reported by Bloomberg L.P., or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate the last trade price, then the last trade price of such security prior to 4:00 P.M., New York City time, as reported by Bloomberg L.P., or if the security is not listed for trading on a national securities exchange or other trading market on the relevant date, the last quoted bid price for the security in the over-the-counter market on the relevant date as reported by OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices). If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then the Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of Directors’ determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.

(d) “Principal Trading Market” means the national securities exchange or other trading market on which the Common Stock is primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Market.

(e) “Registration Statement” means the Company’s Registration Statement on Form S-3ASR (File No. 333-265168), which became automatically effective on May 24, 2022.

(f) “Securities Act” means the Securities Act of 1933, as amended.

(g) “Trading Day” means any weekday on which the Principal Trading Market is open for trading. If the Common Stock is not listed or admitted for trading, “Trading Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in New York City are authorized or required by law or other governmental action to close.

(h) “Transfer Agent” means Computershare Trust Company, N.A., the Company’s transfer agent and registrar for the Common Stock, and any successor appointed in such capacity.

2. Issuance of Securities; Registration of Warrants. The Warrant, as initially issued by the Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant to the Registration Statement or an exchange meeting the requirements of Section 3(a)(9) of the Exchange Act as in effect on the Original Issue Date, the Warrant Shares are not “restricted securities” under


Rule 144 promulgated under the Securities Act. The Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

3. Registration of Transfers. Subject to compliance with all applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a “New Warrant”) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company’s own expense any New Warrant under this Section 3. Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any notice to the contrary.

4. Exercise and Duration of Warrants.

(a) All or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by this Warrant at any time and from time to time on or after the Original Issue Date.

(b) The Holder may exercise this Warrant by delivering to the Company (i) an exercise notice, in the form attached as Schedule 1 hereto (the “Exercise Notice”), completed and duly signed, and (ii) payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised (which may take the form of a “cashless exercise” if so indicated in the Exercise Notice pursuant to Section 10 below). The date on which such exercise notice is delivered to the Company (as determined in accordance with the notice provisions hereof) is an “Exercise Date.” The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

5. Delivery of Warrant Shares.

(a) Upon exercise of this Warrant, the Company shall promptly (but in no event later than three (3) Trading Days after the Exercise Date), upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder’s or its designee’s balance account with The Depository Trust Company (“DTC”) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in the Fast Automated Securities Transfer Program (the “FAST Program”) or if the certificates are required to bear a legend regarding restriction on transferability, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. The Holder, or any natural person or legal entity (each, a “Person”) so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder’s DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be.

(b) To the extent permitted by law, the Company’s obligations to issue and deliver Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in Section 11 below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Nothing herein shall limit the Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

2


6. Charges, Taxes and Expenses. Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; provided, however, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.

7. Replacement of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company’s obligation to issue the New Warrant.

8. Reservation of Warrant Shares. The Company covenants that it will, at all times while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and non-assessable. The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. The Company further covenants that it will not, without the prior written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding.

9. Certain Adjustments. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this Section 9.

(a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital stock issued and outstanding on the Original Issue Date and in accordance with the terms of such stock on the Original Issue Date or as amended, as described in the Registration Statement, that is payable in shares of Common Stock, (ii) subdivides its outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii) combines its outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv) issues by reclassification of shares of capital stock any additional shares of Common Stock of the Company, then in each such case the Exercise Price shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately before such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, provided, however, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Exercise Price shall be recomputed accordingly as of the close of business on such record date and thereafter the Exercise Price shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the effective date of such subdivision or combination.

(b) Pro Rata Distributions. If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Stock covered by the preceding paragraph) or (iii) rights or warrants to subscribe for or purchase any security, or (iv) cash or any other asset (in each case, a “Distribution”), other than a reclassification as to which Section 9(c) applies, then in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the ownership limitation set forth in Section 11(a) hereof) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for the participation in such Distribution; provided, however, to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the ownership limitation set forth in Section 11(a) hereof, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until the earlier of (i) such time, if ever, as the delivery to such Holder of such portion would not result in the Holder exceeding the ownership limitation set forth in Section 11(a) hereof and (ii) such time as the Holder has exercised this Warrant.

 

3


(c) Fundamental Transactions. If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation of the Company with or into another Person, in which the Company is not the surviving entity and in which the stockholders of the Company immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the voting power of the surviving entity immediately after such merger or consolidation, (ii) the Company effects any sale to another Person of all or substantially all of its assets in one transaction or a series of related transactions, (iii) pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital stock of the Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv) the Company consummates a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or (v) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by Section 9(a) above) (in any such case, a “Fundamental Transaction”), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations on exercise contained herein (the “Alternate Consideration”). The Company shall not effect any Fundamental Transaction in which the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i) the Alternate Consideration is solely cash and the Company provides for the simultaneous “cashless exercise” of this Warrant pursuant to Section 10 below or (ii) prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph (c) shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type.

(d) Number of Warrant Shares. Simultaneously with any adjustment to the Exercise Price pursuant to Section 9 (including any adjustment to the Exercise Price that would have been effected but for the final sentence in this paragraph (d)), the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the par value of the Common Stock then in effect.

(e) Calculations. All calculations under this Section 9 shall be made to the nearest one-hundredth of one cent or the nearest share, as applicable.

(f) Notice of Adjustments. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company’s transfer agent.

(g) Notice of Corporate Events. If, while this Warrant is outstanding, the Company (i) declares a dividend or any other distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such transaction at least ten (10) days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by Section 9(c), other than a Fundamental Transaction under clause (iii) of Section 9(c), the Company shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10) days prior to the date such Fundamental Transaction is consummated. Holder agrees to maintain any information disclosed pursuant to this Section 9(g) in confidence until such information is publicly available, and shall comply with applicable law with respect to trading in the Company’s securities following receipt of any such information.

 

4


10. Payment of Cashless Exercise Price. Notwithstanding anything contained herein to the contrary, the Holder may, in its sole discretion, satisfy its obligation to pay the Exercise Price through a “cashless exercise,” in which event the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section 3(a)(9) of the Securities Act as determined as follows:

X = Y [(A-B)/A]

where:

“X” equals the number of Warrant Shares to be issued to the Holder;

“Y” equals the total number of Warrant Shares with respect to which this Warrant is then being exercised;

“A” equals the Closing Sale Price per share of Common Stock as of the Trading Day on the date immediately preceding the Exercise Date; and

“B” equals the Exercise Price per Warrant Share then in effect on the Exercise Date.

For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in such a “cashless exercise” transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued (provided that the Commission continues to take the position that such treatment is proper at the time of such exercise). In the event that the Registration Statement or another registration statement registering the issuance of Warrant shares is, for any reason, not effective at the time of exercise of this Warrant, then the Warrant may only be exercised through a cashless exercise, as set forth in this Section 10.

In no event will the exercise of this Warrant be settled in cash.

11. Limitations on Exercise.

(a) Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not be entitled to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving effect or immediately prior to such exercise, would cause (i) the aggregate number of shares of Common Stock beneficially owned by the Holder, its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act to exceed 4.99% (the “Maximum Percentage”) of the total number of issued and outstanding shares of Common Stock of the Company following such exercise, or (ii) the combined voting power of the securities of the Company beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act to exceed 4.99% of the combined voting power of all of the securities of the Company then outstanding following such exercise. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company’s most recent Form 10-Q or Form 10-K, as the case may be, filed with the Commission prior to the date hereof, (y) a more recent public announcement by the Company or (z) any other notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three (3) Trading Days confirm in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage, not in excess of 19.99%, specified in such notice; provided that any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to the Company. For purposes of this Section 11(a), the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act shall include the shares of Common Stock issuable upon the exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (x) exercise of the remaining unexercised and non-cancelled portion of this Warrant by the Holder and (y) exercise or conversion of the unexercised, non-converted or non-cancelled portion of any other securities of the Company that do not have voting power (including without limitation any securities of the Company which would entitle the holder thereof to acquire at any time Common Stock, including without limitation any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock), is subject to a limitation

 

5


on conversion or exercise analogous to the limitation contained herein and is beneficially owned by the Holder or any of its Affiliates and other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act.

(b) This Section 11 shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in Section 9(c) of this Warrant.

12. No Fractional Shares. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number.

13. Notices. Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via facsimile or confirmed e-mail prior to 5:30 P.M., New York City time, on a Trading Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile or confirmed e-mail on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or (iv) upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery. The addresses, facsimile numbers and e-mail addresses for such communications shall be:

If to the Company:

Chinook Therapeutics, Inc.

Attention: Chief Financial Officer

400 Fairview Ave North, 9th Floor

Seattle, WA 98102

Telephone: (206) 485-7051

Email: legal@chinooktx.com

If to the Holder, to its address, facsimile number or e-mail address set forth herein or on the books and records of the Company.

Or, in each of the above instances, to such other address, facsimile number or e-mail address as the recipient party has specified by written notice given to each other party at least five (5) days prior to the effectiveness of such change.

14. Warrant Agent. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10) days’ notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder’s last address as shown on the Warrant Register.

15. Miscellaneous.

(a) No Rights as a Stockholder. The Holder, solely in such Person’s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person’s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.

(b) Authorized Shares. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the

 

6


taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (a) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (b) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Warrant, and (c) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant.

(c) Successors and Assigns. Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns.

(d) Amendment and Waiver. Except as otherwise provided herein, the provisions of the Warrants may be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder.

(e) Acceptance. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein.

(f) Governing Law; Jurisdiction. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.

(g) Headings. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.

(h) Severability. In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

7


IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.

 

CHINOOK THERAPEUTICS, INC.
By:  

     

  Name:
  Title:


SCHEDULE 1

FORM OF EXERCISE NOTICE

[To be executed by the Holder to purchase shares of Common Stock under the Warrant]

Ladies and Gentlemen:

(1) The undersigned is the Holder of Warrant No.         (the “Warrant”) issued by Chinook Therapeutics, Inc., a Delaware corporation (the “Company”). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant.

(2) The undersigned hereby exercises its right to purchase                  Warrant Shares pursuant to the Warrant.

(3) The Holder intends that payment of the Exercise Price shall be made as (check one):

 

 

Cash Exercise

 

 

“Cashless Exercise” under Section 10 of the Warrant

(4) If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $                 in immediately available funds to the Company in accordance with the terms of the Warrant.

(5) Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the Warrant. The Warrant Shares shall be delivered to the following DWAC Account Number:

 

                                 

(6) By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 11(a) of the Warrant to which this notice relates.

 

Dated:

 

                                 

Name of Holder:

 

                                 

By:

 

                                 

Name:

 

                                 

Title:

 

                                 

(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)

EX-5.1 4 d535079dex51.htm EX-5.1 EX-5.1

Exhibit 5.1

 

LOGO

May 25, 2022

Chinook Therapeutics, Inc.

400 Fairview Avenue, Suite 900

Seattle, WA 98109

Ladies and Gentlemen:

We deliver this opinion with respect to certain matters in connection with the offering by Chinook Therapeutics, Inc., a Delaware corporation (the “Company”), of up to 7,553,572 shares of the Company’s Common Stock, par value $0.0001 per share (the “Shares”), including 1,125,000 shares of Common Stock subject to an underwriters’ option to purchase additional shares, and pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 1,071,428 shares of Common Stock (such shares issuable upon exercise of the Pre-Funded Warrants, the “Pre-Funded Warrant Shares”), to be issued pursuant to that certain Underwriting Agreement (the “Underwriting Agreement”), dated as of May 24, 2022, between the Company, and SVB Leerink LLC Cantor Fitzgerald & Co. and William Blair & Company, L.L.C., as representatives of the several underwriters named in Schedule A thereto. The Shares, Pre-Funded Warrants and Pre-Funded Warrant Shares were registered pursuant to the Registration Statement on Form S-3ASR (File No. 333-265168) filed by the Company with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”) on May 24, 2022 and automatically became effective upon such filing (the “Registration Statement”), including the prospectus dated May 24, 2022 included in the Registration Statement (the “Base Prospectus”), as supplemented by the final prospectus supplement dated May 24, 2022, which was filed with the Commission pursuant to Rule 424(b) under the Securities Act (the “Prospectus Supplement” and, together with the Base Prospectus, the “Prospectus”). The offering of the Shares, Pre-Funded Warrants and Pre-Funded Warrant Shares by the Company pursuant to the Registration Statement, the Prospectus and the Underwriting Agreement is referred to herein as the “Offering.”

In connection with our opinion expressed below we have examined originals or copies of the underwriting agreement pursuant to which the Stock will be sold to the underwriters, the Pre-Funded Warrants, the Registration Statement, the Company’s certificate of incorporation, as amended (the “Certificate”) and the Company’s bylaws, as amended (the “Bylaws”), certain minutes and consents of the Company’s board of directors (the “Board”) or a committee or committees thereof and the Company’s stockholders relating to the Registration Statement, the Certificate and Bylaws, and such other agreements, documents, certificates and statements of the Company, its transfer agent and public or government officials, as we have deemed advisable, and have examined such questions of law as we have considered necessary. In giving our opinion, we have also relied upon a good standing certificate regarding the Company issued by the Delaware Secretary of State and a management certificate addressed to us and dated of even date herewith executed by the Company containing certain factual representations by the Company.

In our examination of documents for purposes of this opinion, we have assumed, and express no opinion as to, the genuineness of all signatures on original documents, the authenticity and completeness of all documents submitted to us as originals, the conformity to originals and completeness of all documents submitted to us as copies, the legal capacity of all persons or entities executing the same (other than the Company), the lack of any undisclosed termination, modification, waiver or amendment to any document reviewed by us, the absence of any other extrinsic agreements or documents that might change or affect the interpretation or terms of documents we have reviewed, and the due authorization, execution and delivery of all such documents where due authorization, execution and delivery are prerequisites to the effectiveness thereof.


Page 2

 

We render this opinion only with respect to, and express no opinion herein concerning the application or effect of the laws of any jurisdiction other than, the existing Delaware General Corporation Law.

With respect to the Pre-Funded Warrants, we have assumed that, as of each and every time any of the Pre-Funded Warrants are exercised, the Company will have a sufficient number of authorized and unissued shares of the Common Stock available for issuance under its Certificate to permit full exercise of each of the Pre-Funded Warrants in accordance with their terms without the breach or violation of any other agreement, commitment or obligation of the Company.

In connection with our opinions expressed below, we have assumed that, (i) at or prior to the time of the issuance and delivery of any of the Shares, the Pre-Funded Warrants and the Pre-Funded Warrant Shares, there will not have occurred any change in the law or the facts affecting the validity of the Shares, the Pre-Funded Warrants and the Pre-Funded Warrant Shares, any change in actions of the Board or the Company’s stockholders, or any amendments to the Certificate or Bylaws, and (ii) at the time of the offer, issuance and sale of any Shares, the Pre-Funded Warrants and the Pre-Funded Warrant Shares, no stop order suspending the Registration Statement’s effectiveness will have been issued and remain in effect, and that the Registration Statement will not have been modified or rescinded. We also have assumed that the issuance and delivery of the Shares, the Pre-Funded Warrants and the Pre-Funded Warrant Shares subsequent to the date hereof and the compliance by the Company with the terms of such Shares, the Pre-Funded Warrants and the Pre-Funded Warrant Shares will not result in a violation of the Certificate or any provision of any instrument or agreement then binding upon the Company or any restriction imposed by any court or governmental body then having jurisdiction over the Company.

Based upon the foregoing, we are of the opinion that:

 

  (i)

the Shares, when issued, sold and delivered in accordance with the provisions of, the Underwriting Agreement and in the manner and for the consideration stated in the Registration Statement and the Prospectus, will be validly issued, fully paid and non-assessable in accordance with the resolutions adopted by the Company’s Board and the Pricing Committee of the Board;

 

  (ii)

when the Pre-Funded Warrants are issued, sold and delivered in the manner and for the consideration stated in the Registration Statement, and the Prospectus, such Pre-Funded Warrants will be valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other laws of general applicability relating to or affecting creditors’ rights and to general equity principles, and in accordance with the resolutions adopted by the Company’s Board and the Pricing Committee of the Board; and

 

  (iii)

the Pre-Funded Warrant Shares, when issued and delivered by the Company upon exercise of the Warrants in accordance with the terms thereof, will be validly issued, fully paid and non-assessable.

We consent to the use of this opinion as an exhibit to the Current Report on Form 8-K to be filed by the Company with the Commission in connection with the offering of the Shares, the Pre-Funded Warrants and the Pre-Funded Warrant Shares and further consent to all references to us, if any, in the Registration Statement, the Prospectus constituting a part thereof and any amendments thereto. We do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.


Page 3

 

This opinion is intended solely for use in connection with issuance and sale of the Shares, the Pre-Funded Warrants and the Pre-Funded Warrant Shares subject to the Registration Statement and is not to be relied upon for any other purpose. This opinion is rendered as of the date first written above and is based solely on our understanding of facts in existence as of such date after the aforementioned examination. In rendering the opinions above, we are opining only as to the specific legal issues expressly set forth therein, and no opinion shall be inferred as to any other matter or matters. We assume no obligation to advise you of any fact, circumstance, event or change in the law or the facts that may hereafter be brought to our attention whether or not such occurrence would affect or modify any of the opinions expressed herein.

 

Very truly yours,
/s/ Fenwick & West LLP
FENWICK & WEST LLP
EX-99.1 5 d535079dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Chinook Therapeutics Announces Pricing of a $105 Million Public Offering

SEATTLE, May 24, 2022 – Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its underwritten public offering of 6,428,572 shares of its common stock at a price to the public of $14.00 per share. In addition, and in lieu of common stock, Chinook is offering to certain investors pre-funded warrants to purchase up to an aggregate of 1,071,428 shares of common stock at a purchase price of $13.9999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The gross proceeds to Chinook from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Chinook, are expected to be $105 million. Chinook has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock in connection with the public offering. The offering is expected to close on or about May 27, 2022, subject to the satisfaction of customary closing conditions. All of the securities are being offered by Chinook.

SVB Securities, Cantor and William Blair are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.

Chinook intends to use the net proceeds from this offering to continue its phase 3 ALIGN and phase 2 AFFINITY trials of atrasentan, fund a phase 3 clinical trial of BION-1301, continue development of CHK-336 and prepare for the potential commercial launch of atrasentan. The remainder of the net proceeds, if any, will be used for general corporate purposes.

The public offering is being made pursuant to a shelf registration statement (File No. 333-265168) on Form S-3ASR that was filed by Chinook with the Securities and Exchange Commission (“SEC”) on May 24, 2022, which became automatically effective upon filing with the SEC. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC and is available on the SEC’s website at www.sec.gov. A copy of the final prospectus supplement relating to the offering, when available, may be obtained from: SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbsecurities.com; Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 4th Floor, New York, NY 10022, by email at prospectus@cantor.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at prospectus@williamblair.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Chinook, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney


disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 healthy volunteer trial. In addition, Chinook is advancing research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding the satisfaction of customary closing conditions related to the offering and sale of its securities, the expected gross proceeds and timing of completion of the offering, the expected use of proceeds and anticipated preclinical and clinical development activities, clinical trials and announcements of clinical results and potential benefits of Chinook’s product candidates, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks identified in Chinook’s filings with the SEC, the prospectus related to the offering, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect Chinook’s results of operations, which would, in turn, have a significant and adverse impact on Chinook’s stock price. Chinook cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Chinook undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.

Contact:

Chinook Therapeutics

Noopur Liffick

Vice President, Investor Relations & Corporate Communications

investors@chinooktx.com

media@chinooktx.com

EX-101.SCH 6 kdny-20220524.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 7 kdny-20220524_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 8 kdny-20220524_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 9 g535079g0524093930449.jpg GRAPHIC begin 644 g535079g0524093930449.jpg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g535079snap11.jpg GRAPHIC begin 644 g535079snap11.jpg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end XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
May 24, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001435049
Document Type 8-K
Document Period End Date May 24, 2022
Entity Registrant Name CHINOOK THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-37345
Entity Tax Identification Number 94-3348934
Entity Address, Address Line One 400 Fairview Avenue North
Entity Address, Address Line Two Suite 900
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98109
City Area Code (206)
Local Phone Number 485-7241
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 Par Value Per Share
Trading Symbol KDNY
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 12 d535079d8k_htm.xml IDEA: XBRL DOCUMENT 0001435049 2022-05-24 2022-05-24 false 0001435049 8-K 2022-05-24 CHINOOK THERAPEUTICS, INC. DE 001-37345 94-3348934 400 Fairview Avenue North Suite 900 Seattle WA 98109 (206) 485-7241 false false false false Common Stock, $0.0001 Par Value Per Share KDNY NASDAQ false EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d535079d8k.htm d535079dex11.htm d535079dex41.htm d535079dex51.htm d535079dex991.htm kdny-20220524.xsd kdny-20220524_lab.xml kdny-20220524_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d535079d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d535079d8k.htm" ] }, "labelLink": { "local": [ "kdny-20220524_lab.xml" ] }, "presentationLink": { "local": [ "kdny-20220524_pre.xml" ] }, "schema": { "local": [ "kdny-20220524.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "kdny", "nsuri": "http://www.chinooktx.com/20220524", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d535079d8k.htm", "contextRef": "duration_2022-05-24_to_2022-05-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d535079d8k.htm", "contextRef": "duration_2022-05-24_to_2022-05-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.chinooktx.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 19 0001193125-22-159696-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-159696-xbrl.zip M4$L#!!0 ( "*!N53V6QO:'18 &-\ . 9#4S-3 W.60X:RYH=&WM M/6ESV[:VWSO3_X!1EW%FM%&2-]GQ'4>1$[TXMJ_E-+WO2PD- MWA;BJ%\Z*+!_G?SXP_$P@H;0V%--1\BWA6$4!:EJE6JIYT\W_/B4=IE/!Z7:1+LYD1A M!?M5H%$)6HE0VDF_B2N]VURW<9TZ68>'AQ5ZFS2]US*=H%:MUBOXNL>52)K? M.MXTU]P>2L_W;Z-)V?9'N(1:=;?62 %1=<>BA$O24]%W+/3 M2>(H7 K2807>)@VE\ALU:W\%_*9%VF&RK*T%;3U8K?C]W?7YK'FTN/VL:24* MN:?Z?CCB$? -CK1;JM9*M;W,("7@BMQ "9>L&^<@PPPXN5RUU#DLXEMGCCM- MX[V*?FF:+N<4Y/0"L;S@#OZ-9.2*DX/2I^.*_@C?C43$&8Y0$G_&\NYMH>5[ MD?"BT@VP9X'9^NEM(1*3J$(CL@KVJYA!&6/'/=^9GAP[\HZI:.J*MP5'JL#E M4Q0!43AAQW+2Q.8B-)^EXPA/?X8F%YK_F<='V%?(YNE(> [\'YVY?&" F$37 MH@^OXY!P_ =R:ZFZ6ZHU_HC\S%/AI,]=)8XKN<'O32:=MX6/!,>WX4^2/ZIN>' M 'KRC15,F/)=Z;"?JO1?X>37GZR]ZM%Q)5@V47W]1+4'3Y09M@&#L/L+8'T@ M34G)OT33.DB?^WPDW6GS1HZ$8A=BS*[]$?>.Z-U8P]WS7>=H 7F^7'1NVN]9 M]^;TIMU=#D[UF<#IMEM?KCLWG7:7G5Z\9^W?6Q]/+SZT6>OR\^=.M]NYO/@F M&&N/ >-7KL#<&42^5V3ORZTR ^6(8IV#:V[2=9R99XAU$K60,_<>Q)GE*C3+ M,^>1EM*:]^W:,-D+&4-E\(R8C M*+\#OW+"DW#"H\@N:)?K]L4-NVY?75[?O+PNN8I#%7,O8I'/NL)&9F-6G?DA MLW9WG#\B]@6"G=L3@M758;RR'\]DHBQ8-@G,M M C^,V$[R+#A8-$)%3-Q!2Q;2:^&\::Y7"%=D%K6UM;2M9F#:BWM; ,^OZ< M(^@^=/AT"A )KW#RF4]9K5%DV.=5A3R'"JDU'H/1EK*-]NRNQ4 J=..C"WBS M]7[2^MBYN+S\Q&X^MJ]/K]I?;CJM;I%U+EKE-3RRG6ZH/@8F=MH3#CH UZDE M+UDYXXIU V&C=^,PZ3$9*=8:@HNJ@-L4 MO:P6Z#G@CI,\F[G,6FW?=7F@1#/YL)I',@R%9IK&AE6M_F)PUZP:,)O5Q'M# MP$+]Q\D[A?7&+^C/1\[C?X;2X][T7 M+A_#-GA?I^$JMF"#A.?OM7\!')Y)5\"['JB>[<-Y5JF^7V_L_JT0D[(+OSRC#*D^^ =-OF_PPQ_%*5BS)YPZ3BB4,G_.P2RWMMX/ M&M4J.^,RO), V2FX]3$P*WCUP_GMH;C]NO7? HLMI_]Z^I@X?QRE89:&#O%5 M"*N2 7=9>R+L.))W@EWV082%6A'9^\XD]K*M=F,UU[L/.>S7TO8=Z,(V#W=)^K6%] M?[2>A:5^_>F@9NT?*3!%7!'@8IE'JRTR$%0WQJ@( Z^4P^*_E3<>!_8S<*3! M8OKY$]83KC]&JN%+I"T[*'UB?>DBXTD%7!@)SP%J1CX0=!2[$?>$ M'RMWRA0(H.I/J:?IX/< #]H:-%F:H+&+T<+PR#+U.;74$9 M,O3<8L^8YNJ;PV4]WW=[',@5 =,@E@_W&XVC^YIUG4\V[T*Q/$79-V]O1T#DS1JNX9#YY*+F%/K5,C1<[^:\LNV6 M;-L%[6H#PKW!9U!-H)_,JQC6I9MWQE MVD=GVJM0H)[%LDZJUL&=,@1W:GMC]6_$O("4DIW!REK-:S6<4FVG]V8S5M9M M7YGYJ9FYHU0LPE>6?AA+UT6IL6-OQM*F[;/'3C%6EEHYVDX7(5CZP:(",!)0 M8[?#"I:;Z:^5 7_?RH"'Y!XW\*67K'8H(U%"?A"@'\8AWR;Y\A3ICAL\5Z3K M]^PALUVNU',EHAZ*Q!=.5]V$'(7WQ1-5:CJ"5SOJV1*'_Z7T2LKFB,&%V;!> MG'JP_8 N (AF>U1^J_R[U3^9;7EJU7JD<[:OV 3S!+#6C7S[MLA^KI;QJ!>[ MXB'[C;NQ8%=@DW2'?Y]B)Z-GNB3F6V/KT_N+_WQGB/A.<[0)8R:V[$/*B>^Y M!:AGDB*\&[ N+[AR^)^:>=EG'MZ*B)V?M[XIBV,]!9IV,M!^<'UP;S019WMH!SL'U&<-&D,TP"[!%AHC1DC[2#5 M>J7:@K$6G>1(!T5G:=8O,VSY:7.FA9/V$ARMR55F@(?$92 WSF^>1TQDI0*\"1R3WA%022'%%]+AAQ0G.Y4YQ\ M+&%JI(<'\,&;4-Q)!?V >[EG8_24VS86#V-CO(S X:&C=-;)6>;QUG=XZO%F MV;+,4HPO_^(3Q#JE:1*;/_X .^)"3A2C>XR(7V5,N)X 4H,) MYX[Y5.'&"(/CM0^IN0?>OQ\V?SJD_XZ2!0637)BM8H!8G31^W&/A/_[P?+LX MB&,D1AK]P#56F;6Q4AZSMS[C+$FIL/>HT"55_9P.0D'!K#);KBKV'D-37'H MP%0#EYPN*[*6OI^%P28*KKV(P09212R\+;,=%#FLC*A5CXS2I"?KZ TC4M&6 MA"OS=(!M'.ID"4_6E!OB2[9)NNQT1%(>W=_>9;T^^)]- [NFZ?8.!2P]H4KA$[)NHHYK:8=*.S22K9W M1 2E]25&>FDM2K@N(I4/X.7 G%9$-;A7;-0.BKO[-:;0;2"H\0"5K1T-1;9: M%B+R+C*PY"S[19$=F%XC;Z?W1G\ -)7ZB [S8LQ#W#"4,0%WJ,![12$'<<\&>\$T_V*FD3<3XV6J ,X>[H%YI>?VJ;I)%+5M- MLHIY0/@J,.IEU+?K9P=(5\Y>3&>NKVS M,<1$A#88!IG.%.E0,?QCV*MLH,W(3HZT.1U2S$D46C(#' /%:IX=U@N GKA> M+3F)LO0#?1[B/K_' =/J#Z/CV @TAU6T:KM%6/(J&3#\I3#00UC0K)@L0:A( M8L89L0]-/7"]P$BR05$HU@_]$75.N#EE&*HIFE!'=\I^/CPHU_4"1J@;\4X* MW@U':G(.%.D@^STR(%^3D!R9O.*22 \)916P!S4UPB_]OP9 MA8U6G5>,UOX1TUC-H3.#18V[57OBXYC/CR>V&TF1'WI^?RK&[1E80JZ^"MT2_0$EUEB8EO@^^#$3?=&AN_ZUQ>E*QZ MU2K.9G3 (G/]@,Q):+*6^*V/GTKU^EZZH1%\L)^A?";[5.#CC7,X*:630_)- M71Y[P' YF+5:#L6(2\H@)YR>01C5VI*!F>CAF'Q>F&H @A/2)/H0&VZ?\$D] MAV*[6;I;$FIA/; EQ2"7,-$T9PV#QB\FZD*FVCWIK9#=,\Q+E-)JFWC*=GT% MTX%F$2%L![H(=5972H,A+D?>[,32K%Q59>NM$86@B7J@CL@;6%H6:*)>1;3M M^8AB%9IP*0N#./>$KN-R1,XBIVUX*-Q^&@PAD.AVU,:#PKE[#AVC$N?&/SU.OU4FUOU]H[F!FV: 6,876@FH&W\A30JGL.+8CF M-%HR.SZ(,3SM&+1;J>?E+W ,-=%C9 ^*BH.6!NWHXQ4#'PR:82R0QED"Z&7R(3CPSBHX4E" M0V*-GM"Q+1%IMPR8Z,^8N[FK*U"-@!\X19JD=PLF?-6/02'098(K)\>MS?:# MZ1H094)^0V]X;L5AB*_,S3;;L>I!Z9/^P-,-L3T9RIZ,F%6VDA7+] @NS(P^ M+RP\NU8M:!@;_>9].8$B72A7*40-@(BP*I4YQ4 1NO(C5I(;;1O1)L:>ENQ M@;%A:!%/S_UY/O(#V%\U*LZ$-Y;V;38N\A5O/CH_ORIJD34;/?:[@\6!1D_' M,0ZRQ.)MSS-QV53I)#JV^)P,NENV5F+SX(F#>P<4W-.'YMMX>]3*'?T)PW?9 M?8 "2&1@T3%#("L:LZB8/?#K;*+P4/N;=$BDGZ/?O!;*#;(9;<\VT@)T+YZQ MS68"?GBXCFBL/PSG$O9)43?;3S@=462VLNGJ'\ZEL+G?#"H9S1D* E5S,P MX[P% G:_2BDYY8AO%J E\QHT+HH8<$+MF6^2NE_NLI")P!)\-'986&K$F;Y. MW-FM[U;W#QTQL:SR,(+1EIC!L!&0IS'RX>L5V2ML]$CI)+8TDW2]>1:I2+$_ M9X&K=5SA2VG_3^&SQO/S652H#%6OWER-3R/66BN*O(M&/BD]J[SGA\;UXI" A&1^FY*7AX:$AX14[A MM7$*YP,'2SS+UYUOI855;3PI.5L^?,NN8(5@%X$APG7HENYQV]%)>VR *& 1 M'RB=R 1WP'&,NP]2B.TZ]%M$#'^,B#GF'NPW61MY367MTSCFL'N/>>B4SL$, M1-[+N.-/[(#?9(,@:XT''24Q!06>_KL@U)7D9O13WRS.U8O37Z:IB4S%2$JD MD>!>1@2_E+MEO&SJ#I-/64L8_I@+0JX%!6_3/,KA+AG /L6V^L(A0U;-NKI\ MK,KLU)O.9U#18?Z&+5;/+RGN:ANU8\$ H9D Z*=5'"\@Y)5#F2HPP>359K07.= M5NORM\[YD'9K",HYI0&F;&*_GS+)=":[2'T*BI65BG>E] M33KYI#(YL'8KFT/$X/RIYR$ZY^*45K7TB3#P[YAN'P><;BC$:ID4PY#_+F97 ML3 )IM(5/( 4ZGSSUXZ08/7"!$.A0QV1W2"R>P8&Q_7)V3^ &*O!;:.[2>0HCQ52+ M Q^F),68&&932/;9-FY$N#8R]K-H3F1P% M;M2SJG *;+V6AK_( :]NY\/%Z!'>,;&=[3)?5QGB+S.& MAEDW.PY47'2"Q(G=J=[$G%RN5F?344W "U_G3'MBR-U^4LQ PF8:H T18V$Y M#0>T&H+5\!<6=3Q>FN/8'(EXN5Q'XWZJ0S/LTFQ'GO/WDUS%-NF/E;<6S*4_ M[D>]G\E/RCAM];5YC%4_B[+R"OA-'$QDJU4>)KW_GES,PLF[:?,1CLL^U5T0 M:\XN;:G&*JK"VGCB[V.9O?L_$=X.?3=Z]D/I"X,HSTF"!2CX)RV_-92BG\G( MZXN4PT6AB:>_XA-_$*R9"77MIJ&NA9;7<47_LC'][O')_P-02P,$% @ M(H&Y5)W:MR\FDP ?/L" ! !D-3,U,#3G]R_? MOWK^R_/_O'-P]^#GO_&_X.._R=^3GY_^_NR_DJ>_'OW^ZO>W__;=GW]_^?[Y M=[\DTPE\Z2@OV[S^Y>=G+_\C>??^OUX]_[?OSHMY>_K3#W5W2;8L3LI_ M^VZ9+]KOZ%EO]&NKK#XIRCMMM?[IWKI]DLB_CZNVK5;\T:(JVSM-\<_\IP/_ M[T6V*I87/[TO5GF3O,[/D[?5*H,W';YZ^>OK?_NN+DY.X54_/_WE^X+1B SBX?X,CF-&2?/?+T=]?OO[]]W]/WO_]^=O#-\__ M>/_RZ%V:O'Q]=#?!H<27XI.,9"^;3I[ER^P\J_-D5M7KJL[:HBKW/_= 'J?>PU^?O'[Z_=P>/2T MG!9M?J=99[/\I[(ZK[/U=[^\J?,[+S;E/)___#?\]B_)GUE=9V7;)&V5O-G4 ML].LR9.#]-[W![BB8ZL9G]G]AY]B9D]_^>/UL^=O_WS[\OW+U[\FA[^^??[\ MM^?^?Q7)99*OD MZ3(K:O/NZ03D<)V5%VGRZNZKNZ,:[T8&DC7)VWP-9P!$$53;&1^&]C1/FOP, M5R;Y XY3?0Y[D]?-)U'!P\,G/(*X['XKIY(N=BH<_ M_IB\R>H/R>%97F[R3_TZ_,__JNH/:?+ZOZ:3@WN?0]?A.@\=_N0SG_V#1_>F MD]=5#4+^%DY^W13S/'FSS/Z9?>HW'YT6L^P$Y/SEJ^3Q/?A_GWS=7V5SU"5@ MMDPGOX*N6^:KO/SI*J]M\X_MG0*48MG^]/!?+C_QLJH^).]/X7RM\TU;S!I8 MA7)V-TVR)&9J)GNHC/_U?QT\_/[)SW_\(B+R\]_^^ 4_^^')?@K?+A=%O6J2 M NR<[ 1T%\RM3D/XI_-7@USN+N']*\!/S M,-RS),]FIWHQ5?!_ZO!:*K-5/D^*$C0T3&IVFL\WRQR? ?^4_^%!'.*_$OA] M#O;@WJQ:+O,9WGI+&%&PSO;Q^)N41Y. U0DC@4]727.:+9?@IS45O'FVW,#A M@9DE&__+I-D<-VW1;EH8'=RT^-ZBS!;XIW5=G<%YPU'C%N!6\Q /[M'WJ@4L M(UP!\L9PI]SVD#P'*Y>@_&3PO/($7UEW+O<]>%VS@0?.,K"'DUC&LZ*3>K8]QY^%/C;/@9V_ -VO!ILL[JY"Q;PCWRO^_= MO7?OWD&RQBW!;[M'ZDCW[ %S?D!7"MD#&?$_8.WN+ +_X]SX'VX9[#M@_BT\ M/,D_YC5<_K!8=3'+D_P?&["]X$=F[-,)#;ZC$;8.:M@I"G:WR5N4-]AB$)'+ M'"-1?M/!E]B-@HT,]SO. &]73XC+NBI7'/!J91-,TF.P9=M5E7YM3)*ESC M,)F!LX:O\T5>U[ R>$8:EF)_V_&O) !AQRZ>QM^>O?P/.'02)IQ.$OK_?UZ# M=KM8YJ&IDJ]ZE@I^M,Y.\CO'=9Y]N'.$D M1NU;^4.H*)-L P.&M9W!PMQD: M8,:08]-1?]U9+_PHU!0IBW-/&@]G?+/]^.!!BB()!C$JJ<[JXI_QJ]U+B*PK MN.OYK;"TFR4M;&/L)-TO."RKS?(D0^E#2SSG <5?!,?"/2NT)-/(N3!OM5[O_B=M^FCN,F0P.D-4T6>493*,9_HE=K>,+ MOA>KIKWCAT%_Q:\V/&'4YRT_DM\1[F'.Z1->2WQ<(Y;4T,_Q1_-JMN%7P,/$ M^X,!P46-BH0ND>D$+OC@KS!I&S/:)!G;&:W8 KQ!\2&^A55*'CZX][3S MPNFD(TO&8'>_">2K:(+[5]>FZ7H[1B+>J43@@Y[(;:QN6IJ<5N=HI:;^#N'' MQ)^A[B(HPFK3VFV"W>>)[R*9T\GE1=,=6GJ+_/>B@"L0(P7P%E85I)30P0SU MCAY-^C&[N,<8D"@Q.E3SF9>9EW -^*',8=0R:]W?@6EU_C9S!R_D(9W/$(WOC9&[7U/__I(S-&5_1N M\AQC+F#4+(L5F+3U!9X%VK--DVP:MOA!+DHV^OV=WS&: MERN\3;NX/62W92 M>I].SZ4)!^2\!S*@6#(Y%?$5$^M^.GD#U^>Z14^7+$(VY'#]C"5WP4L'.LQ9 M@6G@2Y\7<"SA16L*]L /T>R"$2P*]&3-/L%8,K(S^\<,1SV#=9UGN)!N]TCA M-7KWLSCGN$%$F6$/A7K&:6FSJL@ SCR1AE6%@ M[2PKEF1(1\((I,5 (J\ED+O>PJ/R2%)]6P32*^HW73'$<> 0T>MI8L*&:M_- MJG'*(7K585CA8CJ)RSW+K1^ AA[LEW \63+MRM!4[K2441(KV) M_$9HT!6_.*O6%UW?P]JL9C?P5GB.:U=7)1CJS[(V2W[-<-_@/6ER".)YT11\ M<[S-V[K(SS Z=-'@+N[)\$&!PKHTF"WCO^Q[\7_^[-?#MX'&(I\A%X\#>5:0^-5.H3]!J,?SS-^0X22#:+'/SU\E+RY^]O=--$$ M77)4M&K/QWP"EB',$%!J@"ZV3%(A&@ESF75W=78\]K%M^HQ+\VM>4MK]6=', MEE6S@;/^)IM]R$["5<*)O&R:#4Q7?_$':, 7,./D3XXMT%TCQP[U/7Y[CB8* MGOVZ0,N/CW5G-_C(KL#0!!6 $)4A(V#/*T\0^&]$@FG-4*,4Q MQ3+H3,-.M!7%9(9'Z+:P*/'68'TDZ@"T]?8TT%/]<)LFOG,@BM@$O%D[6HNX M.LEQEJ/AE\\H0B(75A:,!NZ)$?^HX!\M\$<:G#)J7'Z586 +KG!6+F(L/G#A ML1T, ]X ^%'HKCE)4H\)!:[-Q#+200Z,3@:W%QO=O461,+CCW8.]F_93?-D 4R=NN,7U).S14@QQ3_0CUXPN^93IS5 M@.N.R5[Y(<:AO FQ)^;@*:8/-.CW\I?CJD1/>0Z6P.X4@@]BED8?*^O*_@#01O\>:-819M]R-$8 M1].IH-!2)4?GX/&#I_C4 "7P"#1_UT#[\AO!R_BG3/_ZV[)M0\@Y[1EQ?D,^ M_0A"D=AF98[:EV!Q]Z-67R U?1C&L'K!$+PXT!@H9RC&+CW1S1G@O_@BL=XF M)TE-C PW'8P,,.;"!E MZ.DP<&!7F,##49C %=-"6R2*!/Q:(@5[3G$TA?7L+E:?/QK\[OG1^Y>_OTX. M[@H0N_=_.[C?JN3M%.2)8NL^OP;?R_8'A_QRRY [01:T]3D!I6%@AXSF7UJ@ M+KF$)L/$65-)68(4":PQ'8Z>'BVK!D\C12MM7.HX7U;G^PX:\@R?!C+R3.6E M_UU!;:+\<&Z\-SR2T$6UA&\W7S["[\)A W(VA+B /]),;=":Y<[NVBK/&>N@ M/C;K6BP,52:OSC'XY,>@F4T]&D&KBQ!_5BQKA W M!D)R4AP+;"-XU?$%2Z@..=4' '[7'K(AOZTS)MFRU@X"S>=#*%A.D-#AX2S'UXI:-0FEF M M*QDB:(@S='/P7NT-F.7M[W,HH\,3R5."_8?%*&&BTE' MX1$%OR/9*VB9]CD\W!D;S<[#\(TI>?>K#1<_^!8N_D2WRR44U3;EP$:3 M,52; ])?"V6D S"+AE/'>%K!#AS&@ GT['Q2%SLF(#3(=-FL,.XR1V1+H"H*3@D\SRM4KE= +GCK+Y>2W/!JWN%V<7D^G]7;69OG 4^?W.8*U. M/.*& @_]/:94*CTO!F2O@^- 7SJ'0> ?<&/9C<0K>I<#0NY*01@$^.1B\,"8 M--7 B7G8/3$];_R+YPN&#?&Q#0+5'MDA_UJ/ZH0[<<',_!_ M\%+UX"?V %_GA:3RAE9D.BE[R$)[%057NT#)Y$@&OCJ?U)AKGB8^R.M3TZK5 MY0/T##=E6V]R@W=')\&?S@7A[^ND8B60(3$1YU6HVG*.)X>IW,3\&@KK,,_0)[B:'3C'T(AIE5=)2[!V:(M]AH%J: M[#U5/$N)ZFE>G!5SK&?NI_V&DG&B3B,H*SII[.V.#0'%8>\H/HS/E]@)TRI; M)I5LF1-=991.4,!4[N7&4Q!\4@'TXD7B1N;KJ)PYV,,2Z:54Q&9%#9YS[O(>F*)%[1GQ4SAS2NJ_18="% M4Z&3%6VX[,<%Z=X&)=9>G/>&+*W]RXM)Y&$#\82M>ILKA2SRA"@><'G894=9 MQT(".@2*:[!'P-<=J75^8$UEQN;RP/C5R GF&BH<#6D.5P"Z0-B.*Z+TH:=9)GPJ M[7F^W"*LR=5D%;3>,9AL_]2D66]LT\F.I&#)2W_P=JSU^EP>]JB+'0%/AG5" MXG!7VV"6J$_!2VP#%Y@^\4:&54[.>1XW-&*&1+S,:'M5<.I3 2:,HV KK%@T MD=_ADFG"PF' !2]0"KK ]02RDL^E0+6:$W:75BU$X72*.<;RP \>[)WN[S-O M@5@OERYG!2=^*SX6SZ>Z('*YV7<2)FX9965 D'X<3H0Q0XU(I2;0G8Z$JP?* MCZ\>VN$R8A).S(3)FW?D.="O6QHE3\$1@B%BBDU_ MOZ7VD8(H^0D#-X*331 .9(DL%A=2_4SRH4?7SY(A%?-\3#:H8.A!254 M@6W#9\9<;$0F9D;Q $_W0:<53"AIP\3D.!Z[]WM-\+B-V8JI@MJ2HP MJB?Z!U9B 9E3FL,Z$8/J0:U*>';,J^)<'$A^^DR%8SB%8A<#=XRB$IXTYAS% M^ .)<:-BS%?"%NS@+3B@P^>32MD^0Y+E-[&%(GA1=_[UEL_+$W#.&66"$,+/ M7EICBA(_][NMC3ANK@B(#RPZ7^N.\ 2^;]C(8[PAH_:.-Q<(D1DI"SIX^/!P MP&(VCS*O@IL;3"_*$_H2LY$7/+IW,$24Y;0W&0T4!_6I>) "2F_Z;8FM!Z+" M27+(NOW<^]9%KCO&=^?.=,=K\,-NJF0?4P ]4+Q%Z2KW<#V_\.3TG%IB$/S\ MDCG;46JURYZ:0#:0*'8)@R.FDL.MLRT4-=7SZ,G6X"USH1(,Z!2S8HW&#IL& M2:\2G"V%B!EBC("'>Z?*/3CLFO0)"@1&BI]B+GDZL04DUBR0W)BI7]8Z0K?N M;!:,E:C?>V3\4S[4Z 9M))N&,;0<(_9@!]LXZ&CR^MXC<3Q=;;7)H75W("2, MS- 1T^&#N47C_WJQW8^^I0H^G1X:5D3_3<5#35Z?(?4Z*)W_N0UZHSP[Y!&K;!>DKX#],SD\K(HAF\XI3=O$2W.D$\Z/@QE%*PY7C.@*LF\8Y MD#E6F+D(Q[4=?68"IZ)/O),TI"K=7QX&W^N!4'5,T\D;?K,J&EE47(??J8$1 MHDV>5ED--M\?)=F.-/'F-B1F/HZ)R@NWUVZGFB>[T,2^KLH[OQX>OE'3Q3_H M-W D-[4MHHL*E.=-JS\K=J:/22$G/3<5YHSBAU'C/JB'-:+;$1 I=Z88,9Q$+@3V=9 M N6H9HWGLGF24+]4J(BYYT3C;E3%*8+T?CC[KN[ROF# M.S_#U 1.UY_Z-5AW8-:A^O-,;GP<#,/]FF.Q&'EBPZ2A0HCC#'D^!QR#8<'!A7:F[%)+&5]?]& M]9ZG!088J":'Z#%9Q63QIPM"J7<#XSW9V3BC7:]1B;)ED_JHJJ'4Y%#:#[E2 MYN[!S:[9^AU'9C.PZ?@]X_:DSD_@&M\I("%L])V+T._<2BY"$TIE G3LXE88 M)-K_:B#EU+N P,=- WR-O\E)WT[^[3B..PH2.1.:"S*P0 MD"L-V?VE-C$C=KO_A*\VY#@^W30%)3O>YBJZK[+R9,-!K1N53-CP8?W!>B-Q M[ M=+<%=G^AF&;SA674TX24RE._S>^;H]=P6GVP*K/HK\9\^9M_>FM#,J-%X M1%G&<++OLOHX@^G<^?WC,K]0@I?[]^[==W8@6O.=)00-"-NRQ*,K*1",F$PG M'7O %J+W:L?GH/9F%*4E/L9%,2.P%PM046O'0>V=!">04I@[P1H$\LG,]"[ M,CA5)W;;N6D"D(WPM^,K;5XV2(T]A,>KI0K#7U:9."CRK29Y( /X\=YC^TUQ M[ES4\\O+UJCS^KIR>97D<([>%>PXLP;!FJDR8:'REZOI0L':('Z%!,G5*S@/ M\'*^++@(6P0"E[II=[0,=G%W1FN<3#$4=GXS1\D)<2;K-M-U8W0DHAX++@CR M8U1<&BZ>7)(:^,0@)$SZ6!5XMD =2N?,?::IV$$;?IMO82-V\) R3RAP!!9V MD_=X@N$I5+TB8ZSPID9;% SSFFDQW,#V,M/VKB=1SRGT&W ^N6R-+JQ:B+"R M5!F=R3FC\9%\]=%37E-UYY[VP_G;9^$:5E%=DLPA5OK?6?6.2S>^QJY+3WUZJB<*-P["P"1J8^,B$LX:[JDZR4?#2E?\Y [.94VUTTVLPY M"QJ#@]8ZP5> M)LNMP9:9:,]HH\**+K7-K&6MYZ^J)FP1>\.!:7XU23?+-L7J M\IKC@W@9^K/AUJ?/\F@%$1U"W!$/=:"51\T#>B#8@=9?2';*O(&][5&N<;Y^ M_MJ TI\7,]U*OE_(+Y4W"U[$0)+]-4S&"N*$'/'Y.:Q;0X%-E%H.AHQ39H/E1#3I/\+S:+.?"?]YLEBW9 M]'TCDJ_\6W&<+W6>.9+1<7JLNA1;.*-]E(^[SE(ZD+$=!M;OH="DB>$<=^^\ M\'832MUXH^3.0'LM94?5$)+'B![:4>T$\JW5U*4]/7AS\>ND.#[421AD*V#K MLOJFU5.RLW:ZGINB:]A1)T9K)%N5QAX?2M(+5,@$YY2VHMEW"N5F50DX_5]* MER175267]C\[U\YT;U7&-0:L4 MK;UBA2_C;!164)7.F[>KZ9NY]]85WV^6%5$TLB6P[V=%)7%6>>@:[_TU:DB0 M>N&R['P6$J/8;L.3X?#+ R9F6YH9 88;?A%[M1G![HXK_G& M>W! S=3NW8:+>13R?V@IC7"9@U;IN#4!07=PSJ83?]#2@2[J'<_D%JS')98# M9_(L:)9CVX1[+\0VLB(5O-[4,U@J/_V0^\X0=XKW,D1M17'[!N%C,]84U&AX M&S-BAU6=K!GBKS#J=6B'>@^:3LR33I"GJ07%>:&9<;F[*!(CB!-GDX\-J(B.XYN M47J%P478TI=PE"P LIO).[YBA_?4VB6U(/'"TTY\&[##]:QHG#Q?1\#(ZBLW M>$G!*<"44D%<;\C:DN>\5R#A-1YL]UY;:1>;XIAB^20S\!)DLDMQ!9/&M:;)7?ACSQ>'U(L(IO:8X6:H".#Q+:4^EGHTDS M\Q,U63JVC+OEB,;_++<&34'W&CZ#M#9*'EF9H2$XQC'BXP2QY^#_@LG4-4LB MJ*IA&S:29]13PX0B[I[M!"J(G/L&Y=*_Z3PK"-%X&R1JG CVN%%"H/]0#Q[N M[6?Y(MLL!?YSI 0T?8I8W2_EA#3A 6K8JYG[;H" 8R&:FW:#'D"]9C M5FK&CW$%(7Z/"JWP$P2'I0GOV@:I*'R09HZ=TM%"J#<8O4%4"SV1+$_[/D1C M:]35'5GW=RWG9'6&A\(1/';SC<&F".>.&K+\(]E1MEM6:E,?5YM20X>2E/>0 M)!/W1< EFD5]JS\Z #6 .OQ/+GY^Z)T( O-YG1V %W+/GR+W@8@LT\)H6),0 M+"=LN(L 9"C.^TVX,;WFLTFUV L]=W%J!@H MT!Q=0D%W*:"KC(!Q&PP-T#1!OQ>AOQ3NQ)NUE0P#;^"?N%A1O'ZR;TYZDO>- M=]:D<8X)60T]T^9^6IGP$-$RQFQVH@BZ>;B_8=\<9) MXI%OR!5:NN08S'SFPGWSRI6-&GZB4U-<4]4!7]%)<289'?AJP??-&DX% ;87 M4L4+>KA"/S5D=1.>(XZY($R_YI3V(F7%P5<:_.?;7 -NS\^(,[0/.*/IITR% MU)B;$)2/2Q!B]TM?0$,7&:<1\)IF?+E)*"CAYT5X#R2#UT!/AQAS3KJ[#:I] M4!D=#> H\5)9%]0V[@+H+PI]AM-I=#Y-9T)6E1!QP;5UR3XSHY.@,)',3.I- MW$]A:2)I$\'>NE7\A'929Z,H41/1]LD-7G(194^,^,0$YM@$O3+H[*3)P_NF MO=0Z+#3+V%XY848)F*&/R[*YVI(E=LSF&5UH?%MJVW R4N'8'(..9G#E$+$. M[2T_7K-(3/>P[UU1M* D6,8?YNJ[XQK.'04.'E 3/J?<9XT6&U81L(S0ZX*1 M]4%FW2V\)7[(J"/RBD$/T;R)H=A8X_D0!W(I. G!T;_.FGGVC^37976,Q9U$ M:#>=_);5'W+J1.K";JJ+%^Y&O 69I_&B5>.FOY@ *SA(#H.T25].N=/ M3>,&M#.JB[R?)8V==(8[)*9IG>M2UP/7((1B!89G7K:>9M8@N^BB)!"Z<&X#6@R,FP)U4L@/EMRT39H>ZR)@-7=(%,YG'+\YPQ\ MKFJ5,Z);';6J5M0QU5"(,S2CT\FVY>XHJZ\P:OO#MZCM)SO5NQ[J-[X)9:?. M8SJY#+SFTJ7A6J-45F*?H*8LVM2TQ<1#@5>7F$)($"7&M=)]H@E+$)96Z=LC MM[SQ1M((_R*3<]HQ$&WP%<= &7 L:GZ!8"=*U=>;$SBRWE6&GX8MLE\\.[2N MAL XGF_0P,W*Y#<8R(S*UP[9?0Y__?PW^^M]6-#S6!?0887:GJ(UGF/3(W Z M)$6*M[]+3FY1WUHYH2H+D6;9\9)".?E'W'&&Q.T:\]CM:0J57W(EAM3AX+_H M26,! NLP2/7JY7SG?H]X7R/O'/6N>;08]A ]1-F9^FJ&Z592QAM?$T1F; _9 ML4AL.[NG&V'=:N8 M7#1Q?/D/D7I\,$F[+]EP]#YQ $%5,Q[OS MB;?RG)=)SH I]7'NUO7D]1;8;^,E?MQO#<-RB^E$4&BQW(V:)+2_OEN-W]-. MT?M-;6^_KMTA1IG %($7,NPM*1\>*YGLGL:]PN(4'2I!>_2I.J%;L86[IDI> M;&JR$=\: (0SQ4VKJI1#I18WEHH/DRU3);)&P"888UR,2*ZSS=JE'6BQ]:C3 MP#_&./38DKGF6LXGQ2JEV=SN35JZ-4&B>9 M="IC]^O^,SRAT,MR#HY*[9K&8K#_T,?Q7Y:SNX:%Y<7+UV^M\7$;W/UM)1]O M*L+1R&Z_8OGGR-\;ZIH;89B-UM>N^4'2X(L[[C;N1#7^N#7NO/%K@NS(/S4Y M,9"3"HZ8CM9:BV&7>7HG.*2X\_W3B<,.^F(IO-]>CF1 2J&%/G<5LZ$Q3FN, M:(TV7G4IQ*D7AIHW9N5-"W3E'Y66XX$6<*.*>3Q68)-^M2[ >YOO!? M7""""^#*=NW5%:L=C\Z2L;-;_32PTCC>C'#W:D:@R+E::,LE='D.B,2A+P4:V,!: M4)Z:3D6(9T) 7/HD%^>V-].BI)^AX:03B+]!)NP87$:_["JNHL/HKPVG7ZYV M7(9 .3V]<$HV]RQ'?)+F0B0:;KW8+HU_**/?_3T1H?_P6H?V$ANIHS<_[HN6: MFC=2DCEHEG8(2,@!.='HXXH< F:\TB?BQ06;L#35GN>EL?6(- L?$/R"];X- M!-D?I:Y4E=,7D2)"I'X2,%JC)8--JMGQ7GUA([6##2FBMB[$'ZNHN,WDSPT3 M1=<9T3DAF MY.VK39-K5Y0Y_9Z"]WP;T.>]9V]/X7)HTA3#$BY0X=#'\B]G#G2MVAV8BM(M MG#F$@.JTDA[-)J*5$=2'?[)@5:K6[L!]3]RV(ZC5;ECV-&O"JY'A;FYUI9A6 M*K\JZF"8F?I'#,S66HW$32^4GRH$J&^%2_)Z&]BE;#0!8=RN8Z4K-;+)CN$2 M3L.L ?SC'QO,EU0.[3[X]NY"()9?HC/P+'1PUX'?[D8TMR,B#M]5T;C6XVZ- M'9A5OWHK0A6[70 OX2Q0; +A,/;P!?%7T;$+U\*7]+!-'8CVD!GQ7RCE6E7 M!+AN4PUXQY#=+YXLZ+!_;#"VX0L*9AEB8ACA0B GB>:KMVEKRB0B,3>U+:@R M4;EA:J^4&-LZL]R;P8<8@:MA%'BMZG\G9;;*Z0:KS_#4RC_GL,W87IS_-:O6 M%_Q6_56#L53\YU9T%;J$=TZK#!;FOKTE@%T..)/RX:$BMXSLLS!VUU6:WR:Y'.P^0;7XO0RP!W& 1=HL!E@ MO_7#27D\='0/'4LP@"HJ0*[*DZUZ?HB%C!O42V4B:>RHK-)U1Z372;":;:M@RJZ"8 'MA;0%:V"=& M%K=OPW3B]R'>*&=HR1>8-D'E!%>F"1QS&,E73S%2-&?+)+XM&"CR(XAO4)<^ M\?K[,QBQ^?0;A 9_<8E-&CDK&@""G\,EP494I]1<#3[*- SLP+EDF-P=M]VT M_\2K!!IIN^+)?86&JHL!WX%+ ?ISX,BYNR[2J]P7EP4@2)0OEHXT*EF+!JYS M75R3GFI>Y8R(U-/>/>P1]'_OY"?"VNA=#[&0T#+#;BW8F3EB-3D$)4<.&+], MTMTJ-8'#@'''8NS)KEB4@+=H5)$U@O0!].XWH/V9,"&E<)#A]RZ$(>WT(1\ MI4'*@WO?HI0W5OW?T=4G6(LE3-J<:'9^D"FJ]BY1(CSL^A?O]G2+H- Y$EP$ M*>SM<13#&Q9QQCA,%'U?-L<2$=*O[DQN2DL,0XQZ%5>%PW\C,"X,M>*=U7 Y ME5.EK),#=2I9"E];XZ]]T84W>'N;6QF[A@^AV,9MV?&JZB%U*Y6\2-!82[6N MX&^KM>B_I6%)TT*8"B)97P5%\) M(1E[K5E(A&\3I+[5V#6UJ\5 &!HZLGLN9ES4P=^#5B#T+!L0"1D"X06G)2(L M+A)NKQ,+>&PB)R8ZNZ(,R4%=X-1BM KG8^]X$+L< V0NR7)M E" XZN2RJ%1 MZ\.[[CVU;$QHBYMS#3F"/AVFHL4:=S'JQ)!:3/@\"%O8GA;U7(Z]6S6]'798 M(Q]QVUD^:;][J^*QO_@=0[=!7J?R.A%1+KHKN1PARGJHTA(;W9O@""/)$2!U M)H'RJNGB+SZM2T$8@ZV^7?X1YMY06.]R?AZ\.YZ0D^2;S:=1/6L^LW0M0?YM M[S+=S9&XRHU:XY?N:E#YT:89(]T9/-J)-X?T\,Q0R,:NOUU""3O> =Y8J JT$U 5%&S8?8!V*G"+^ MR-%O7;4$)B.I'R#.L 8, M6EZW(PTT#EAE6Y<1JNRU'9K,Q%WJ,VY%%+>$>08D"YQC+R[&O5/"9..B[-,) M?^RB%U2Z)&_!G[]7^SKYG2Z73NW1'^_>O/^]2Y-@'$Z'PZ1X"6Q8J87@:_\. M9\,[QA Z4\ME/.=B3'SS-L6.AN A9-<*< I;@DGA['1!H^MA]R" 0+_?7F\5 M[A4C)8-=P&5U/;':R"ZA/(797F)@P*KLZJ#_F<(6[\"Y\A0KIWG&K9O90-6PS!BC=S@?\9 MXD81]M&60]L7#,OG!)=&,3!!I^M!*A:>;WS &;999<_1OBTC,H9RB'F19$,R M@X9K1.!S@2!WCG:$;P7;& X_<(4K:FC[V]!=,],)7XP::PCGXE=M]$^1WIJ=#Z5=@EQ%*LXI4)4TV ZR$-P>[S <)3;[.JG>*N?;7.#;>U ME$!80QK3"3A4"ENUD[$2#;RG'B>]<&TZ#<42P]-&12#7,(M58&BE2R-@IF'GJ3)_@:-/'>![===4!*R GSIG4 MYH,#4AA$E&$TB+Y$D(&FH?_>H%5C6^VE"/M%%#?]F? 4;<'?76;'V-F8G["J M!(60(4,6E<4ZNEN<>U43#2CRK=54B\*M1IB\IVJRI;NEPQHWBO''2]L\DME= M: XFKLEMFCX:G&;R83O!B'>VC;+#,?_]41+[/L7>FBVD&P.$&^D8U<8 S0:[ MGFB':LDASSM>:[I;88H!7CF=86YMJ<:Z@]^$5VC0#G@[_ M->=_B5T>:4#@)/\6ZG6L6T,@G!H-&* P$O> *FB7\ M&0][4J&BJUF/%/[ZS)U+I&GPI-<-38,V8R0H;00!B]G( 0CLCKF#*-PH*!MD MCX_* !M;Y4M8U0^YCWMUROQ@:>JKXAWW7*V20V*;+.=T$F[S8(WY&$3X.NOC MJ/D[X]BM+-/A#Q@GU<_E>0@0G)X0C'?8.5][9U;U47 U=N!8!#F,K MI<0F9XP7,R'(A8:%0O[H?;*.X^-NL.F@7L%?-053].2&R3S'CWK6]$YY1/-T MUQ6A%GR>M.K_LP[Z',\!*S=C#_K@E7:B7/,6_DU90'T6]U3_2E MLB!D[< *43S)#W&?I6[OS!JK1#T8YCQ\LTL,+)[0->+A$$C/7F+;G["'D:-) M$,(5*B[PB1),)G$ECI@077Q%):RZ?D_C-QQ7-N]R:"BDM*V8V9F.44)"FDM-IIEJ>QTNS%TN3(\5A3;.B M1-IJW^J0I-_HLA\XM]4\.'%+M'6 M2VQ2-PASJ45'DROUZ4#.OX/]P'''5*R,99/;?CL5YX$]VX73UVAUI\;6%N5. M;IY<"+PF:^09%@?0W(:&RD.#H+;'ER,JZMKT0WKMJXUHWO\6T?RD4:O1L-51 MQP_[>YXMX7^.\$I4YYH"61ZB35PLRMI#EHB/=C8Q'IQ.8.J47S'#5W"0BIFY M!$?KHE-[P6U+.M] =F3'G(=W;8/S4V49PRL>81>2=VC)+G)R\/3DLV^+.AV+V MX3B;?2!O!E,V>P_OA[/:H>'O@_OWLCO?'^\=[^^[/H >N7%ZT10SV-CD#9.Y MXXU1@F=;YKR,W1?""=[QC:?AZV;%6;%,7M -<40&/+_@P< ^?7__1[=1O#1X MP1<(!0D> L?L6LN2F67!#79O(?([@P^93LQ&=_;7H@R/85?1E-(^GW#:#G[0 MX;W+)9AW_X?']//[/WS/L^L]W W$]%GPU'^T>Z)N7I;-AGM=O &72FO \.F' MLUFU*=U'AVSN'/SXXV,3J/S[RS>'0:C2+R?U"<8!\^G#19MW=D7 >G!3TX)= M?2OV>UTJ663 X#]40V?2@L$H< S0;Y8G=$_8 MI _3$\!:/Q&'4OU)9^.XCK$<_A(]YO2:B6,N^_$XGK@7CLB-YI!+40^AK.J= M_8 !$/*0%7J66S8^$REUK+.\BTY'IVRMTDZQ<7=@C209L4U%>B/LLO@G)3TFG,A2KY3$X[!;SEJ<-P MBNLJJ)E9)TER2!]814)K%()4'1J4TF&8'#[:L3,5J=Z5M)>^U5Y;8LA70&DJ)=JVPH:.YK]UTK3&K M\J3"M>)@&_S7=&()!ZU:V1I[8I@W 5F!&^QPSL21F+X:\)D2$#>A^EQRA"\"$D3-?R%"5MP+,,-X!YWEY5M25 MXQ=T;N#S?G+UDF4(V&UA]SJ$GRPMRZ5+]F)YC3!WWD^/^GP;18.T$L"UXJ+& M7/U^7%S% ;<8*@N,,JTI^D5G>K-D5JL9-XA&RT\>_]<&4^]\]#N-)0LF \LE MA-0R-6FW%&CD :*8'.NYEES4ID3#0L=AP,N-*BZI"+#.,"&>6Z3VHLI)1_+#D#PE_@7)'^BZ:549^0\V(Y7Q:+ M?*LO2I9A-Z;01PKRV&)(XL6>=M72WSS8IM-OV'0Y8, 2+^[IZF!ZGI=%>Q MC:$#+N80GF,P.0$%UBB0)F4&><'7@%4&*[\41&=D>(-3B:L> MET%G,]D?:Y8!7#MT6L6H\'YK.@0U4%! /+$^1,_MDNSI +.WTA,+[=QQ+ %91>QT5UJ9TF2#MOR,MW$-E M0X=[[1VA0 S31'.I^4E^21*?N&;OK9ZE%-H*9^-[R*91E=,=@])?:6#]P;? M^HU!A;,>',#CC[J-+4C*QLZU@U_$2>.+.L@$/;&\2ZWM8',9QC/42^XF"XV% MH,\U6PAL5D@_$/8-J4H6HPKN/P2A9O ,4ELK\ =&\UOM51FBB(XYGL02R')3 M1\]WHGV[!O5&R!+LK+KPM=W:H\%^4D.X[Y$XA]6F\JEX?CUR!Q<46%>M4 :X M" _=.W[4%54+"UMP#O?W6OZIQ3^R1AQ<0:R1?+L$([;F/U2;&C=HGJV$FE@+ M?OPG-$+RGK!I.8%9X#3597ZA72 7$MWR84U8E88$2K.P$ MGD:4@3LT=7&689MPCAEUPV_'U?Q"@ZTSQ!#LT-=OV"#RVB"=,SJC@Y(ZPD+!:\GUD2!OT\\M5,2!FG]$- G5RCFQ)U0KT3 84+USW)1?7 M"WJI\SWZ%EWG'7(B=[*#1S;SLOTGC^9W_$]\2BJ>A_:Q)G$6P_Y5#Z>33LLJ M@=*N0^<6?Z>)[NEYAF,&VV+:0,6LD.R:&LJ-X#YIVH9[)/W+! M3*RB#X0C8P8GQW0E=!WH:X.Z0-17Z/H\\13OW5=A@ Z?S_SE ?J5+6>!O3AE MX[?/@F$;8=)T]9F 4DXD5JR @C/'*,E#@&,A= M"D&L2B[.O-*J=,P_>.DSXUCXA1@:)96$X0FJ;;)!(A>XCC3&3O=IG6OE^(V33RVRHJ8ZL+Q1C'[ HS3+J$416T<#(%@I MR',8K(@(M )ND=.M]3>)"Y3,$O&KM.LSOA=;KC M-3QPI^(-V>WIN.\K4^#(@%//AFI>-AOE-+7GO-N'U=%]=LQYU]^.\5F"=@>DU%[L GXU_0-4A+Z0N8W#5%-6\T3O# MZX QS2+E J*D0#%M5INEQ]6Y %ROB-:=>'=]V=P SA$NBQ(3#Z5%(\N*CJX5IQBO M$)I+T'Z RZO]1\?D!5%G]]-LN;@$?3U?ND);/ 2*5V #$OE@I8!&6GVZF$5] M)\+^/-:?,CIY3F-+=0O&0*JZIRWT%9B'R(XK0G2,$YN\XS>:?(16!'4Z+;E> M?=I&L%H$7:4%@]!6]-TQ.^%R]M(YU\K-B?,&3$O?2CTUM?5^\\5P=";G3*O/ M.];45QP"?_@M!'YC(7!G4\=M:,H:5W!^FM2:(8Y(%4V4 *X3J<-"P&=8]+(3 MY%CPU*-P:BG@&W+R+5:Q-1VX\7LT0XRYS>%&2U:$D^,[H2&WG1QGAU?Q$$&4F1D"=N1H_*?@;]6]B?A*Y=3 #C$PCF+M:!6_JMXL8 M3HN!=1X ;VS)B]Q\.T+P!^XOU)9T50WJ3'0ZP3EMB&1$F[V;I/:,^QF!5&G[ M+:G*UJ=Y]4RQ2*N!;TX!/]EQ05WM-];LD:+V@K*OF)-6/$H73RY MQ$%B;R]>.=//!@X>^5A-#9.[H+Q[E4:&/>*0A.$-?Q)=D")OM#.%9Y"W$8$& M?1MD Q=T%J M:M6VWSE22_>%O90M#*D73/<'B_,^^YB+.X*US5&(&VG0%9*M?X0E@24/XMK# M78VRZW3Y'(O+;!Z46MV1N\ZO+[]S"\F->SK!(_49%UUX"'%#N]WH%U M^6KI)\8-,8Y?-N>\.,< KV&>(#7#!<.B/;W4&L'O,^V.$VK]7=L!B"RY[KNP M9*C6>,WD"WHUTN!MRA[8 3AX)&P6QU7UH7=VBM+E/^1NEO,F/!F4KJ 3 ^<-AQJW%6A/'&;TA74CC81#Q4/K.L9O03 MY5&5@TM[.X,;L.!2+Z14EB<+?:D+F2ZQ0?&F=)'B32N9//0;:G)EQ:A?89Y0 M?6-86CQD?-*+Y@.9^H5+1(:-@XXO.)-8BE%GCQ6]TCN.6M M:,;4#XR6C]PQ7L[STUP6V9F^^<M/-I5^B4AB^B*U!4ZG+5]M<#H<=]= MB0_#9BTWCR,NI\!/MG1%2.^P+Y%X+K#.W!6)KDSP2IRKA]_L- K$C\K<<;4( M?)M]J4_:4C9'W\+-G_"8CY[RP^-&RXA_@]MQ+6$0/N:FS-OQF*1<@#J, M_]RE[I#,B06&\*B K.O2"42'ZS'HU$6R:_[W^&4M(M>J.?V7O$M:K[(F;ESZ MG.)@YR-EBBEY$UQ+[L"XFJOBQQEF>58J#4.9_ND@F2NSL*XO85WXXNV&56&O MKQ6Z3!S?H6F2!;+4@<15*1>T#F)7/9H@^2V2S[\=)NIXEYL7$FP]JNIZ RKL M#4&R$.7GKB?;%L[7NO93L7U)IP\H7N59*;GUH$.5 Y%RI>J,.RPSD>-FS43S M:)[7.-#,T2DP)3;R;E^PK8#A+PR](4PS8PT4T.BY9J,7MD$5$IA&5=OR^"QF9+,3@0T\31"J0E M+1S B1IKT<;#=NQWRG?)$R!>[\0!Q_6Y-CE"_ $*5&#"C=X#^-AH0 ",,8R$ MFPGB^WL9 >ZS,]_A.B&>8CU_$CWQ#@/#*PR';"?V[3*Q;A3T '5@Q!!UT#+G M('6 8WU(EJ1!#83!73&VT !7I"AY*_6'^MGU/@0H' L*2%X%BH8@9'PS\Z>32UI-M+7?68"D%/4_2&K!U;X>_S MR&1;*R\L9D_JD]S=XTVFG1C&SD3;S6)-)UXX=\+C$/'+,]>44R?^'N^-3>WR MP=)?$?ZJ2NB0*R&D_BBU0WDMA_R=NAA'U0;4GWS)M;. ;^,H_@[*X[?LKQP< M8WV;OMW8,5AR>(;)%+,P"A*83H8H"M[IEP.[3ZAR[09302+[9B?@.?U3T2<- MU?.Q+4L5(QQ$A,VH"ZKNY%!I$V[F(G$O[H,.7$0G;DJ3O2D8+0XUR988YXN8 M\L3[HC5:YN54O$^]D9&*^FV[ +9+$MYSFHT^2O"LR.!,TE#$ZA M:)1".L1[P4)-1W&Q$;5O^-'81'/!5$?DH#^3&A!FZNJM*+L26,'J =N"O4*K M63"2(RMNGL_#!7U4HK^./?5")M!UK"DF M[3,_*QK41QRAJ^I@B_:#&7S%4;7'WZ)JGS)X/EHM^DILA;>Y6%FGQ1KUWL\O M?T&)>OF+JW["^U$+,VZ^_,DJ.T<*U:.+XX\=^&?I&RL[A>]FX77(<59^D*_I M+X*87D;$4>[<,934DXNX4:"#SH6+J&X])M[K15?Y/A#THH@7.N;TXTU+H%/& MTAV#0CIG/ZL7=.P,\#88:LM1CPIE 5-YBJ/]C9I]W7DK9OZSK,T$T(162^?+ MW!GLCOH$4L#()'6)]E6_HN@)<-_D2@@%86@,!%,K24+A4>CQUTC2$Q.JBY8$ MSQ1V"AL=8ZE@&H5KP6?!OVDG<^_34MW8@J)&>>:>OH=9"^4I$G&B>YJ6S&." M91:W()6W'#;M_QO$YBV#0>8D&_]S&Z1\"TH/"0O$ST:91KD28K4=40FDV#A@ M:D0([/9U0_DZ%\S!+4:("IF6A8\9MHUC\L @X9SAZB*(KL0N589QETVS&W3('$>D>"@[.$G MYU7]H6E=4Y]*OG@*$X-OP;4R.Z4,4M[2-U,^;P&=%O+W4I""AD&JC;[$@:%Z MCB'S_70Z::I%>ZX1HQ;0&D,K FAU9KNP M8L"Z:EP%J8FW72+/?BF+9=>S31OGC_9TDB\67+U:>6R/P0L:O$^J:0"&'AG] M (98UK32DP1DE@?@DG/(5MLOTC$ ;.6Y"J*; M$'D_GAZ/VG?YG-FJ8,0^<]_(54*+X':3)D6)8R MFV0(HPHGN*M\HUV,!"<2:,)$C>D=[B8A_=2)^F@EZ21QNI7]*$9ST142_$7\ M?G A$\-_@#':3:F)*E:@!?)PP;Z*N81I(<\K^2W+!0;6H^ M=B'8,Q_C5$RJOYT[@F$7P$J%B9#'-Z&'\)* +)/!7*:5)3;X RM=+6KP3&P@0 MA;A.QQ>WPM&G!B28%LLH_J'@ VM%]9V=YA2.6!JF.\]/"Z;5L>>UTW;.M 'H M9C8[?5YPW0\>[>I$5PDV(S.H(K#^YNQP"D\N;D'5C^^=<#7 M4LK>1Q8HT[0IY?%SG%/-R: C9M-_UU:S#^!T5TMDGU$O8+VIT=VC^@BT?YD3 MAQ"0](;.B6.,=_X172D3);O&"G&,KMRLCAF=WWF?*V,KRJ)E[XV4@X8!$<* M>'S\M\.?V_%1AN@T+^^87=BASFAXP&-VQL'] 0F_GD0?#QL5+W_AU+"[1X], MXW=,.E!@&"Y>_W$BWHPDW!QYT;?.E$S1@&S;9+ MW?'"@'S"7=3XFR#MW_<=O.A&>]#91-\B2%PT MGO:?F)OY@E+*"S4H/J<8O'M^]/[E[Z^GD_MW1VS,=YF\2S0]N_1/DB.P M)6&-60]^=F'.QH3Y)9_RH%!$(A$[$+(-'UH^";]+8:12]8J99.2DL8)"'IJO M41&Z"93#T-**]A>0'Z+?BU;0:9B+("N=1 Q.R#(F@1A$/9.B-LJB87B D $, M<)]O^T42_L"]T)THEV'ST)W6X-37V.$'E;"? YY:%#%PM.>;)94+PC_E?W@/ M">$K<&2OU./;>BTU?/E1)=4:KKI"4/5EYH$-X2JNEYC+PDWR%:6?=BH,%^V. M1,KGJ)15/&A6N6X';86S)$^U>63/RK^7:,,+D=ZT$U/1;H/9_*\-URGD)G65V-=4.$3'>$V-P[=6 MAJF7I6?X13**4AJ.FV8]:,K,EEF?\2XQO!JZB9&#K]U?.]_L28:"G^ECNQ'Y M7&MDU61%!BH8Y8-[ I@ 'T[RXOAD@ML+#)_S^^&/F6>P6DKDCX*GB71.)"07 M92]([^._<._Q?\EP]ET78B9=)^J)Q!M$14,;%EKPO>D'Q <$Z6#Q"H0.7*V: M+76=C@8#9-W4#G#SF(M[I'$BXPY<>+*&R&804H)*([J/C08BO(+==DF!E\#R8N=M@,A*6KXRH0)SEW8B M04%@99[52/W#WVS/J]CW_/L"3P[Y-7BQ!:/)*#ZB,,+C6OG&B6:8H/(6=I^* MQL@C[SQ1E+ _03$IE^Z>3GK;DSJFW[Y:DJJJ$>U$^$*GG\@*H82F?2F,J VN M]+[ DA@RH8<^;&[D=]0:&+)+DM (803*D!4"+T>^"E7WG0'WWWJY6[V)'O'_ MVV[OV=CM+:Q0?&>_\35<@<_)5Q3EZP/E M\S_C1-WV4NA ^#5YI^2G(^X-A< M*W#BE ]3&;7J06M#H5<9'("53#Q;K9_ ;]L/!5Q[KUZ]X0U2&'_P,70212GU&/FX-Y/]^0&.[S[V]UD#_?EOZKZ0W*$:X1Z=U]O M2U@YL&$075'4S,>JU@$%]Q'FI1KKX4\/[B5OQAZ((HEIBQ(5W7Z@]@:NT;U- M258$G,H6ICG(>S]N7.^GPIKM%I/N%FJQYQ4W8LUBFEB19M==_&0O?JU%;TA6 M;U]M /V';P'TJZWD+]@'G'T,;@KA(4WF5@] 8L^,XALPA174V;=?5#^UIS52 MI-#7#( &6?G@DV M',2G*W083XJ"YR.>ZE]A57?['T]32QWAB^H ;[W'%Y MM8$[4P[=_F,LGZNEY&K!SDBQDE8UZ(]Y-;$II;B-:D:(JI!B- RFB[08]%WH MYB9S$=ME32B9[@GR]";F-U[J5'6A)(R"[9[SE?*PSK=*RG1R)5&)WP1127E) M!9""]$'&25)AO8P642M8=%TD1"$+4-1N0;EOR8P@2D9-I4RAR:R8J<2B/E@V M#/9O8RHO;D'L0(P^EF870S@23E":SI"2C565"6;>39Y+W.'=?SP-'G $;ZBX MP/Y/N!.+;)4\75*+]@ XJ+&(K.D?\V@T X-W>Q@4"N(\-M*_WUW4@6MDT"@+ M4F=7]#+E\2,K2V=D.@D.21<)=GZ** /6"@[M*J#'#A>K-2'=29?JXZZ&3M5P MPFB'A$,YTL:(W$"I,5D@4RSV BYTIQ!OI0$K.GJ%+V"B2+HW>3"6[3V"2[O, M+&$%:Y(^QF7FODD>;2SAO:BP/U'STQ>(U8PFA8\ZD%,CX6\[).Z^@Q3\B6QF M2-R:8$?OR#O6.L)"'+EW"N%][][V+HJ-77PP?WGFKC"Q8PQ.Q]D MB,0 1:/0?^;LEAS.HI VLF+A>$,_]36<1-C)0=2FO>-[G1'1R,H4L,7+,MP= M11E%_W-M@^ ?0['S]9JO17VH*?3C!W7(I%/31-ZENOB.$-0RU6#0/6LRSPX. M:CIWR_?5Z_%V@NZMLOKN.O/>UX,94GE89XJ=^G.MRDF&>SJV[%7O:XU%P$=L M"L1\5V19)0=V[,]3R2C@Y"7<5)B;+LPU-^)VT18 C2X"Z.DAZ2&R)_%]YL1= M12Z1U/MVWBRH?Q+'6F+"-94/Z1+V"D13>0-%_4SS"/X$,W9!XXB.);9@+BK! M_-8,"Y44A67,L6]AT)AP\OFV[IY8*^BCKE*E\7C!QC5F8?*/F?KL0?8]4",_ M$)2V3G[8RQVD]N#'!P\(3@N''8S14I=Q8*]0+>RIG!0A,HL/<(^ (;-MH.G2 M(IH*,ZS#WF N#:T.[Q12>BQ)Y"MK?Q97QV":$S^\_Q"UJWIR0@K!JC/6'C#H MIV">D.PIE0J5 Q.$NK1?V/MA'Y6X4\I8X2/%NU3-@XS1+0'%.LUXLP:]!*+[ MTLX'RB9!'A]V^JX65L+)#9*NN42"1O/OSSHYMUU9S#?[)YZJF?L!"1CQ.97N M88)':#3<*!W%/M$F1:OJZ =D3.9DP9L*.$9IYB1G MTE MTP0KZQ%DQ!:"*<\FC2^!\ZZ=QCFES>_F%"8H?JQJI<+4586G(@+:)6J^ MEML7B;C8:X)7^:N-?08MO?7U>Z92%(^?*\=* M<3:;]3S38R;!_J-L.3/DM,$E]"+/A4)2.?FCX[3K PLDK,%4X7%%\]15WM'F MR=OSCZ?%<>$O.-?PFOJ7V"O8Z-O]VX;1/G+4CL.^S'3"Y'@=;R6)>B,J!NF@ M4+B_/'15/,$'5GZ:2H :TH^>'&KNIV=L,8N(_6D6@A)L^Y[9N@ M!.4/U!V"."J5C*M:^ !980PC9XQ4ZZ*4C1\%]O]3[O37ZC(_CT?/(LMZ<:5U MA2NL\PV_;G[@6QN7.,.1>FWP"9@5-3CG6-N#N!?7^,02V+%0![GM(PJ>\0LT8>+J9F'0XBQ;K!T 1KI%U4_\RL<.5B(*&,W!A;E5U;:1UF%I=< MF@5X4$6)VFP27$ MF,"1+#KY?$XN @=R_#%/?'.^'A67#Y/3XX4;)_I$Q#K9"*$'1T:*P48O#+FJ M*(X1L7S<"O9QZH*L<+!(OY;CZ]CTGX2R:3A )/+8:]\VOHZ7>I]$HDAO+\TN]QIVX=?ZB56"6>" ZLH-^;D MFWE^'R20:^N*".>0+-R$>F5(&K7D>3CSKS4P??_>M\#TE0/3 M7:MVN[3/-XX81W)CGSC&92)5G5B(PZJZY%X8C1RTR#O.UY[IR$9OQ8<1N#;O;#U7LC'[H6GV,#JW8>+Y/^S^?ZA MN+?R21EOP%)+27Y+?H(%/LC?'=#U(D<1&L7W'_A#@OR/G#BW+-Y,ATJ(W!Y@);G(EZ7BP M_I98NY\UP0F6J'Z^0T#?!PI2\$#/,6^_Z$C61B[&CR>K_T0\#9Q&= M;XLV$(:Y9CB\D7&51#3J.YU0M,%W[O;8<7A,000?C-$^K99S89V(0.@PZ)]G M#*CQ <0.O55#D&4Y0B+64;V/'[@.YD$ZZUAZ6RTS!"9D=78"FO:T7PIXL)?U M0#]?8J=/QG;Z#[9?WTBSA1'EB],(&B];N"[(][8V#<3ICR_W8Y5M44)9M8LB)$TZ.>+2P M(^; %)W#/(:[Z&IU7V?-//M'\NNR.B:D.=I"TI'B"X2X1KA67V(#!+C<6"'C M%$4\.W0MT\DS-JXS-:WA.S_>X^)<)]M:1]M-W_2"KH3/4O.=] _%*KM])GI% M!HQ=ICH#@_<=ZO6JG4JI_UI*#%*IHX!53BG^G/&,:[TZS9<\7C^U)&L#WY9' M$FF)^5::U(5TO1<*FX ?IK)=L'S-$)&P*.N@&!$1IAA%[9K['49TAJ$OQJ4@ MF*Q6LHE,&ACDPEWJBA4[CYQ.-/YK6S$L,0Q\C,E+!AY'*4HC*)P8T[8("EHO M)U4GZ4M^* ^=IG:>K1W3'IF.CKY7/S;=K<3ZDG5DX[?+]C+8(9A#^%AK7ZW M%"51!!]*('[5.;88PU8_$8+:E_MI-E3K&"V8MEAM0^ MC%/K>=LN^3*Q19!=,3!EAXTM0,$:YN8TE#/<8I/-76_ *)U1?4Z);?#(8 BR M'DY7FKFEX49(2?_X9!L_6TK5P1!88SM)2/#TTY)[LQG]"TJ%NCQLYP:5A0(C MR)>C//'9U^#\4%VE7SGA".UP&T5I,CTAE#G+8D3QJ7. ]. 4>L9NTX))GM]E M*Z)PMS@B-WW+/X%-/XHM21);$=S2-?M,5E\%7U6")FO=.G"!=K%48Y$;172* M<#[YA)_M/&$["<:QRT2VAA+*JKRCL]60@G;W1%0PO /GSEJ=>;823&5@ESTZ M/O37&UT)5F5F*9*]Y^;L]+#5:]'*(ZH=<8^([]XALO*#*XU&;G/0&.C_ MTN@2C.B%@O<%2!V]WLS59J\Q*I.,W'68I!J[W2)8,0J&S?ZQ*1HI=L=.G:"$ M:VVRGM$LIH5ZT(Q5FP3Q+4K&0ER0Q]7V(L52U^QF^V'S3I9YBU; M>VH/KO"4S["]_'2"%H^HT<9U2?;970KQX3LT^C%8;?0(\>E\RSXA)-NO1A?: M,@ZY\8B"G%PC9 FG:6S*HC7]9;-S:E.$34CRZB5@&Q/Q)0?4=./#QZ_.#1%_ B_QKW(K6[^UN##HN4E [F M:/PUA:#?SY*D2<9S-)R HN@LXC<<:*'SD-W2%T&\+U[)U431SAZ6'D,_W4T. M7?FD=I4/0\X,1HL=KC!Y&E^Q)AO ^C;-EHW-7)"U1" M?PHOT'BN76F@J<6SL$U@=0759#6C(0MM%MJAC"@,#MOAQRA",9:3-%UF\ UM MT6XHQY&,3XD]$O=3[_39ATAX;X&/4+8DGRE-)N>^6+[$8REI5$VX\IK758:=)ZKS1/NR9T:23#M&V02C,%9YIG6YNE1[ MNX+W<(K4$E5D40E.H"Z6X%3\][M(E<*Q8!1',VB]4AYON(7E MJ-NT!(V4JU]J\?:%1A(3I&<2U)G#?RVKM2+9^J4PM/%;7H5!Q"7;4J@U5:/1 M9WY!;+\VS^R]Q1&^3&F]@!2YL;,;B"_@P-9Z.Q=P!),9KY2Y=$&'JR?:N82# MO,-C#E:V)!=IIRIDI+J!VB8,T=V) [?Z(L->Y6H?^9 M3GX3"5-"_2&=$(,PX-?^E OGTX^5%)V[T\;43K*#UIE.C-KY8I,8TR*7J0+; M78G &;WE6F24V.?*2D3H@K^WB,_* M#RZ:TT=*"]P."I$*_R!2\W/A+O_4MW55KH&\)A.C=*4]TXEE,E-OUA9D6TO. MI:[8!<2*/M?NON 0#_6.D/*V432^P1& J0I#PI-N#C&A]5T)P.6*"&PR=7"H MS)W0I9'L<4(Z<.H(=ES:$6RYZB.HD]V1J/K-6=40.7]3S0KR39BHS>%-@PQI M+-%,X;4^I DS+IB-H4"CR8SVEB_HNCGO4*=>AT&S.R8K>$(NP_D0DV?% $*; M?P*\320]+QL= MJEPD#RS,8[#APIIKT=?:7H%+-'9L714=DW]@!^@^WYC10FQ1JS_$)#(*H.@LI[N1O.BM@>NEM3%*=3,'!DV+31M' =T6#T6/M<4=2= M!X>)?Q_Y5.6+1>*V[Y?4:G<"9S))VGID+BN'.-I6E#F)DK39358P&EYMK>AY M-^KN72-R--_,="M\0*]9@KW!LR;D:S%#ON"A%<;P%W@U>!"FD[P\@86.4IF0 MS+EW! N4XC:!KT3/7U;S$\)==!:\CECC+I?6V10O..Q_ZP!]U1=N+,T '(DZ M6[3F#)/(8+A8@CBG6>T(_H3!& M3C$<^>+EZ[>.#Y#;R2DS8Q3(B_KQX^C9@IFPWSMTRCO8TY"$O1U'E_+:['T< M/X66!RLF^,3DF:U &&VV<\7,X7JE1#9TF9]D2XN(Q.9RRR([1E[OBWUSCKBD M5M8:#7)#-:D_9BMI "]-? &19@+L#DA^&6]Y7S/;Z73;BR]28QT//>LAUL%9 M09MZO-YCJQQRW[K^L$,,O8?*G5FH'!T0P09Z[ ?F/^%7_YO["3J?W_7&OHN- MZK%JBBH")*FBM%/!'!^FX;\?XV8&GWR?]L<>, P6M77>K8YEFWO48"@<;^MP>"%R4WYB,F.1IBB7M%$>=7;H1Y+*_>BG*"O=_3/] M36.YXF)%>]+?8^)\=6T^BJ N6%/C^7R7YL-;PS.@C>Y4BSMK\'7RMA.9B8C5 MS=AC7S!6\VBF>FF%4 M-IM=Q!5HKR-KQXSP^M7S@>&=T:%DR*[96GVDMZ\3]'[HYUC84 WJD2N9E/S= M6S11GGM7),6!!0VU+S8U_<9WF[UU)/'/NTS8\>"4C[D-!*\XR]RA2&*>$BEP87:&\,XE-6R:>A\&82)/MZ;GLQQ*/=4ML'5X7G M*>,+Q6M0I)QZ*P/H$FEYL6:%4_ZK TV ^[;'2C)S!Y3%._' M>.A'J-NI:*:CE!OX2[/(G+\T8I3'V(MI/2BXR\\=I#"^+)OM((?VE4EM70'\ MM5AMD]U);1V9M&&S-:M&K+;2Q^;3DMI.)S?":IM]ML"IE&+T>RLJS#%[RGMJ(/]EVCZTP: _JEI^QAG*Y%Z+Q7A2V&4+_+R MO)A]D&EP0U34!]0-M6M$&?+2$RY^\O3X?N(OBN;4/N]M@9&!.:B'Y,W=H[LI MU[52\7OT\;T",JQ,6J+CBRXFUHCG2-N9 **6DDPNB4/KP([@ 1931JG84L M1$'X!4*>RI4A$^GZI$&5">]!-X >B9GWG-08 R&7V?(;$+OU):R543ZZWV7N M$EXX\N,?MU1J&Y%T_@NR4@IO8U#FBDX6_D$=!=>@< VA*\I3ISXU< U;4IT:(U:H5IK44^!DBT56$/,[ M>(;ZH5JUNTD49F.*.<4]<(G*/*%[;%W3V[7Z'$9!%=/PJ>$"!R.>_=9912$^ M>)^.PF=4=KD<,BO4.FR$E,R*=;:4TBUJF!:$=7RPA9-/G9^9)8U&@]+!.T:/ M.)>G4R3>HG1@WUTHH!0RW(&=[H)F+A?PBC1RH!:PFYQQ-HH;<_9QDQ%.LQ8D MB=;7(^*%NJ+F'_'US?+"=2BFU)Q_<; ,'<3*L(^/.^JJ]AOA\D*-33AXIE!U M,<>2A! 9$Q1BQ5$TX:/SOR,/SG(OPWX'X^-:?TUGW%@X*.(==R(_GSC,D_2C M/,1S?N-AGJ(>BNQ\B4MDE+SNT.$[-"8%XDCMLUZ1>19<)12(D4T6Y:$PCQ"% M-ZB@W)VOG<,P7O4&N[Z>XT&'T]3D1\1^1T8G5IZ*\D'MS_1>N5-\1O\RGD[%>-Y\]>3A*&/<4:U[OS#$O.G(.=@S^ M7%?8A^Z/R#5*YC)XX0O7=M7L,-U)"B\7079YVQ.'5(L,8;K(9ZQ34GX]*K.U5%"\*DSL(BA*N@)8*?]!21EE'#N<(UA M8S*"II. TFQ02$QTN]MO-J.GY=Q*T<%*=@"1N':9)7/NJ+MBFR((A/!+W#W# M1'#_C2VE5=EORA UYDO#X"07GA!]63X&> 6L['..QX>%L5+U:HM=Y>Y##(Z##'23 M5%M)'4)6RUB_BB\A>L,L"..B]U5&=1]^B^I^%GZ"WS(B6M.BE+>95_NOI6&D M=>E*##,@8+2QL0$ZUX3MN5;! DW 5\_/T-;L?FOG#.HH2.?Q@!C*1ZA,2 P_F;'P MQVA,%B%?AW9+ J>VOR3=P!MRI<4#=LFUXG5,&\K 7GCSE=,QQ(7G>@*C.JUYSV M3P:S_GQ%QF,XXXG'T3/4!1CU%+#&2D5W$[-,]%D=5) \CP+#-AQL\FRCV5@' M9"+$<>?V],_"&/9[&T)ZULL-B#L@W*SH]@D M?:F9A5+S917GV9C4C$39=M:9F0ME43?'X;#:-2+%#$X?$Y2H'Z[9HNX;9:-[ M(;B!EP]%YA8N,HV?M,B0\'XY!LZK<#IKJBB'LV1*?#8#=XZ:7'MQZ6BG;?_A35H+L9&PY8 M1UI@@6[KMCHAWP*_(>F_%3E;H!D]MB6H\Q^H0\L:]9=L0DZ1 (ZC)2?&9P9" M3">VL,(0%'0=-L\P3CZ=C'^Q62Z*Y=+1ROC?^[QM:@=%7IW4 S/_BDM- M=I,_-\E!FCQ,D\=I\GV:_) F!_"/@T?T]8/',BKP#\ZXH.M"Z+?LR)F2$F,O MI+@WRV4/QO3Y$ZM:3OEXK)SR)3Q\53HRD5M)>]498[?NXU*NTNA>JC>P<818A KO;PZ2CGXAW M4A_J@W&1V3_8WT^E8]URJ1D$Y28@:BF8'A$LD?@CH+%B-H!JV= 9L)U.XYRX M8;'S(Y-RX($B^#(,M]_KIB7P6'%)IU1O?M%(R:"D9"<8^^0[2FT[N)::U.N1 M%&D$BE4J9 X,0Y02:EC[U)A6221IW\F-Y+!BARTH.Y=G2JQ!_>>.F.Z,KS4.B'W M&3V#X#61*77L*YK^G'_"MK'&W[7=++GU.YO[F>&']8IX.XQ0OH=HA2B*?'00WHA MQGEU9A:,?T]QY]A:C30X]9<+^C_O[W;B+B>2T\G7(I-:>9!>52 EGD#F6&2' M8PKJDY#%\M7/7AT%6\X17X\BTJ6)'6T0^L7S;)>_/).=[DZ-Q$N]D:RA8^(1 M$B4N92>04RN4D*KGX:[>>#)Y^R&ZH1'$5N<#49/@=K&@B7@5\\KN8X M#9!0C#UQ"^=3(O0O)4:EOC[.U,PJ.:;T T7"'!78&-6M#E:&;R?^DV^!A MS["/A"1$F/$]SL$>V_>#,2L'ABK['):>+=)*U.BL6R&4 MZ&1G@>X7&V:F6Z;NGS0Z)PW VC3>^_-J#98O)8/#/&9%HZYD>V'QH?UNG+2_ MXXH3C0&9?+A @V8N:)'8 H_;O.9[%IK^N3R-"!T%.1KC!D&BJ9"KV 1%266N M%"H7P5:>1:+4:TT+'NLYO_0SNG5D&9'@AX.:/%/(,$U405$<#WG>B6YH!'DY M'A[!8@J)CP2H%HQ2&(2R5N<0-;VBE3$Z(4CG84%+=XQN=$$O.T4KQY1-."O9$LU*DVO:ND$'9TH$NILA".M8,$$V5.:#K%C>6L8F?E1BTH5Y M=;5[8]4[IT*'+H+N5V_17<#%[I>I2_^__BX8)3LYE'R%"O ;6.(B;YXDKZO6 MA/"=^E?UCIE3SI.PP8*4 9KCXY2)-"!IC(V+B&SD)^-.7YBRMX^\H#9C]$RQ M5(3+S!NB.LJBY4FD_%>K$WAN( MM\:([ (I83?Q(5,,DRUQS3!Y +:RM8E15K1JHFHX84D!F;_@%,RX?-#UXE%Q M%UG#-S 2OC\T>&QD%+(T+:T)I;0-J WQ/Y4K6'553A'#U.'P-7^]9DD))<*? MR4X*X#'H*S:Z/49%+-6N2/DJ.]Q!BG&-H4\REDY9=1SXWAG?9^*8 MXWQD@; / GR5Q*2L AF-#@C7\C@G.5UZX%",8];RK'O4&A)SZ&CV\&#,/9*" M'::9QSSOPVX1JW_N>!:%0]EB7'"LL2T?:&4.(T"8D7K7[@VH8IH"E'%67LZW%-U2.)3B0,Q MY_@*-3NHCNF$*HVPPYB M"#?0F\6T,MI&ZJT%%7L="IDA14/$40S"Q]6H\.; P+/^W=M/TCNW$[-+S6XE M9K-<*$2R5=02;E,Z*!(6GX%J$U6*-S2:D]U;GR^:I:&>[\HOLR^8C0YV.+7[ MBZ.C[6'^$AW@O,KYEG1=WTPL@NF^:'/A[+OHQ0)N=[@V8?*;Y=I!/;"_KKGU M,71_3!_#3XYS.",+%=N81OOLY>NCY%'O?%16C_61;"UXO2_\+-\JTWBT=Z&Q M=SJVG",_4"!WW#2"-X1+<*OB(D=0,RJ,J MN#5)W="4-8^!?G6#D4O9 $N8-/3;6-6YIQ' Q[JV&MT99#!K/.UM\N!>#/MM MOGJ<4]L3.U\YL+N-SV$JG=S,P]7PDA/AQ*5O*FUR0#:A!?J=\7Y!NOGOM]#- MNQO%E4T$!VC6R7DO.#/9N6'D/BD\^Q%;3]A?-SL#/:!>%OVZV1"_A%S7(6PI MJ@O"^U%CT+D):9!Q0(J[26TO$W?2+:&(2X"VB* =R>NV!X M3"##8X.*-X?I'D8W]T["T=R8_ ,LBI/R8/QBP[@#D,F,1PSS7DJ7:BE((B!Q MF2]0O[@3&CH.J;*&H&5[RL6W4AX[>@&4YN2_ 0L@YZM'?1E7>LG$.++]\=P)8,1,O$TF3O7J-Z7I!'#Q<9W;X] M!ZSA>8Y$HNR M8 ^4^'5AFW7%UK6Q-,-2I5W?^?F]K/=7O!;:;E5==.V-I#*JG_>-;BXN4L,> M>ZL*Y:UE\AFFLM7H0!= <4DT\$!*W^-N!QJ@2[A*4KD^$T/YD,*TV3(-A&(M MXE2@)5HAK!INO8F+!UP;0[8)]CZEB,/WC1YCC$@V# #K;^]BT48@^HIHTZ8B=""7NIHPT#; M(:-09HVZO9Q(GOM&#C^AI0B:Y4 NQ*-G4XXK//=E_[W]L0+QK06-^]0'APWZ+ FVNOPJ<6-C0,@=T4AD&'=UW.>_4EY7+1HX&)-W M(,&PSV!$.H@Z.4#5J+38\@?C$G.NFF0;]QR3.9[!.6HZ:#GORCDAUI;X/^U= M:T_C6-+^CL1_L'IW)9#<&1*@H2^+%!(#V0D)2L*P_;[:#R8QX.DD9NVDZX7%=V5J MV4HRR^9!<304S'B;Y,,LZSP\S!:U4^0,)ZH^3@!,/TE/IRJ78:7ZR3>+LP"C MVC(&)6/<,J7&FCY@9),>].J?2IG%\,S/6;04XSP+",IN< MW!X.3:\3*Z7A>'!-$U#C(XUY:('D_KDY*Q=Q\/X$U&!/)JE<$8V$=>01AFL2 MCB0MH=&YH3^@P/*7RZ-V]RZ ]9Y'^5HV*5^)^'[D_!Z%:_5N'\[R;K=L@@U7 MCHLLUJ))=A&)03G03+&'Y7%3MS_8M^NB"J1;C(S'M$V<(*5U_,2>CBS= MAF $4[6YYL[#.J(O\7;I=&5CD&*-SU6TF-F'C%+G'2. *RDJ&+]T[T]P="PN,D!X6RIU6>#:K>)T16('["M.[2#I^EQ%=Z2JFLGX GPU8'A/%P9";5+<9'1Z M? _ZT3UA-;"F'6Y[:E) ('4'+POM DVPV>S["!HDWI82BD#,530(NQ8GF.5S M1RFA?5\+.Q\="+^$J<+A:-H:S"':# D@WK0A62FXI_L@J')_SF<@DZ)DRE),O H,4#:)T6V95[6<4\Z(4+]P=;)C1\.!@/Z!<_\$^,G/" 4U,9?46T8^$/>2O_/H9&T>_Y5OUK MZ2YRE4/VQD$@4<"=2=A92XGJ>F94;N5)K=$J*V,8%YGMZ1N/[J(8I(1(#I2R;%]0]E]=.\$5,#"U=8L/!J?;M..V.Y]N2\-R M5L2W19L >4$T/&H<C!0!:YI&WZPX2OC;#2YBF$C1\+"HGA;3O M!%TV[/ A[ZFZTT!8&U%W>)ZB8^$>@THP2D<8?"PYUFS:VX=N*U?ZRDI[-)QW M8$>1Z8$X3D@OXTT;W1*W[,FXP5-Z9A#G>I&&T?!]CUJ/U4C(DY0*+IOJ>&Q] ME2I=0=E-X"'B9%N 1L-E;D[>."G\$444T##GY"ETM:BXC-B2%6DK@4F96DFY MNSX[X8V5EC)MT!4.E$T3"0.UAI1G K^8.XZEO?)8U\WNA-!(^DQK;]J&:X2YP+#)>Q3KXSP2Q6>"S%B0J] M6-6*7;_,_:S0D:PEBPF;1:?/_#0D;!FG@)N;$#2%U!;MQT6);7.W+D/:-,I* MGD8 !!. @H2+\RL%8,P(@-/32@:(GE/"F_+FY-".#A4N1II$/R]TZPAUR^Q< MY+>V.0!S^)1ECJJ/Q;-D5ZR0((9(]4#9^',DBZ#[7K&O^..;KWA%\F<5!3,3 M95E(TI CSJ8&!X5EZ6?\E@ ER7)U/X)U>YD&+*/&IFDQ]K-:=-V6UR9;W-%U M=.6[S0UEIZ2M-LMS:+XYSX;&ID;)Z![LX?0IP6KB?"YO:"'FMK!%9QA!6*49 M$6R8LV35 >#B+,.)1M!(!TB.5WES8VX=Y!GD$9'D#,S438!V&P9MP2DG4/Y< MUGYSE27-!YD47@$K?:@$315X0^)^KF).:3^6#IV6CRJ.C&L\KQ9GG5<;&-U( M= B8PAU<>((\O2;_8VYA.S$'TJK#73H#N#/=:KVQL$LYRG C>AWV&:LF9BLQ MLEA P@'*Y<<]1U9H'8&_T6Q.P>$.2!,SWS:F0"J=;=N_'5N @Y%3W-TI.F71 MH+$Z.Y8'0N3%2G"=8NE+^U+-FK&-[8L)^0X1[J[??X^J^).8S'='H[LOOX@[ MCIR3?A3!F57ZI5Q'_R6T?O$C!)$PKYC43GLT!K.D)?KD3\04HK%>$6L5!&WD ME$?#COC_.@6Y-%N0G3)XXJ'6AABP MD[ W[H80C6D%%,-([L)[$G,+(MQ5(&@#XL ''A5>1 UM;0%3RH-,SU4PB7;@ M)HD1MG8=PNLY\Z']7'E2LAM,A1JZN$(&/D9C<&G\>M2:)8V1Z:7XH- M'R/!=FW50C8WBKNS$8-8 =LZ^T @OLUU2UN!4(>$,@&[?2!MQ6Q=Z!2H53<8.\R(=+>O1:X@I 5*R"ILSZFMA-HQPCZRY=8&1V)RE#*+_]G(FB M.V&Z8%W*(Z( LLY:[/L/B3[BI@*Y3/"2^_WSR^\2 K:YD9(P[,SQ606!T@J; MJ3#^YD-6)8PR\-"%\$N%ZUD-%;F*%N=66M]DSD!$C]@_<\3*7J'YA M77'^0)1V+OBI6T.NTJNK!H8$,PN8DR#%O@*G4)RC2@&>^.'@LU,\W"MN?=O^ M##4\^"WV&N!70>L2:05AP ?K_H@&?S+PS_R$+C\A,)_@R^A/IF22RV#KN4VO M%$X*+=7TTGZI<%@2AOYG\'H!&WCJ]0 !>:J7[QT4=N'5*115N@DG[=IJ6@"N MYM?I+M_=>7.7/YZ^."UWNX>E LJ\LU61"];2T MI%26'*06R]#HPER) =0X* M)5@1T,HB<1AK%ADJK+I5EO5E8>D<&N[=,_[6$;%4#S,\1EJ2LU2TSR,A1 MC?8V'D: 1V_D=:-)')O0DL(EF0 VFS)S.%%K.")2D7-=(;(T03%3, *0J#O1\"7:. M^I*4O=L?)P8Q3FY$;LD)8VWIASV5$[OHG"TU'3W5'Z/QPTBZ[*;+)S+(2@=S M&N2ALI=S\]13+.VJTT1X AP&8HG%Z-"4YQ_YHC5JK_U9VNO*#YFFIH.X9M&3 M?XWC2=9[OP7']5$B$_30@VPY8S8W9E*C6;E]6+?3\,*27"L?VK9._LV32!!Q MR,47Z_M[U$7:B >?Y();!% K.*GS26UFP\Q*!BJP.Y*#\?N8:I[I]6\<6#DK M1WVM/F;UVK4&J=.O7R%\K&Y MT3FKM9WR:(9[<[K4MQ MI=9PRI5*LU4M-RJ>L%T[9^(I'C2R[31/7/S0[H@7B$].P[MROC9;O^+OFI<= M\>[3<@M?7>NTG-%4\:9UAN+F46Q*8NI_&13;GQV]KFL8 MPQWQDBXK.4[&D(ZC:;VS#X+$JJ*<&I650:$Q2.D8##!J*^F#-:1%Z'V( M585]Q0V,HRW)-?Q>+T8:XT*?S2WTX+C_;OB78A]6NR,XI>MJUK;$_K- MZS@GS9;8-\4EK]9PG?:%5ZF=U&!+%B^ ;=2IEK^*O?)$;-ABJU2[:*76^8J_ M6>-0S4RBQ\,Y@B%8AS'H5MHO=[ 3???[88]C&>/4#Z7>4*E@4/OB5JBI.U8T M?'++'NZ,^H:$TX,E8[XJ_T4DR?->1Z<\XKI_3.N$N*?9M$T"1TDWBLU-#4N? MPH%Q,.5N-[$LV!!,R)Q"T]^P_XDY\MMI/85C\S6.1<'.VH%;GVZ$:\7 M'+U;?//VKE@)E&8F"J)9%L2P8^:[Z722-=X!!0V >,&[I+L MAM;WS :S#+AR6V64[W. S2X40^AS#APE=]+>IAO R1G1;<"H4FG<(5Q, M <4@CJ[+7D%DUW@&CXGNR_<02HMTL> / *I5278$EIHE@[%TE_X:O.JR6(4: M%A4*E=:^UQ:21X1<-V(^=W9<,/EQP#S]K(YYRL""A/ @XP=M^3*R1@!R$?<2 M2?1%RC7E =C<" JW!==Y>'@H@ D([2V(V=G6=S!@E@O"$O&GQ 88(P]5UO2 MY4QA"IH+CT#EUI\8][%#V-!ZRIZ4Q9MD.'6-Y]+23*RSI\@@S@B#EFB/DLR7 MN>-OI-<3]/\-^NK8# /#>;HH,1G-/R>;0GKLL2*.3 MCA>,P7$9(!0>IAE9;C03&&>G@B],4F\FNLR2I*D$J14K:CL/-ZH6?W[J+9YX M!]G,-507C-H@$)\UVD]96#J]>_X_Z(ERY[+E.1?E4V&;5?UZO.5!Z M,P=6A6.2N(LXN(WPH)KD%=B9B'.@8ZTB]'*-C:7FXH$T"7#SHF47!V);R8!2 M?4O_2]:&!XQ:*F=9B%J*(65]H$*GVGK]OK5O*\P;P*2 GR.4-,8J_(,\ZG-# M-#E]1L\09+-G5ZPQQ"6]3*:N&G.5H RPD*#O'&7D2Z=\7/>OMR_*E5KC M])_O=M[AYXMRM2H_LZ3M@: =-UM5KX67N55TY;V0SGKYHNU]DG_,%(&TO(#\ MT0KJM([XCZI\\<$_WHFEUJGJ+W[CKE!G]5J0/[3O_UB2U\6_6L:;9!>,E1@B MV=4G_WLD]O0ENY!J'&2^.&(TQ- V8!T?_88<%#$8%"#9B:O;9+?'>+#QW#.O M=GK6$;W\8#]VVE.>J5>5LUJCV?P5/!JM\H5WV:E5VJY3:U0*C^Z>-8FYW2ZM MH]M'QY-/9LM24JB6V]1?.(WFE1BCQ?>L(ERZQCQ"?>D'!(9%A_ZV@_];4O7^ MDOSB>+$PP*O1]2 (@QC5P_./Y4H&LB%.1I_2W7F=74&HSB?G0AAS84\B""IW M87#C>,1I*(X538K'F[I,_ >4^!%9),Y*=HNWK>'9E6BS<5)KG7M5"LU6P/OK M55^-+..M914"Q/*'-V$,$'R,N/")Y].?8L/#9%FOV4['-Y*^UJV'Z^I#[RAM8,A^$;._:%_"V>D*J/( M\O:PM]WKE>Y>Y4:GV7).:IW_.Q6'@'J576K^X/ZS^.';0>"E'@3:0"'R:]#O M3UZ5CLP]!9A]>9W]8(W)?+YGB+. @B!0A &]2L?$ _NF.O\\JO.J5J_7RN?. M<;U<:]EJ\US\YJOKU OUPILOY>6JT!&0R)W[_6#TQ[<_@QI-]>=U]H55Z;)6 MYZIC8IA2"Y&Z).A_EQPU28:$5C*N8730"AA 5:;>DE69UA'J^](^+]?K1S+B M]^47^NQ<\!?E4WV-+W6:ZLHE7P*<^14Q_N4C<3\S M<^W*F5>]%/M]^ M<#\N):@?@*59H&R"S(<4-^X68+IR;B6<\^;&HXJK/0K&\(AQ8YZM!0:,26*A MS@+C=_*8IO2X(L^B(X:G^&'A<86"W(0@DD3)P7_'?M^NL9F>YC0.&SG!_[Y3 M.-PS.F1-6'%_QH0]:KITPU4YWE6U' /5_8DD7'I\(^V:+:Y%P]&#>LQ>0[M,\_LOU?ZL*I9"RS8\?3I_/@4C:]_OOM;MQL$-S?OGN%$8FSN MCJUIG+F\^3"28&*:<*GW\N)RZ$6;HQ7#3A<+#&-6.NB,M("XY?\PA2,JN8IS- 9'X/,M\F7>^S*TX6L;J72T]2UDMZ*0W5P/ MW/'[HG2Y/W=$&!@]XK"+E;:P-"M&JY\ZPC@]T]DDR(-Z]P%Q':JM84J8Z^E# MZ4?3GF&CDVOL&!V#$A^;J%)F$_O1/SB>+RX.-&G+!<9_3L#>=/TSZ?K2 M&G7]"1"$77&Y.UV+,-!Z_RF75@/(4M[$[7G%;7>-XE8/$]115TRD,;>YX[;J%K#WY"NN M8$(@H24]@;=\][%J'\X[ 3]T\.=AUK1\=G@77!V''SH#@;= MTU$P.@O.+P:';[O#7G!X]N[=V2DLYNSPUWM=GYS9Z6HQCO(@FP7#>9A'Q7[P M[[^GXV+Y<_6__PDVK.T;H--6L1K_%DW*H,R"71 MWN[N#X^"UV>#H]Z OI/@5A/NN?#WK[Z8^-^?>!44 >)G98X.) _CM1" MGN_] *CUX^C(_/)>WN:MFB6K!]T!GOVDOH?_#*RIU):6X67T>)Q'X:?'<5K$ MTV@_O,KB:7"W+1UXBX-C>60?7N >5U"+0_(5\K/]O9W=W6CQ<136SP>5 ^L!_>\%QP>O8!N)&'X6?P;YR& M2= OBE44'(5EM(G^.L&3W2=/[$.#?Q!]#^I9_%?A%P>'\SC-LD_!:![EX3): ME?&D 'Z:3G8Z01@<14EX#8PCF&3Y,LO#,L[28*N<1\'?_[;W[!\_(T/.%LLP M72-SP^]^^GF[$\!8T7@=3**\C&NPF05CA,< MFS"01^\$.'H>3:(8$ 8>#(K5;!9/XBB=K)&17<_CR3S -13FETGT?0R MFG8V\3>8/2X+&/LR+H "(UA'48 L+;P=O'-UK]:6"L(0CSC(/H< MY9,8 +7,XXF]C>CW%8 '(*7W:G88%B(WX" 9P(#;="CX+_RZS+,KP*MI$,/6 MX< NQBD+PEU8L$UO6L4YKL)>Y6J)4%_E>00L*6>H 4JH;<&*>8X;PY(.\R"2<1 MBDK:1#;S-B%35&"\%K"D=<""Z6'L< :H3*--@57)\!XFN3RMW4*FYF"41QRS M+ %JP/TSF>#\0._3&$\#U!%/VG]U]K:W\ZHO7/PHFL4IS_OJQ_[!3G ,>P82 M768%4Y=]IIW:U0/F :+/PRO8N?O[(@I3^/?+=F1+NV<_W'&'6^&V.9XNL,HD M=LZ$EE80!IQ'>0%'/8V!O9;)FAABJC_!L90Y; C0;[SNZ(^X.WAPA9C?;@D' MDA^#Z[B<(Y-@EME!JB,V((<-9+HJ&)WEX(LR1_RFT8+!"KC_L]WG\A$A"G2Z MRN&08(_="9S">%4"=L+J4'8469!D2$HRBUH%'PM^BM-5M+-)D?U&9S#>=IDM MD#'@6>40<(<7@(, @6$)IU38^T4(]83H S/(0VQG8F\GR0K$@6&85#@C;XL% M.R)8P;M9XPD!0>%7R$J8F)*P*)&7316;IR,EH:%> \S")V&6=!(OPZ3=&L'S M./N[,/_$$M9]A5 .F")(7L+;X'6296CS7 8G.^>@PV2 E?&,7]+C!MZP8U ) M4N+*V1+U$.*())=*Y/C38)ZM\B(8AT7,YS3- &)I5@;3"#4(?*-NB[3QM'[W MVP?+Q5#YF^:?@$!]!9GV+'>.&<4X]=,R+36(6 MECB- #W&:2D>0%8"H.-2OS@3;(7& M%3-\7NBK'_'M _FG=MD^1,]&AX(91? FST!70WTXV$(L#XH8B"9$87P)+/^_ MK!+C+Y>DH<*93J*( 5'B?KF;)62[D$DP=/@KP258GNGW>J+$E8AM& 2IGAN M8_PKF:R24!U?Z-!,B"H@*.XK7-=4H^]:J7?P1G29X=B P:*=U4U704G2>N + M&I.Y[)@Q?1;&N<($UCT!AHM5">H:,.MIA (@3AFYV%^10?.")YE^6%K_SR_D!>T:F1G0(S M@$+_VVIZ20H7+$'OK'X%.VA'UIVQ1D-TC&(8SH*VAM_1>:), M&!*,%2-AEA9C[O P'9&D MN)X:=T+')>A?L(HN#>RZ=/"1UAMZ@3/81>>FEM0E'P4;BN-7:NH^C3-%P[%-FL 0)Q M@NJ7VB1HRR:'BD$DMUN*@(&93A=Q62%?7J>UR,H"<7' 3Z(EF^?#L%SE\%V' M/X%)I/[&!WD+J'T&LPA]94F01)?PWWF6Q/B :%.N=2&LW@'#.$P_X9) X2WC MI5$.$E)Q(5"]=[H['<=KISB3=LB@ MSL=.RER85:[U7!MK.NPD2T4]+ H\F.425+*2K6,V9T/@40#\+X+9G6#TQ'A% M4)B$*2M_ANA!57'8+_RH?%?L.T$U1[M*0D0@>(\XGWBP7+V//*@9\$3RNJ)3 M%_0[=+[@Y-I95,_Q0=79+ -+LQ;Q,!+ZXD)(#S'>A<8))I,L1T)-UAWV[*CQ M0E2-0AAI032C@'6[E3/]&:5A$46ETI.$G/"Q0F!O')1/M\+MK9?;:M?:*X"L MF( M\D59,WTG_\R)T$F8Y[)V.>H,_7=@ M1 HE>5YEIFVQ:.&UL\N;-5)A"^JYC%V$^,L$7=\+$$SCB*4:8)FMM57[8+39Q@&D4+MBL!^TI9O0X!\*4$H[%O62Z010: 8VFJ/-(=9?R!1,4@ M"- MVNCR/KD^PWS]95K8G=#YJ1$6ODQ0XE6$PM#X_L%T!#N0>"7ZB&E_EFEH MF52@2BB/A$T"Y,>ZCM&O&RJ;W)7F, TP:TTI%(K3D9(90Y0/@%PNO&(7IU*' M22K<[]P0[^%36X9KXO'J]*S=Z664X6?8X59,Z+&]$UPLQ3%#\CYWH)GKU]"A MG@+\KTUX:>D&B]HM449QE>.BA*=8^(JW9U'9ZI:>U1K9">_AB=<$CR+R#TR4 MV&H"99'IY2-5:;-4M $5*I5'HD@THL":U9\*A".P,G*5Z4E1.%NSHBQS9R9G M+RD<-RR!'!;*"84L(YR@*JY4(3*GK;4).S4;P(]$Y'H>Y#,1>Z^LL<8"=NM- MA9S"23%9@+W*V1AD5*@U;FN)LY_ZRHV.*^XHET!;.X8T-2OUC, MXH\/QIR?&>:LP]>X\J-5D^9^_U9[N$W.2L6,P[R"GX:(1(02&Q6:JYYES$P4 M1L=37*+WLRR5SF/+\)K -W"039'O&DWZ 4S8\381K&QW$5JJA;/!\5I1H\0; MG&2.>)L1(P1YH=]G3-4Z'0F+L"S#R9SR88(A_D'J*Y$,C.EJBAK+3FD@1T\D MH1^58N+!*$ UI+$Q-6W%:D5*=FK[QDZ\T-I5JI,7?3.F:%82QQ&"0FT7+!O1 M38D_A)\B1T0J\0?*Z#P!LUR_)T80!@XSBI%/0K'4G?4R#!QKT&%L>[N<#;3- M#%B%9D1;1K'@G0ON0$[4B"Q]H&%A1U:0"LAN-5H608T&:K.[-U"0(?U*3\01T-8%!!+591C:5>PN(A"FF*NVJD^6HG?07A. M6#NVY,NZ@AT";9.$P?%$M$K4^$6[-4%P)(D1%W5KPWEBR_.Q61%!">UH8:YZ MTH2G2A?9 3 SU"V8*H>0,GLZ)$H\'<31.4V:&[]\R5H()M:-UR@FP\+LV#I] M-1(P7G@G7,X[=EX+6S&\+0*$H^%5/ CZU#HWD.A5&"?$Q6><9<,SZ-<5;[Z$ MHTZ9%;,Q&! =PK:8U,(%1G2#H@PE7,)A-T1PQNH=Q-EO[C![;J<1&?3T\]H> M3+Z28:%)JS:7R=5CT#&QQ*R?+V[03PRU:78]9%EX-0& $P%K8>Y#S/@ $L/(E^W!V.U$_VZLTJ)(]W0C$% M.!MD-D8(C*,0$Q*2")9(CO"07*F!P%XQ- %5A M+($8+L _CUE\$">83G-D#9C\!38.YA4W"62T:ZTU=VP54M[PK!8. &A?0HW# M2_N)7+3IU&@K7QM_=RQ9W%%J=(KA(D"B)>?TP;<<#Z+A))/7L>\Y^<\^X"(S MZ4O:82@+@S50#O:5E@#MEI)J%8LW8VD\CD !9.$H5A4EO)"C4&5F5#4Y7\JS M\SK.Q92E$"H_PEDH=:-@@CHQ%:,TN<0.A*DI.K-R7&%D7]VPD1WT9J,*U,Q< MY\U\('.!=TT):Z5K$B7A=:<.YVUO Z8J*7+$+!56ZSPPURB=&BNU1)'[U@@)<0VF4!Z# RZ M .:R@P.8]%1]PV!1J5CJDYCH"X8@\=Y7YV/8#TYC:#\;_IK&C+E/2H*UFAZ6*MF/8 M#\0NI4X*575HN=FJM/ N?XTFHBG463E!'D"FKVXHW8+P/PCC?@;)2=>44)D M',TJ"%_#-V:PU%6N72B)]D&X>D(>B2>/>&>]2%Q5U58K]%H86]./M]I,1A@N MAO26#2&]"L<-;!;[DU'@.Q<<=*7,\EHL;;=JT+3.=[G Y&Y%CQ-:EJN-Z-Q+EK56R !:_5U[VK>BS76-D1]G*<+$,IBNT K:K$06'PW$& MB@61#G )CE*(UJK!*Q-;J:;+,/8CSC_K U)E6'@:'?WM/+L&>S.G+TTTH];9 M;AL;RY =[@@#%@#L-8#O:4Y*GJT4W6ST8:+)=9$*O>)"0[CMF$ -J$, ,*< M_/Z8'0;OKA*:'75P*=YQ@EX.\G* !15]_,G;K(OW#K?]AKZ6?]CQ9E/M9J2P MD+4?S*7\\YARY$$MR@I.8TXBTDFF:(QF:_RIM.LP)65!T2/'PCB9HEJ*I]1= MG3@G!#UE2#F>1Z4;LMP&V;IB'*L9P//SV:Y(JP!*I7M072P,)98)8@LZ_@#[ M836\R.9+>-%JDE#Q(N\PC^'./T>&" M!7)%62B+SXX[HJ(SR6.T_?J^+SDNK*U[%!HJC*V)J%NE"PY[4+H6+5H6LC%FDVU4J/(2"^]I&6:4R_-1+$@5#-TK604UV48382,Z^TAQ,#;>V M GTU"4UBK2B!?(,+GR!(B91.;B5LA2=+&MR-91/P/$,FS=+'80$Z($7J=W1T M2Y5&*(A1@@F%776' /%Z8+D8JVZ6_ (;'(=DX859M[F8^59O :.>JRPH&4?M MR2K\%X17.KGCD/!T9;&QC: @T2W/^M>0NI$4'C4A 30R0)- OM'^ M0Q99V\O()*?"B9FV%([CLYH,]?(!',BA1/A>71SP\1Y)62 SR2$6!0(0+P[\ M>LW.#8C0;OF2=?JUB@C_CFR1!Z6_&5S$;G6*#] %HL'C4;ZL+/K2XYSND3CYNJF$'C M1!Y:D_*M3!]M$KF1*F(A[9;Q_X!:'P.I2%H@D#_S5JUG86L!%BIVOKP4;]X, M"PN\\0(=QUS9R[X^"1E>J8(D"G%%:4;A@*\^*1@6%/\WDX(=EZYMYD?>,-MO M"T>&QK5F )6\%+TT"B.:"DI[LR;M0 *+%,93&K-;7HV[PDUP,-**M%K!3:Z@ MUMPG=_A*)P"AXKBO0(;U#ZJN*]5@PEZ3E:8TCK"R,/ZL:I^<.26F;ZEAPDYX M9_06>8MFF23=>#+,T 04 MK-NMIBEU5;GKH'=.U'S);E4?7EO3<]A5Z-:XF]'%0Y MH+!@.W#11%N<&/4U3;G0-T?"F79D9Z[92^NX<@FS1UW;%4VCDKQICNO,Y E9 MFW'[L=E;KD@Y.^_5U1FQ8P\9,]+=HT9V=2J^I'8+$ZXMIFCRBB)=E'I44[S$ M*9><:N 7(EQGJV3*;,\:3C@*#!H[;O%YB$9:,KV=, HG:(89E5SE&S?KYEO* M+N*T) GA8_6V242H^K@[)L!:&U_%Q9K"/"L"ORFG =/T=")N57S;*2G2XE!Q M9=@/6FNIZ7YTY @I:7&49@XO5V]US-"8'FOB.4:&-E%UF"M?N)5VK+U3)@DM M2VO1Y>>*^ PJTM-)6_%PJ1H_=_%3ES0Y.,H(*$Y6UK!UI!_+[2.=C?('CK#) M.RL1J[L2E:1[$1"V,IU_-H[2"%M?8H=(NPX4-^X>E.M79C__ADFVC=_)9/M6 M5Z;%/)$H0GP,A8*8A]ULHHQC!&9HE = MG57+?:OSR.BC6BV?,0+;.6>=I/?5SMFK6]!+5PNVJJ]TR4'@5E[]59,3GGY/ M3OAZ[?2TOG:,?3VD5<;(=%#2&MLMM#3;)FNW-%G902G68KG-"%B=ER:IC;J% MU.5$D8.#6 _)2#>A>I:G*S1&+M&,I]_;8>.ZK MQ8+3X&4YQD# >AS5]8-GUV:VW4AMZZ;D/8Q6V\T%.S?'90#E&4;J%1%72V!C M<)K*3E;1F6(RC\021Z9R&7'G?\_L!44M',.O MVV1L:Y2I&-P-8M>QO4FC-Y5Q-%##>U7%7YN\G#H\GTTFU-7"ROEKVF(\HT1D,-!QV,X&BFH8 M@7=F*D$(V3=D&T1I4\0-CA;=HQ7KOM:X#YIL>TPHX-XXXHIPRZ"Z"9 K=?(] MM+U8%HK4->I!+407MZZ;@0GH?C<-2@RLAE6I)CN%'88F<\7AT:N4JBD=';%Q MQ$+EGQ"B^7)5[/C"]/&-,=X1IE&V*C:745>;Z]Q8,"W>.J6Y*'3+6G8,4R:Q+LY5;ID MVDD,)CIJ.IFPZ#1%(TUG7U/PZSCZ)*^@ABF8#A>\9;L/D1YU=28;Z<^^U)5 M<6R_#6N0,W1#&7+N7D"ED2!>^CAXXU#D1*L(!=VO9%5J"I[%W-T6[.:4,XN\ MR GL?+LA24SM.W"2L(4^IC=D3)C6/))PPI&W2'TP*A>)FP[U^*&,*V.-V7!P M4O%\R$KPW%2>J^TW3-XHH=2JF:I98A>;)S>-^IJEI]D(E14ASNB(JT/B':=, MF_I95$_?CLDQ)RUOS.71\0):ZD-4L$>&P@Y-TV@AJB[U*#+?-K81>NF58J@R MKQO-IS3" R[%3$JCQW.8 A3.5/?EF.;F0\!R)G%JKA; M!ARXDPB%$+VH5PG.H'Q4SR4EVU3"5&IOJMGEG6PZV :.6Q"+%.!P)>\EZ3B[M$+R]>M68G#RR[7&0;\6 MR5.62&^I35]W"Z@>ID-U#0$>RN5IP*VO#!6BL_<6J>@V]+0B/T7_0"Z)<"9Y M14>@VRT_7HZZ><>Q%A3F:7O2K9WRT_ L>FAP7&$[%]P")=?-K*3NVT?8-[KZ MM%-H#,IQ'.;8J]?*'5#IS9Q'CI M",UF9GC'A&]F<)-B>%_\92K_2)I(*<6>-LCIZ@V]"CEE@ZJ1HIO=C.CYS.,P M,3G@RQ58#1-)STNIOI@VIN2E?7QN_8I'TFKIRBMA>^FT(Q\V R>^MZN( #-( MM3)%T#+YW*KO1.ZE])C^6Z'V<7(T,9)6%MB9VDM:-(VLO&@N#'^5E5&E;-K? MPVU"X2KX;=57V\4^%/$@$$E7V8@4R](I04=W O7\>$"ZWI;W"3*H5.3> UF6/B$H$,Q/T%ZABJX[H)7R]FZGR\^HV*DT+I%%5 M0Z\?(P.-M]9&M]?]TP_K/O8?POO3IRU]24G.M45636IM1$.3S]JT.Q MW,0WY@&ON&E(Q1%=9NQ34'UC?0\>&3S$^3+ >"2^/&).S 6_:T[U=_R,RWK_ M@&I)UMCYLJ-:7RHQR>Z&*B.3XE"'C=6ZBNSV0:D=9;9O'3 >JD97F'/O*E_;W4?O][^L?L?I3'=]VHIP+M__Y82H]^_ M!-OHGM]B,_XX5?D.WOW\4,O_6%T^7^CW$Q%=\U?=\4PE!X786"[VGV.Z9YCE6U M9:?3W3V41OK7'-_I!!6]T(3VE(]4/CV0>WZ;_#L^U/@9<>HM,*N;71U8]"(WE+X M9VX_VO+,/0T9OA-0^GVJ&XN)M^GFU-0GE*.8JO*9&MN+LTW\-LO3F^XI4KTOK">,UU.UQE2$6=<Z=W0LB'4D:ZM7/.&=TFJJ^LPM2FY!T_OV9-BW@C=<%C_?4+@P9N]TPE2# MN[J')>Y9MZ6?N%D4BFF9'L?W7*#<;C7JT]ZM"Q7]NLX,]_(VFC'0NY"V,VPMG<#7M%Q.PF$ULE!%BMKI<#>C226O)T=J%\7D M+@-Q9\U9PO8V)L)]KB8[JY-89$5)WC'@6G>X5G=O]_'_^FG'M[CIW1G@5TEC M#@L[G.!<' ?8:;,#2[>J^D)53MC66H5H.'59-L?>QP!O7%^ETG.NFOJ^]5^K M5)5)03RWU6>1@%1$LMWBGHYNR-D]N9M+\*W0_0TA]:K$0R#%FWOZDYLV7Y#O M!VF!_>ZPL0AQ)<]2@,^"XL(;O#Y-77I\,N*8 L7\5''JG9#84MJ-VX?R@USI M:+2#*V!,$FBSY7TCY=L9 "XIN\P23.&)5JL)E"Y4)$T]7'2G.BMZJ23:702F!8?T\*O*NM[+U$#MMQ>_'; M<:I*R(L5',N[+DM138Q(H](F@JDA+.+/Y?HQ("9@^=:+O:+#-U;H_AN<=-"*. %(IEH5(?SH!^W4TI)<4<( MIY^'OMT)L[NX,R8OB!O@WK*C"0^O8>4N5$M"ORFUONVGW5JEQO"\6\2XZASRWP3L((P6G*9U>4.8Y,D^QM7=>,#UAX[UOI5=8B2[+? +Y81RU;:M2FV^7\_NMV?PJ1^OPQ7K3?B*69)0G04T#R;/DE&,V MI,/49,-(A'Y=I\S>[M_U>CH\^_1T2^^ MY)H=F'5*E4GG%REL84HE^,E7L=TL,55ZVZQ.;OZ)W0L/=7UD5;U175^D;P+U M/;V+S Q=XY-+R]! \([.29C2VCDK5ESBYFG=N6GY:I6]&/=WS;2Q[=[>6#1" M=P+:R3]^OP=JGN,)WV_?Y'COB?&UGF;!L?2*@\7;S8WAEYGYI1)+="XXKEYC M@LG(S;Y-,L!,8_*U/5-A%7WGCBXNABL4JE++=@FXIO8(VLVQ%OKO*& M.;Q;R[8-B*A<4"QPDP%E E1\:R+=Q: -)J5F4\<5=@@X7E[57(@\$N(EZ?B9 MHYFW0=>FNHI#3 >GPBYZ]D8]4CP*2BV,'J/[P"KJTXZ=+'B^_W2WW3K?>;?3 MH5/ZF.6?@D.ZYH!ZQ2 IVQ%DO^\"H9 =83;UUW^VK1N=/R13%LF,.J52^J8; M)L_M"QD11L%F$*7K"I!L*-ECN[> *B#A,KG::$:U82B&V0 C_HYYM9BVZ$@+M537XZU'W-=%H@ TQ: ZIT/%$!)%&7C,-L MX1O]7A(K$0VY>^R$7O?)$@II^:$V6N4]S!H+,/5 ^ISE5WZO+8A2+D M?=0WFP3,BP;N)E^A[+[8OIE$G_WT_/$_=I_OW9Q2]VV6W$/&L,_W ORZ@]E]%&FCBN1XNNT7 M4U0$V0E.W[K^=H.F=N9MQ M,O3N@VR?&[)]%Q=TZ1GUO'BP[#"KZ+;=&G#A*36?&II:,:ZZ'5E$+OUN5%HJ M6QD*Z),0V'C,;99"IXV1'0ENS >CLL LUPXKW=ROQR,T?86.+,+D,I):0N>LGL MGF#F1FTZCN1&=X%DX+H,)',OT;63!]U.=5)EL+%=V'35'+?U:D+3["8$U,S< MH"%V,%LLN9: 6W?QU9;D%7:ZK)69+A1GKZ;E/][:W"?!.1EU'\L&5,2J?$8A M@I>])FHA 79^7KW'4#)E^!KZK%*Q_1"]"*QK KKF8CJ[7U&/R\>MA@K2A)HD M6WS%RHC0G#A8UKZ>5'=IZ]JZ6JJ#8)4\ M<')AH;Z C6>0#KWXY%\U>/OB>_#VBX.WZ&9N^F<]*]D$$23\6 M^%"J-@-&Q"LMMJ[D0O?CN0S1T$;.'Z*#'$7)!YLK*(\TJ-11'B96_P+3"XM] M"4Y7&:T&5#G2U[CBT;'1E=_"OB9Z4XH75U'H M]H"K0DJK>'RMQEMM\%.7&INJL-348/=5B(34LM^R9Y(P.3\)I:3%H4+2 +:5P_ M<6,'_?W>PV(O^2_8O>C5998W7&,I#7#X5CEMU=\Z.V G&-6JJ.-8WQ'(@E(: MLI #T[WSPF]$;O+UB$?%N4$] M[054Y2D^G!A3%^GH7/1'9S5S;/%J;"3Q%Y5]X:A_=CH,#L].#WN#T_[IFV#TMH@P)\U!]] M!#VM=WI\-CCLO0-5..B>'@5]5(G/![U1%Q\-SH[A]?XP^- =#+JHFKS%:5[W M@C=G[V'XWE'P^B.])Q/ %_A)1L7A@N[AX=G@J O+ 25\]):6<]+],.2Q>P#, M[JB''TY['X*/9X-?Z;&SBU$PZ+WI#HZ"T1D]=S[HGQ[VST]Z]";,=WS2/QS1 M!Q@.'QGTSHZ!EKN';]78AV?OSKNGO$+\_/;LY*@W:+?P65AX?S#HO3\[[+X^ M^1@,+UZ_Z\-P,EOO7X'X!L^&:+TYAM@ >AO$! J<]7A7^1+"%7^A??&\$!S;LT@/M%CP\ZKT[ M/X%E'P6R>W@8QCZ\& [E.QAT"V!\ DN +=! @][P'";14+&P198G$+%F"X[. M#B_PD>%VAV!4 ^T/70#MD'_NOAGTX%!/SVB:+BQG,"+$.<53Z8_@*0'^ )#@ M[+#7P_5UZ/?#DV[_'2R@"V_ _WF4\]Y@>'8*B/JQW8)C_:>U ?\P>0Y &#J_ MVR!/\V[TO 'LX'W_D)":%CP<:AI!L.!BU/>O>PAK?$&H12VH>>=(/>J>\;O73-BZ6%L2["P#2C*E' UP_++EW?(P01AP&Z,.^:8/] MD7VX=$*\+X$-;LS-F'L.+X^/^81]QK &0/(TA>?C\%J#!:-[M MGQI\UOSJJ =82[SDI/^NK_'K0_.!6\23T9/(44.HIG#Q %X=,=,# MGG,7=!$4P=707 2C+I!-'_ %?@?$_/C '5'?1I1\5IA(S%R^T2[O8E$M?:1&I?+6Z?@\BU@W5<4I. GQWE4;8WFX2J:O%V8=* MEHK<J7HXMOTQNBK*=RIZ MKF>PB%<4\[M+UR$*VG#&&AF[*$+>DKN?Q *=?T-VV.BFH!@WHZ'R$?%"V5$D MTY+#6]?,Z4B5NE!8C6#F]VR[;Q_*]5VJ_Q[T@(FS#@ ]X%+P^Z9[^^I^_K-_X']_]QE^)8X'T KE^BH+L XO*3L4H)$>!>RFFZC:[ M2J@Z8;(JE6U9M%NA"55EDHEI.HC)G>@YA3FF%"2:LONVPJZMC3PQN-B(FC8J M$J3E*,CQ02?Q:@2J&$CAWLG)\+Q[".K +X]V']'G T*,C\\-[V0IO MUF"<>M!]_Z7^'OXSL&926[#P/:9ZG7V.; >=LSBW(59,U@3O.VA-@3;?>%NU_K>S/O$WOI];?O@ M]7K?7IEW7AHQ&Y\ ]?0#P.CV+'0/OQI3+,%\]9DZ+$^#O^W2_^[:)8\6V?1? MHJK[!^Q7@>IIN(CV_ZJ+'V%RQ[Y-SO /\K$#%GW!=QGXQY2)5Z\/AH=O>T<7 M(!KV FP-==\Z&UYO>#9XAPI;[U^]P6%_V%/VZT,LY]^C3)KS:;E>G\?35&QJ M6E&*NO"?;Y_1> )FJ)02OX%]).C#_:+.P7W%@=S23T53_,BG.A$.2ZIR@6IR#-VD>14EX3V(6F!5LTWW=^L8R'3:&87A6/;!P[Q6\&S112FY"SP<@LB MUU[ZIB?VI'IB8PF:^T+#N^+#MM+;G []-\GK)X2K%1K-VDA M*T7%2]U070KFG5:Z[CU>H/YO3>81-MM)H^T*69I%O;BCGF^4^J^JG=MJOV\= M^-:#+?F4:D$R,O@E:%(N'GD:^[,?ZA0"^?$Y2%1'QY:_65+^_6\O__'LF?.> M_;NKD%@P#UPP!W\46WX.O(5A9WV#%:[ZJ#28[SCP_S<.B&3Q[UB0'M&L)OBW MQWKIS_6(\TU5B:UGVT'?CG63%R22;HMAX&!VIQI?5A_C<>3H%:#P3OMFH1? M+0&7]+V-]O5Z3HHB=0]+VZW:AI@Z63.ZXJN9 MM";K!U#)(VS#47Q-+_.=7# ?\YTU&*<7P,XNN;OLH,EC]>6=Z!_O_ICN:_7DSFX^VHK- MRA]P+P_"]6_'R^^F CV0E_K/@9'HYF909#/^EV7 =R3]CJ1_&B2E2-EW=/R. MCG\.=)30X'>$_(Z0?PZ$5.'>[QCYI\5($X'_AOX%WYC;&L:7:5AB%=L"6^]@ M\X^,;_I ?Y0$VJU]J@_&O0ZO?_LG30/VOOZ$US>-]^S]N7MU>_L\J9[.[B]/V\\O.N/>HT. MJ]?@IJX($A%UVE?]#VPX^GW0.V\LI9?,SMXT3V308-R7T^"\X8M)TB!9=_:V M.8^F,MA+5'C6"I.WS'P>JR11[%D M]VK.X4T7@_[-^_-&)*%7[LM/[-)-CF3!8%6OO7W;:^W>=POL+P@]!>$6= M-6T:G5^"<1R^12FP[FW+6'_.*N:2I= (9+C^;S=L>-\];TQ/CDY:KT^GK9/# MX];IT>E1Z_CXM/E'.,4G1^>-P>W-K39=6?]O9#^KYF]\Q0Y/'';8.CQD.Q9- MQGOJRSO=F0R4^LA&,Q'Q4*2)=&.']0.W^8V7W3ENM=@UE]%"PK6+A0A2X;!A M*A/!3N&K1]S]Y-L]WE,/>">A"L\\-@-^-H7 M"1 3A2KB**=>>X%"?OGIX/CU6T".=K_35?.0!ZOV?K^#V(%?O7G[TH$7L31$ MQ5X[)R='SLGK0Q;/0%R,WZ 0\R ^\.IMC!_GH.@P4>Y'AX4\8@ONIX+]J]5L MM5H'+ 0#D "VIL*0Y*YI( /73SU&&,(W<&8\%XYXG\2+WC5B'8J5]??M^E$'\#*3LQ2%WQ5F@ MEF#F1B>,Q-X$W^&U]_'>#@,S1SQ(XO6E/2KL#H1=EX0]&&$5>Y14UYXY<%JO M#YSCPS=;S +>CE-W9K^5<9SRL8]/PQWBDXA<&0OKSB=HZK#G6S;;$@RPW+&@ M)0@/[0!+"Z M3CB@3+(4(BAF@@Z?X8=+-A"8HQ_98-!E7=!31>Q:)G]-(4U]C_W"Y^%;>*A) M]S](WY=\SBY]P.;L.R-PT!PTNYC-,4 %Q%T,2D(B+_(LC,4"I=9KQ:!G 9^# MW@ A0W5,6B^YEO![NDK M#5\0UN 0\BA\N%;1W"A0K^U08;AW=#&\MZ]_<2W]SXCV]ZJI:=#1T='>X:N3 M@U=O7EH1$Y#@(0 7G)\C]%"X*0:6*3V]3Y"RP91NG$/\XC(V@;#YKIKUY-:J MW N .O#_P>G1D5.O07" N]'$&Z"U]%!5.*A2C&K2EZ=0]\#:+O?]%82Y"[*9 M@*KC8MQI["!4 2M@\JR]0*HTR_BD^83V),>B%KY: PVS&(<'%)Y 7P&4%#2;F M 92:""2%,B\Z:=%&/+-1T?(Z)2A4-!590IW#$AXKW[.N*=8LYWE8R"YO5Q@K MD@8Y :!+B 0!R.1$F:!A*ZIV\R>KD&K"J%ZKO&R\ C8>[Q9[2?>L@536&<@@ M34Q5 <\B%]A&QL>*1QY^Y\D( D!%&ZCI)=ZS5A$BZ!Q<1"WH0H3VO/D0:P8! M0FVJE%]:K\7HZ1GX%RE(!.T'Q<=GI&'!GB3\TAH+_J9:HPC-LDB#KSSEIN;/ M@A^U<6(KO6H>J#IP#90(X@G)PZC%)\)T[$L7ESM5P*<"33$F(%1" I#7;'YX MJ *426\A8V336(!!0CEW2.D_4Q'C:DD+6%!1"OI/>D1X($,A#WFT:D+KQJ9R M03";9ZJ3/02J*+2KA*>H#G-05]%Z ZJDQ8@&2@7^M?75@J,AT 8RLQ812@]P M0] !527G:"X H!2 E<@&P9,\SZ 'N->BI*R,( $H:T">"24(>Z#;<-%EG M36 'C&VK/(;YA ,>0_DM$EXT8OG)7>.2;X:GX)5Z33M9QS%FF U$>#I"" Q5 M;)$R;_<+3@0/0 #IX#8@S *5X3*6%*73 L(SA7 *\ Y,.P#06$[AU2DU>T$& MT<5LP >!P\W@$T1OLC)P,0>ZD)1$Y8I#]TPIGCDSSL'?T6@&?H+ES5$>W).7 MAJ\2KHN)5M6',/69RP'D4;AY/ 0$H<2)&*Z#.)$.(1O0,=+2%QH7H 4L-6(O MC6CN?B2!$&=0,63L^HHB5D36@0Z;*T\'M782IT&- C<32E/@TU!AE2T) A-' M:#J6+97B8XA45]C7:;T@VH )Q L.7+ADG+C4/,ZQT$N,UT" C"1;1(K<409 M8FKJ<(M(^;@<=S:RK%Y.!M!>JF,!_/676:&Q(@8:IJR>3&5V1]RJUPJB,8&_ M0 QB":@;B3]3&4O$8X/^60-!06(*2=.2HOVK_@"@&F]L:1X!_WQ@)"59QQ?\E7,0Z4V^_NV;#_7P")HX8522/^LY]. MZ;\&>^A?C=Z=-PY:K9^S 7&W]W[4N__*^?^WW 'HL#M8+1KI,)N6AY\[IF?% M=[VICON_3.FG#D8C89J?PEQ4!?ZJ.AS="I:&A@,Z0?4(##9 [D)S9'*:($0G ME.$"2"ULGOX!#5?L24V1U4O%:?2)HI)A$M*QP,,1F*$W:X/J?%+,%USZ- 7%(R&!C@V+L'1I >7),P3K!UUQ>4WXWV$0%G6-Q!S[-?BGG["\TYAPRXRV%-):IN;@ M-'*JUT![%['%:[('T_*NI?_NQ/XAXUM'%S1#,7!CD4\G/6JG*X,5ZJ@D+6[; M+D/6!]"HX0==;N9KN)+Z">5UJ7C5:QL2DX:XD5K(.*]P\"C$4FKK63YSQ$:7 MC:6.;1J*%,UEI,'KH1/3%4?.0^H"QRN-.%!\DO+@!PC>6'DK+1IB#R67B>)" ME'"H^?V'NSC/]_+U8L,S5: HE4OD5!:[#%'&K#FKUOK\C:^^\%P0=F>CB\M! MSXJZO+V_ZMWO05*WY6>*MJ;E4W,GMH(OF45I8K(MYQE:.WHH7L!)_56V@;B MF2<>@HNS8T=$CST-^P!E N2?<&5B:K2=<.I4IY%L=ON6TF#1I[A/9;<-B,#X MJVQ%2,@!)KCT/F\?.E#!'I00G+0"^;>@M<4(8$#EIYJ <$^%^>!R;:ZOI^@T M4&=VF)ZO UH6L%DWGZ?KK*2'])80!1'\[Q[_AQGU3X(^5X+^B!E*6?DW0@ E;9W MTT[QG-B8!Q^C-$Q&OCVLMF7%.Q"LVCSIQNIS(8NP]A_8^J:P]2/BUC/U^ 524@&M4+]N:^C_,*T![W_F*]P0G5A#I6Y[&Z6JZI)#>1B=[AY'B .BD=N*C.M.QI M3CQ?KJC)IDO8UGHXL:8YB6D&T=1&&VRRITH/2NPNZW(&'7&V,#KI!-4&LU*/ MQ8?:8QK17FJ!1$TQ(JB=L9D/35-_K9)GY^$B-4_]*3$0TIS>]<^6X%.W M!(_^QEN"HR)JR9BVO^FH%) 9 9"--!8!;@.0;)S.%M!$H]./ 2<%%OI(-RQC MG=D$M,63/Q,SV=+,TYPZP:.:)0,B.@7ZE!'/ XY^<9.4CC[P?!Q)K^"3Q(S)."8?K@FT$AXK M'*"A(T]:1SN;SC:"2*E\GA7J4T*T/*A$>PE MP#VH5:!_WP,,BW0&(1@Y^O296Q6Y*-N%P@]L_:,6BX)O;?,7]"L(*L=[W^S;L1K.%5<07?3?O]>)]= MBV IW8\Z&/3O71X$@!$X^>^R%AW4]-O;Z][[AW[WU])J>L.17LUE*4ILAZ"Y M#=M,L"6Y.@P !4A 1 M9#4S-3 W.61E>#DY,2YH=&W-6FMOVS@6_6[ _X'P/- !;,=VFO<#XSS:!),F M0>*VF_U&2[3-1B)5DHKC^?5[+BG9KX M\.*\?W97]ZK\Z/&5,9NLK_;WI*JP7@BQ^JHD8B1 M:_B[;LMC*3=CJ5I.9_N=S!VPXO-0.Z?3\&BDE6M9^;?8[RX^CW@JD]G^0*;" MLFLQ9706G&0IO7'YXS^[O3H\:XZW-K<[.GE4\ZW;; M7[(Q@1\<-:YNWM\$(RT#K4CP2%>9RHEGUY(JACOV]W[[/M.1L4XG4FG]R 83 M87@F+?9!)(K5BM_DPD1&[&8V$H1.E MH=>8:*T"WP7X_KP_0)0VV0<^8[VW3=;K]'KL]U^Z6YT#MDJ5)KM449N]N>8V MYE_WV5]GUP]_,*=CO,\++6/F)H)E"TVELRR'2$8EG059>ZXLQV\VUO MM[FUTV-VP@U0ZE&]1B]&.DUA'NMT],BX@]GH9@&904QY%:SYMMWIL$R8<$4; M4!F/8^E@WB;0Q4PJEDB1T^GJM$FJ)X&3QD*V:(U(EYA- MN3%< 2$.9KF))MP*EF?TD4/P>&S$F#M!PKK-SDZ7%%PHMTJOXI)Z+6CH==IL M[^&/U^JU[":;3F0T84;@=U9X,&23T@2O#!TN'FGCSRU!2(0-;__:@1D[W5UPB+4Y_GJ-JDT1P\9&6[*7CH2(O9%*(X^,3KVD$E:3#04NA>*X M)8\<(9W'"WV(I8T06E"/O$BPI;7P:OBL<9=9Z"B>,Z$LC)SQ&1\F@@UGI6A$ M@58Y'( HXV^RT*.1U1L&U)@**T.,) M_-_M;35AU37^1Z0K/% *N.B^J723Y>@.N@7+SC5%M%9UB1(-^7@=_N%#G;N0 MU3LAJYMPU_ +#I>98[F3=L2#1 *4 PL*RLQ?1/<#45#!MED_2>B0?U%$.3D& M>I YAR*D,$ !Q\+8;?;CR]>G$W8_1X,TAK](>03%9W(H3]E)PJ7Q.'D(+/CU MBY;*L2$PMDRN%#W%=7Q,KBUS8V'RSR(>YG;";GGTWN@I67UQ52)X7+Y@LQ25TY/3BK];FYG:0BWI&'BM]D6DHY^@N2AJJ1?@QX>@U MDV4L(3^,2#EU<%,&;-4232;QAIJA=")"*/]AK]B+&@N%1D="3*8-E6XD=8:< MLC\AE >OLYTB+217RF,/QN8(<%]>4$A$,H*J8VFAOL]AZX#9V_/-.XFZ=ZW; M;'-SL]7;WNIN[_Y!E>&=-BF[;VWV[^]@&72=*6)XA,/5Q)V7GWKMOI+J<,SY M,VJ<&@MV.B_![ W8PMN=@_OS4_IA]\#+J=*)LDD-1<13I&%.5<91@"0S)J K MDNF)ZB;> Q32=U[_<"M*#P5$(E.IJ#C!D99J7FY1T+(L"1H3.AXA/#+X-G2Z M^3&\S%T1\70N%C8R8+3T!#)0T5-;ADII^WIM89DJFD C8(TG+A/?7:C\A]^1 M_ML'EDW%T*)/4%,__'@\G4[;J)CML7XZW/AX3.I$.IN5 D>2&L1JI:K E_OE M= (6-D^+&B41D$ZV\ MRF]V.YT_V&YGM[6SA::'#@5"L(T>VZ2^A-.4G4EA'%M"^-,^#1=]I0U'DK$. MRHK^3KJ_QY2<,?N=IQF>Z_:2+J<\DPZ&_,#-HW#(\K<@3;?XP/I/ N4&#Q9* M4-H]: ,Z+<+ M_U9LS4"SD:4&R.Z0 L9*I/EMPO_FGI%&?*S!MZ_8=@?_K+/T=J_;ZFSO[JPR M;T6):4 \),"E*C^EK$E/FJU/0T$- A0(A5=I1[W .NERRA45HIM"W0KB&J'T M6XV*",^6)*5Z;IC3S#&K\A%J)"754]H4LH@?$D\)ISDE+88+/+5+9 8.7H8QYTNLQ-)?0>?O[RZ2E>HU' M7W/,]2/* 'K@.>9+BH4K0L\^*I,,_I1PN&0JL:2@UB8E(>^;.!1%"BE@PD= N! 8=\D(J8YE81 MF."CC)68T?Q!H6OGXT%9ZI%@-+ PE(A8QO!+E1*'J5'2$.A'3X-?(68@%4>B MB=& 64HHO+=Q=OD)!BR60?4:\_\>9G#Z+!'+3A7I*V/2HPQ*MX9&\,=6F*KV M>3+E,TL+D<.+.W9_^6]X9;-17NF74?N_[/D_#?;Y\FQP<=1 5?QMO@HZ/;\> MG-_]WVVJ<#DF&7<3LLDK?WHZ M#Z=B\DM]-%5H+I\S9#!MFCD3\JF(1!9F#D0;/&K=G+:B?7)7\MO+<1\\-(/7 M2?AL,;C2M ]^"TZ,X9J-$PV"FR?<5(*N0I]IKD1/:?5O[] 8,$!J#&O$(.CI M4,>S!6D43SS)R]@KP7@4M)Y0O0+5+%N[E:.+"-J4"FNH$!0FE[>KLHH_K M_#Y0F]6:3F:9,/H9PB&'^/9J0.6\T&43P1,RR9-.,.,+*H&$\,7^IK*BX?$3 M5WZY1%L/;OP6POLL.#TL!+Z5;J\2VJ/,91+[Q*5I2&;D8+\]2.@./@XY;6DO MZIM%<1>-RC!-1%WK[KH/B5]SX>$UV21'H"+^#-I[C+G0C+G2,@YL6B&2$5_* M)KS8$Z0Z%@E,AD[A5QX06S!67ZE\(YLO%7W$Q]+/W30=>::8"F+HT@9&6PSW M? Q6B,!\!-IE U0RX6?T#XP?4V[BUA4L3FCORXG%_HS.L8*+T#1*MJG71@6T MI(!F%]#(T#*P_%1P52PLZ>/']GV;5KI/GBY7F+;T99]L?T.,8% /2>D+'*UU*/54 ME.1QV+"A<=-IFJ/"O@A-LR*"EI4F+F>B[]D-A3$EK*"J4XK7LV!;/J5L95-# M!^>[JQ>K0GK/T;@W+O9DF(=*(,MCT-(MM/? B:5KJ"I&,O/PJ,<7#:!>\WO$ MLAU45Q&D\U,!0W M0M'[';Q")YB8P?X>@S@"Y#?5/H3\H-0]@7[@^O2/JF!10X"'MA MH; .L$L3>+/X=F%YO'\=?G[CCQ#/AZ$@NY6WA50+@677FS18LV(M'PHQS6R" M/ODMQDOTI;EQNT9+]/7 EML0/R10AC*7&[2W"8='.9K)6/F!H-QI!!E,@K)2 M"7EEHK"\]XOY>3.KU^#WD)LSG?NTIPUU @I,,T9.*S(,@RKRVPNBPNO]6^*% MM?DCCI.V\VT)!2W],/-Q2UNJ14/UPXSCC[">TDP/D[(BTHHRB\-ZC?9=R>R_ M0 B#TR@A$U//E(I*:C%T(75](H)'1=)$>8KW_#=M?.2*86J!I_]^JS7_(SQZS=>6<]D_ MD,)?:YWE!@USA*!__.&:?J+OKVZ1F+[LT- :OMA#FPXDS,Z7.>4.F%:=N2I& M=/OC??'Q>/YMXY]1\(I[+C?6$BCBY.7O 0_^_0_P'4$L# M!!0 ( "*!N53U7V[V1@, %<+ 1 :V1N>2TR,#(R,#4R-"YX3-O/NGCCXM2P!UJPY4<16DRB E4P67LU%4FY@:QGGT M\>3@S?';.(:S\XLKB&%N;65R0N[O[Y-BRJ51HK;.@DF8*@G$<:?_]_4/^-E8 MSV&, JE!**FQJ.%3S4619X,L&Z3I,$FS/DXC]0:AH!9S&)+L/?&:D&;Y8)@/ M/\#I%_@<[$BXYB7VL:I::CZ;6_B#_0D!=::D1"%P">=<4LDX%?"]X_P77$B6 MP*D0,/8PXX@:U'=8)*W5A2ERP^98TH,W "YCTN32F:S+4>13T69B,=$B47I& M"JN)759(G%+LM%!S%O6@O\8]PKA2>(E9 :?43 *HD_C\I/$@C0_3'NZVD,LU M9VS.I5*W=A%*%;(_S-[U$ 7R%2 P,\B2F;HC3A!\]'2]G#\=2S88'!+7&=:E M&WL0P>7M#H073UR3])T\@MP?!D!Z='1$@G2#4F'7(VBM#TDC#-K46LTGM<5S MIG&__%&=@<;!__D8\_?;]7_(\6 MP__ 1,FKUY+I;;>7UT12SIKEU1SWK\L#\E6]V:T%GX?A3L>;>Z3U&GQ2*94- MCOI,:%5Q.57ME;OT39QWG3S&*83]E5/-M!*X>\N12JL*M>5NV3\,0V-@KG$Z MBORVC[L][EY-*E:F?3N, M(N/R+GKC^9O#K30^-UP',6Z]A[)MC_I;3^O9P7L_UTX#_.''^&+' [%Z(8BE M"R55N6Q8GBE6^U>H^SZ5Q6?IN"TO7&OI,O"*@+NG9.S4;_927['L>!;H_L?Q MT+_IP'_C9.R:;1C;MUP:+K_(DG!D5K!:KK+?@5F,7<+-> M^R,?F&W'M;==Q;HY)IN#W-[T![ZY:A:.^_D?4$L#!!0 ( "*!N51AW7]> M>P8 +M& 5 :V1N>2TR,#(R,#4R-%]L86(N>&ULS9QO;]LV$,;?%^AW MN'EO-J"R8Q495J-ID3E)$2QM@L;=A@U#(4N,34PF#5*.[6\_4G\:.:9D*CQ5 M>=%6D>Z>NT?YGL/^40\("WE$V>RDMY)>($-*>R"3 M@$5!S!DYZ6V)[+U_]_+%VQ\\#\XN+C^!!_,D6K_O1'662QZM$2?-FD!XM M1TMJBE7BP\%?'Z]NPSE9!)XZ_^K[%>9E)!W)=/\5#]-S:-$@5$;HK[PBS-.[ MO*'OO1[V-S+JO=,%\[,33$E\I;8@]3 2/"8UA?7AM'HOCT^V2Q5/-@EA$;I0F*L_R44$V0 M"ZXU@DC89A4@+P%I#5!%G %NL?4RR,W[=T/ZC(:(^!!;RN#.Q4Q#2BI"7!%T3:4B^@R_#S#S=',807="8 M?%HMID0TFYAR7J?C83# SY:85S252G8K87+?:M6#$/P!#\8(W$:1?KS\+6X$?R>LK#A;9TJ MC>< ?)4Q$_6/8M'0-^JVQ']V8T.A4U3#'8)6K-1-0@,_B.-PPV42Q'_39?-[ MG&:%YS *9E.F0=B)1!L#@VI+0Y!5 E4*\[YE>S;J!L#:B^,[@-J@($$3X'=S MNGH#T-0XWS_F]/[?G@X2N.G_\UH9AU/\/G?>_;-LU@U$_5)N?#/GK.']\OV\ MCH"L-,#-QUW -&LAP9F*0ZJ.==^PG7[+D#9IV@W4/P5-$L+&?+%8L?Q^I+2E MM2*Y(V3KK?":(!=X:P21",XKP&X)9XI;;+R,,21J-!N:S"RDD2W'Y0T)5VH] MM1WZTPE-8NM['/MY72UMJ@QP\W&G98U1"VM1DXN#4H=4WGU-TTJ_.RN:!DV[ M@3H1@?ZP^>UV,>762_!'21TA:FZ=&PZZP&D00B(S5X9,VIG*%AHM(VG;+[YTO MB)BIJ?D@^#J9J\7(,F -/\A;(='I$[YZ6_Q@J/LSOAI9)-;S!V-%(<@J05X* MZ1E?BS8,#_ELO91W7*DM_2M7\ETT^\4C:L__4$L#!!0 ( "*!N52.5*^H MQ 0 $,L 5 :V1N>2TR,#(R,#4R-%]P&ULU9KO;^(V&,??GW3_ M@Y=[LTD+(:'W,RR0-8=>S(-@7^^]D!WPB$'O1N4\P+ M?CC^/O[Z^3@F=G+U<952] Q"$L[:7EBK>PA8S!/"9FUO(7TL8T(\)!5F"::< M0=M;@_0^7K]]<_6#[Z.;N]X#\M% M!Z8F"J-6O=EJ?D"=>W2;QV%H3%+8U?)L+(:EMHU+"GEKF;6+LH[=OD'[I3#*9E[8] MDX]M.E8306MB.P(F]7LSH0+1NY)+R\O SRH\7ZDI35U@V$P5_W_5$\ MAQ3[FH*F%N\UI=TDZHMZUUPSV!RT]25IR3Q2G\=Y[D_H%CI:P_SR;37?%/EA MY#?"VDHFWK5I,\R>URD=5SK_>C"X"A5><\70= M&%%PP^-%"DS9SPY+;IDB:MUC4R[2O"L>RK/:F@N8MKVGA*U]&\T8>C?4@3Z? M$TBM,WUJ2))F%#P4['0H$WKP,)77[NN"@@!6"E@"B0UC.O!?=?EZPW4[>'E< M2($]@7-H$N+:C#\'"1#38FB^F/SDL-[I'Y^[7,\9G8E4 L>JF -J1@L7MI#B M"="V5R(*OJ>ACNYV8KI^1_'L5$-[HJ*A76X=$1="8A';$\%3TN3LVV-EQKE(@'1]J*HIL]X#V6"<*%AZQ(/+:3VPC/C&E-S M#*8@!"3]3;>/NLPMZME30E[S.^/9C,:N[H' M*='_.IW6)^*Z8BXNKB.&+;8 M&LY@L_/)6*?Q5%I%374A%7U:-DWGV Q >]73?7*CKXS.A;0GKCZM/<,6VWMG ML&WFAB',B.DH4P\X/9E:N;:ZT,K]6F:_.,9,+PJXR+C(4SO2&88N7^@I?MWE MR9D(OQ*JZD2_8M\"_N 8X#M"X6&13D"<1W-75W5TNUXMITO'.(WQJI?H-) I MV2Q,7P/M:)"J$SQJ?(NS47<,9R=)=)+E]D,OD2$\#V5I@*IC+#5M$8;.(XR^ M%6'D(L+H7X2NKCJKX]BS)?L50!WY8[@V[5LX;FS0B]T);\4>Q0#P9^) MV?A]#<&#&(Y@//!M65ZXR7+ I<+T;Y*=O[HHC^ (QSW7EJ([^S)F/ND(P.=P M*VJJ2ZKHT[)Q9_/%W,FB@SEG9Z[S#G75973HU7)R9\/E3^U/ >OR-%VP[3)' MG@KKB+BZQ(X8MMCL_8T&,M=.8E2FK"ZS,K:7ESF;*0( 9 M4KQP9P]EKS<]*1<@OIUE21QGB)9X MMUS=V5@90;PP%L-H,B:*GGPI>:BK+K=#KY:3.[LG8X'-PW*C=3KA)__=[8FJ M2VC/J,7CSOZ('6*WJWB.V0S.N=U:KJTNK'*_EIEK^R"W*8B9'GN_";Y4;1U\T1\V8>Y-0E_P!02P$"% ,4 M " B@;E4]EL;VAT6 !C? #@ @ $ 9#4S-3 W M.60X:RYH=&U02P$"% ,4 " B@;E4G=JW+R:3 !\^P( $ M @ %)%@ 9#4S-3 W.61E>#$Q+FAT;5!+ 0(4 Q0 ( "*!N53?^!?% MES< "KU 0 " 9VI !D-3,U,##DY,2YH=&U02P$"% ,4 " B M@;E4]5]N]D8# !7"P $0 @ %*_0 :V1N>2TR,#(R,#4R M-"YX2TR,#(R,#4R-%]L86(N>&UL4$L! A0#% @ (H&Y5(Y4 MKZC$! 0RP !4 ( !;0